<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000256" GROUP_ID="INFECTN" ID="651899102810394127" MERGED_FROM="" MODIFIED="2009-11-09 13:46:18 +0000" MODIFIED_BY="Anne-Marie Stephani" REVIEW_NO="HMCI" REVMAN_SUB_VERSION="5.0.22" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2009-11-09 13:46:18 +0000" MODIFIED_BY="Anne-Marie Stephani">
<TITLE>Artemisinin derivatives for treating uncomplicated malaria</TITLE>
<CONTACT>
<PERSON ID="11751" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Heather</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>McIntosh</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>hmmci@tiscali.co.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Community Health Sciences General Practice</DEPARTMENT>
<ORGANISATION>University of Edinburgh</ORGANISATION>
<ADDRESS_1>20 West Richmond Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>Edinburgh</CITY>
<ZIP>EH8 9DX</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 131 650 9234</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2009-11-09 13:41:25 +0000" MODIFIED_BY="Anne-Marie Stephani">
<PERSON ID="11751" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Heather</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>McIntosh</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>hmmci@tiscali.co.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Community Health Sciences General Practice</DEPARTMENT>
<ORGANISATION>University of Edinburgh</ORGANISATION>
<ADDRESS_1>20 West Richmond Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>Edinburgh</CITY>
<ZIP>EH8 9DX</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 131 650 9234</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="17054" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Piero</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Olliaro</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>olliarop@who.int</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Special Programme for Research and Training in Tropical Diseases (TDR)</DEPARTMENT>
<ORGANISATION>World Health Organization</ORGANISATION>
<ADDRESS_1>1211 Geneva 27</ADDRESS_1>
<ADDRESS_2/>
<CITY>Geneva</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<PHONE_1>+41 22 791 3734</PHONE_1>
<PHONE_2/>
<FAX_1>+41 22 791 4774</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-10-14 18:22:56 +0100" MODIFIED_BY="Harriet MacLehose">
<UP_TO_DATE>
<DATE DAY="18" MONTH="2" YEAR="1999"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="16" MONTH="12" YEAR="1999"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="1997"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="1998"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="1999"/>
</DATES>
<WHATS_NEW MODIFIED="2009-11-09 13:46:18 +0000" MODIFIED_BY="Anne-Marie Stephani">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2009-11-09 13:46:09 +0000" MODIFIED_BY="Anne-Marie Stephani">
<DATE DAY="9" MONTH="11" YEAR="2009"/>
<DESCRIPTION>
<P>The research questions raised in this review have now been answered and priorities have changed. It is therefore considered no longer necessary to update this review. This decision was taken in August 2008, prior to the introduction of a formal Cochrane policy, hence the necessity to republish now. Further details of reasoning can be found in the 'History' section of this review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2009-11-09 13:46:18 +0000" MODIFIED_BY="Anne-Marie Stephani">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-11-09 13:46:18 +0000" MODIFIED_BY="Anne-Marie Stephani">
<DATE DAY="25" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format with minor editing.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2008-10-20 10:09:36 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="4" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>This review was first published in 1998, Issue 3, and was undertaken to provide a comprehensive assessment of the benefits and risks of this new class of antimalarial drugs in different epidemiological settings. It aimed to inform drug policy decisions on their rational use, and the clinical questions addressed by the review were based on what needed clarifying at that time.</P>
<P>In April 1998, research findings on artemisinin and its derivatives, including this review, were presented at a conference attended by representatives of the World Health Organization, non-governmental organizations, researchers in the field, and the pharmaceutical industry. Current knowledge and priorities for future research were clarified at the conference 'The rational use of qinghaosu and its derivatives' convened by the International Laveran Association, Annecy, France, 19-22 April 1998 (<I>Médecine Tropicale </I>1998;58 Suppl 3).</P>
<P>The clinical effectiveness of artemisinin drugs is no longer in question and a safety overview showed them to be well tolerated. It is not a priority to continue to review comparisons of artemisinin drugs used alone with standard non-artemisinin drug treatments; nor whether one derivative is better than the others. The way forward is combination therapy and the main goal is to optimize clinical effectiveness in areas of high and lower parasite resistance to standard antimalarial regimens.</P>
<P>In conclusion, this systematic review has served its intended purpose. Most of the questions addressed have now been answered and research priorities have, as a result, moved forward. The foremost outstanding clinical questions are around artemisinin combination regimens, and these will be managed within separate Cochrane Reviews.</P>
<P>It is, therefore, no longer necessary or expedient to update this review in its existing format. It will continue to appear in the <I>Cochrane Database of Systematic Reviews </I>for information only.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-10-20 10:09:39 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="25" MONTH="5" YEAR="2005"/>
<DESCRIPTION>
<P>Minor update.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2008-10-20 10:09:45 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="18" MONTH="2" YEAR="1999"/>
<DESCRIPTION>
<P>Substantive amendment.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Liverpool School of Tropical Medicine</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>European Commission (Directorate General XII)</NAME>
<COUNTRY CODE="BE">Belgium</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Department for International Development</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-10-25 18:43:26 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-10-20 10:20:23 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-08-04 16:15:58 +0100" MODIFIED_BY="[Empty name]">Artemisinin drugs for treating uncomplicated malaria are better used in combination therapy</TITLE>
<SUMMARY_BODY MODIFIED="2008-10-20 10:20:23 +0100" MODIFIED_BY="[Empty name]">
<P>Artemisinin drugs come originally from a plant that has been used since ancient times in China as a traditional medicine for fever and malaria. These drugs act quickly and few side effects have been reported. Malaria parasites have so far not developed resistance to artemisinin drugs. The review shows that artemisinin drugs clear malaria parasites from the blood more effectively than standard treatment drugs. In areas where malaria parasites are more resistant to existing drugs, such as South-East Asia, artemisinin drugs are not better at sustained parasite clearance than standard treatment with quinine or mefloquine. Combination treatment using an artemisinin drug together with the longer-acting antimalarial drug mefloquine improves sustained clearance of parasites, but mefloquine is associated with adverse effects. There are few studies on combination treatment with longer-acting antimalarial drugs that are safer than mefloquine. There is no evidence from trials that any of the several artemisinin derivatives is better than the others.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-10-25 18:36:55 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>Artemisinin derivatives are a relatively new group of drugs with antimalarial properties. As resistance to other antimalarial drugs continues to increase, artemisinin drugs may be useful alternatives.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>The objective of this review was to assess the effects of artemisinin drugs for treating uncomplicated falciparum malaria.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-10-25 18:36:55 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Infectious Diseases Group Specialized Register, the Cochrane Controlled Trials Register, MEDLINE, EMBASE, Science Citation Index, LILACS, African Index Medicus, conference abstracts, and reference lists of relevant articles. We contacted organisations, researchers in the field, and drug companies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised and quasi-randomised trials of artemisinin derivatives, alone or in combination with other antimalarials, compared with standard antimalarial treatments, in adults or children with uncomplicated falciparum malaria. Only trials where treatment was given by mouth or suppository were included. Comparisons between different artemisinin derivatives and treatment regimens were also included.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Eligibility and trial quality were assessed and data were extracted independently by the two reviewers.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-10-20 10:20:19 +0100" MODIFIED_BY="[Empty name]">
<P>Forty-one trials involving over 5000 patients were included. Variation in study design and quality made synthesis of the data problematic. Allocation concealment was adequate in only two trials. Most data were from areas of multidrug resistant falciparum malaria in South-East Asia. Compared with standard antimalarial treatments, artemisinin drugs showed fast parasite clearance and high cure rates at follow-up, provided the duration of treatment with artemisinin drugs was adequate. Combination with mefloquine improved sustained parasite clearance and was effective in multidrug resistant areas. When doses were adequate, the combination shortened the duration of treatment. We found no evidence that artemisinin drugs are more harmful than standard treatment drugs over a typical trial period of 28 days.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>The evidence suggests that artemisinin drugs are effective and safe for treating uncomplicated malaria. There is no evidence from randomised trials that one artemisinin derivative is better than the others. In areas where there is mefloquine resistance, combination therapy with an artemisinin derivative appears to improve sustained parasite clearance compared with either drug alone.</P>
<P>
<I>This review summarizes trials up to 1999. For the reasons in the 'What's new' section, this review will no longer be updated.<BR/>
</I>
</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-10-25 18:43:26 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-10-25 18:37:22 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="2">Malaria</HEADING>
<P>The 300-500 million clinical cases of malaria which occur worldwide each year are a heavy social and economic burden on developing countries. Most infections are caused by <I>Plasmodium falciparum </I>which is also responsible for almost all of the 2-3 million deaths every year from severe malaria (<LINK REF="REF-WHO-1995" TYPE="REFERENCE">WHO 1995</LINK>; <LINK REF="REF-PRISM-1996" TYPE="REFERENCE">PRISM 1996</LINK>). There are far more uncomplicated infections, which have a large impact on morbidity and the disease burden in endemic areas (<LINK REF="REF-Olliaro-1996" TYPE="REFERENCE">Olliaro 1996</LINK>). The goal of treatment for patients with uncomplicated malaria is rapid and sustained clearance of parasites, as well as clinical symptoms, with a single dose or short course of treatment.</P>
<P>National antimalarial drug policies normally recommend at least two standard treatment regimens for uncomplicated falciparum malaria (<LINK REF="REF-WHO-1988" TYPE="REFERENCE">WHO 1988</LINK>, <LINK REF="REF-WHO-1996" TYPE="REFERENCE">WHO 1996</LINK>). There is a first-line treatment recommended for routine use, and second-line alternatives for treating infections that are not cured by the first-line treatment, or for which the first-line treatment is contraindicated (<LINK REF="REF-WHO-1994" TYPE="REFERENCE">WHO 1994</LINK>). Standard treatment drugs vary according to local policy and local patterns of malaria parasite resistance to the drugs available. The main options recommended by the WHO for first- or second-line oral treatment of uncomplicated malaria are regimens using the drugs chloroquine, sulfadoxine-pyrimethamine, mefloquine and quinine (<LINK REF="REF-WHO-1994" TYPE="REFERENCE">WHO 1994</LINK>). However, the decision of which drugs to use is becoming more of a problem in areas where malaria parasites are becoming more resistant to these and other established drugs. In Thailand, for example, there is a high level of resistance to chloroquine, sulfadoxine-pyrimethamine and quinine, and increasing resistance to mefloquine. A similar pattern is emerging in countries neighbouring Thailand, including Myanmar and Cambodia (<LINK REF="REF-Wernsdorfer-1994" TYPE="REFERENCE">Wernsdorfer 1994</LINK>). In Viet Nam, where mefloquine is expensive and not readily available and quinine is still largely effective, the WHO recommend quinine plus tetracycline over 7 days for treatment of uncomplicated malaria in adults (<LINK REF="REF-WHO-1990" TYPE="REFERENCE">WHO 1990</LINK>). A similar pattern of decreasing effectiveness of antimalarial drugs (multidrug resistance) is emerging in other malaria endemic areas. One alternative is a relatively new group of antimalarial drugs derived from artemisinin.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Artemisinin drugs</HEADING>
<P>Artemisinin (qinghaosu) is the active principle isolated by Chinese scientists in 1972 from the plant <I>Artemisia annua</I>. The plant has been used since ancient times in China as a traditional medicine for fever and malaria (<LINK REF="REF-QARCG-1979" TYPE="REFERENCE">QARCG 1979</LINK>). In the early 1970s, artemisinin preparations in tablet form did not perform well due to the drug's poor solubility and absorption. Chinese scientists improved the solubility and activity of artemisinin by developing new formulations and by modifying the parent compound to create several semi-synthetic derivatives (<LINK REF="REF-CCRGQ-1982" TYPE="REFERENCE">CCRGQ 1982</LINK>; <LINK REF="REF-Woerdenbag-1990" TYPE="REFERENCE">Woerdenbag 1990</LINK>). Of the many compounds produced by chemical modification of artemisinin only four, dihydroartemisinin (DHA), artesunate (AS), artemether (AM) and arteether (AE), have reached pharmaceutical development for use in humans. Various formulations are now available, or are being developed, in China, Europe, Thailand and Viet Nam.</P>
<P>Formulations of artemisinin derivatives currently available or under development:</P>
<UL>
<LI>Artemisinin: oral (tablet, capsule), suppository.</LI>
<LI>Dihydroartemisinin: oral (tablet).</LI>
<LI>Artesunate: oral (tablet, capsule), suppository, intramuscular, intravenous.</LI>
<LI>Artemether: oral (tablet, capsule), intramuscular.</LI>
<LI>Co-artemether: oral (artemether plus lumefantrine together in tablet form).</LI>
<LI>Arteether: intramuscular (not yet commercially available).</LI>
</UL>
<P>The artemisinin derivatives have great potential as antimalarial drugs. They have a novel structure and mode of action amongst antimalarial compounds (<LINK REF="REF-Meshnick--1993" TYPE="REFERENCE">Meshnick 1993</LINK>). Resistance to the drugs has not yet been demonstrated in malaria parasites, nor has cross-resistance with other antimalarial drugs currently used in standard treatment regimens (<LINK REF="REF-Olliaro-1995" TYPE="REFERENCE">Olliaro 1995</LINK>). The first published report of clinical trials appeared in the Chinese Medical Journal in 1979 (<LINK REF="REF-QARCG-1979" TYPE="REFERENCE">QARCG 1979</LINK>). By 1994, more than 1 million patients with malaria in endemic regions had been treated with various formulations of artemisinin derivatives (<LINK REF="REF-White-1994" TYPE="REFERENCE">White 1994</LINK>). Despite the limitations of many of the reported clinical studies, a consistent observation is that artemisinin derivatives produce faster relief of clinical symptoms and clearance of parasites from the blood than any other antimalarial drug (<LINK REF="REF-Hien-1993" TYPE="REFERENCE">Hien 1993</LINK>, <LINK REF="REF-Meshnick-1996" TYPE="REFERENCE">Meshnick 1996</LINK>).</P>
<P>The problem with artemisinin drugs is that when they are used alone over short periods (less than 5 days), clearance of malaria parasites from the blood is only temporary in up to 50% of patients (<LINK REF="REF-Meshnick-1996" TYPE="REFERENCE">Meshnick 1996</LINK>). This recrudescence has been attributed to the short time it takes for artemisinin drugs to be eliminated from the body. Longer courses of treatment for uncomplicated malaria raise the problem of poor compliance. An alternative is to use artemisinin drugs in combination with other antimalarial drugs which take longer to be eliminated from the body, such as mefloquine or sulfadoxine-pyrimethamine. Combination of a high dose of mefloquine at the end of a full course of artemisinin drug has produced a high cure rate, although this still requires at least 5 days of treatment (<LINK REF="REF-Looareesuwan-1994" TYPE="REFERENCE">Looareesuwan 1994</LINK>). There is a need for combinations that are effective in shorter courses and suitable for all types of patient (<LINK REF="REF-WHO-1990" TYPE="REFERENCE">WHO 1990</LINK>). One drug company (Novartis) has responded by developing a combination tablet of artemether with benflumetol (now called lumefantrine), a longer-acting antimalarial drug also originating in China. Artemisinin drugs are a logical option to clear parasites from the blood quickly, and perhaps combination with a longer-acting drug could allow for a shorter overall course of treatment. An important clinical question, therefore, is whether artemisinin drugs should be combined de novo with a longer-acting antimalarial drug.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Treatment policies</HEADING>
<P>Artemisinin derivatives have come in to use outside China largely by necessity to treat multidrug resistant malaria (<LINK REF="REF-Hien-1994" TYPE="REFERENCE">Hien 1994</LINK>, <LINK REF="REF-Looareesuwan-1994" TYPE="REFERENCE">Looareesuwan 1994</LINK>, <LINK REF="REF-Nosten-1994" TYPE="REFERENCE">Nosten 1994</LINK>, <LINK REF="REF-Meshnick-1996" TYPE="REFERENCE">Meshnick 1996</LINK>). As a result, they have largely not undergone consistent and rational development and testing. Important clinical questions about their use have yet to be answered: there is still no consensus on which is the best derivative or the best treatment regimen, or if these drugs confer any therapeutic advantage in areas where malaria parasites are still sensitive to existing drugs. Since they have become more widely available they are being used more and more for first-line treatment of malaria, even in areas where standard drugs such as chloroquine, sulfadoxine-pyrimethamine, quinine and mefloquine are still effective (<LINK REF="REF-Meshnick-1996" TYPE="REFERENCE">Meshnick 1996</LINK>).</P>
<P>In 1996 a WHO report of an informal consultation on management of uncomplicated malaria recommended treatment regimens with artemisinin derivatives as follows (<LINK REF="REF-WHO-1996" TYPE="REFERENCE">WHO 1996</LINK>):</P>
<SUBSECTION>
<HEADING LEVEL="3">Monotherapy</HEADING>
<UL>
<LI>Artemisinin: 10 mg/kg once a day for 5 days, double divided dose on first day.</LI>
<LI>Artesunate: 2 mg/kg once a day for 5 days, double divided dose on first day.</LI>
<LI>Artemether: 2 mg/kg once a day for 5 days, double divided dose on first day.</LI>
<LI>Dihydroartemisinin: 2 mg/kg once a day for 5 days, double divided dose on first day.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Combination therapy</HEADING>
<UL>
<LI>Artemisinin: 10 mg/kg once a day for 3 days, plus mefloquine (15-25 mg/kg) as a single dose on second or third day.</LI>
<LI>Artesunate: 4 mg/kg once a day for 3 days, plus mefloquine (15-25 mg/kg) as a single dose on second or third day.</LI>
</UL>
<P>The WHO report warns that these prescriptions are based only on available clinical data which in itself is insufficient to formulate treatment regimens. The report also cautions against widespread and uncontrolled use. Inconsistent and indiscriminate use of artemisinin derivatives, particularly for uncomplicated malaria where presumptive treatment, self-treatment and repeated treatment with oral drugs is common in practice, might result in faster development and spread of resistance. Also, toxicological studies in animals (<LINK REF="REF-Brewer-1994" TYPE="REFERENCE">Brewer 1994</LINK>) and observations of temporary brain dysfunction in humans (<LINK REF="REF-Miller-1997" TYPE="REFERENCE">Miller 1997</LINK>) caution repeated exposure in humans until more is known about potential adverse effects of artemisinin drugs on the central nervous system. It is, therefore, essential that these drugs are used in an optimal way and only where they have a significant advantage over established antimalarials. A comprehensive assessment of benefits and risks in different epidemiological settings is needed to inform drug policy decisions on the rational use of these drugs.</P>
<P>The aim of this review is to summarise the existing evidence of effectiveness and safety of artemisinin derivatives, alone and in combination with other antimalarials, in the treatment of uncomplicated falciparum malaria. The following clinical questions will be addressed in terms of parasitological and clinical cure, and tolerability:</P>
<OL>
<LI>Are treatment regimens with artemisinin drugs better than other standard treatment regimens for uncomplicated malaria?</LI>
<LI>Do artemisinin drugs have a comparative advantage over other antimalarials in geographical areas where malaria parasites are still sensitive to existing antimalarial drugs, as well as in areas where drug resistance is high?</LI>
<LI>Should artemisinin derivatives be combined de novo with all first-line treatment regimens using longer-acting antimalarials?</LI>
<LI>Is any artemisinin derivative better than the others?</LI>
<LI>For any artemisinin derivative having a comparative advantage over other antimalarial drugs, what is the best formulation, dose and treatment regimen?</LI>
</OL>
<P>The inclusion criteria, therefore, prespecified comparisons that could potentially make a contribution to answering these questions.</P>
</SUBSECTION>
</SUBSECTION>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-10-20 10:11:35 +0100" MODIFIED_BY="[Empty name]">
<P>To compare the effectiveness and safety of artemisinin drugs versus standard treatment regimens, and the relative performance of each derivative, in treating adults and children with uncomplicated falciparum malaria. Effectiveness is defined in terms of clearance of asexual parasites from the blood (parasitological cure) and relief of clinical symptoms.</P>
<P>The following null hypotheses were explored or tested, depending on the data available:</P>
<UL>
<LI>There is no difference in effectiveness or tolerability between artemisinin derivatives and existing standard treatment regimens.</LI>
<LI>There is no difference in effectiveness or tolerability between different artemisinin derivatives.</LI>
</UL>
</OBJECTIVES>
<METHODS MODIFIED="2008-10-20 10:36:45 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-10-20 10:36:45 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2008-10-20 10:36:45 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised or pseudo-randomised trials of treatment comparisons.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Adults and children with falciparum malaria infection confirmed by a blood slide. Asymptomatic individuals and patients with clinical symptoms of uncomplicated malaria will be included, but not patients with signs and symptoms of severe or complicated malaria.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-10-20 10:18:52 +0100" MODIFIED_BY="[Empty name]">
<P>This review includes only trials in which treatment was given by mouth or suppository. We have excluded trials where patients were given antimalarials by intramuscular injection or intravenous infusion, because the inability to retain oral treatment is a criterion for classifying a case as possibly severe or complicated and treating it as such (<LINK REF="REF-Warrell-1990" TYPE="REFERENCE">Warrell 1990</LINK>; <LINK REF="REF-WHO-1994" TYPE="REFERENCE">WHO 1994</LINK>). We have included suppositories because of their potential advantages in rural situations, particularly in treating children.</P>
<P>Artemisinin drug (dihydroartemisinin, artemisinin, artesunate, artemether) given by mouth or suppository, alone or in combination with other antimalarials:</P>
<OL>
<LI>Single drug therapy: artemisinin or derivative drug alone versus WHO recommended standard treatment for uncomplicated malaria (chloroquine, amodiaquine, sulfadoxine-pyrimethamine, mefloquine, quinine, quinine + tetracycline).</LI>
<LI>Combination therapy: artemisinin or derivative drug in combination with a longer-acting antimalarial drug (mefloquine, sulfadoxine-pyrimethamine) versus WHO recommended standard treatment for uncomplicated malaria.</LI>
<LI>Comparisons between artemisinin derivatives:</LI>
<OL>
<LI>Comparisons between derivatives.</LI>
<LI>Comparisons between doses of the same derivative.</LI>
<LI>Comparisons between regimens of the same derivative.</LI>
</OL>
</OL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-10-20 10:13:59 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Clinical</HEADING>
<P>Fever clearance time (time for temperature to return to normal as defined by the authors); fever clearance within 48 hours of starting treatment; clinical treatment failure (patients given an alternative treatment because of no clinical improvement under the allocated regimen); other reported indicators of clinical improvement.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Parasitological</HEADING>
<P>Parasite clearance at day 7, 14 and 28; parasite clearance time; rate of 50% or 90% parasite clearance (PC50, PC90), as reported; in vivo sensitivity as S (parasite clearance within 7 days of starting treatment and sustained to day 28), RI (parasite clearance within 7 days followed by recrudescence by day 28), RII (temporary marked reduction in parasitaemia), RIII (no marked reduction in parasitaemia) (<LINK REF="REF-WHO-1973" TYPE="REFERENCE">WHO 1973</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Adherence</HEADING>
<P>Number of patients completing treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Tolerability</HEADING>
<P>Adverse events:</P>
<UL>
<LI>mild (vomiting, nausea, diarrhoea, dizziness, other).</LI>
<LI>major (neuropsychological disturbances, any other serious adverse events reported).</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-10-20 10:15:54 +0100" MODIFIED_BY="[Empty name]">
<P>The Cochrane Infectious Diseases Group Specialized Register was searched for any trial or reference to a relevant trial (published, in-press or in progress). The topic search terms used were: malaria, qinghaosu, artemisinin, dihydroartemisinin, artesunate, artemether, arteether. Full details of the CIDG methods and the journals searched are published in <I>The Cochrane Library </I>in the section on Collaborative Review Groups.</P>
<P>The reviewer searched the Cochrane Controlled Trials Register, published in <I>The Cochrane Library </I>(1999, Issue 4). This is a compilation of about 160,000 published trials identified by hand-searching by various individuals within the Cochrane Collaboration. Full details of the sources and methods used are published in <I>The Cochrane Library</I>.</P>
<P>The following databases were also searched: MEDLINE (1966 to December 1999); BIDS Science Citation Index (1980 to December 1999); EMBASE (1988 to October 1999), using the search strategy defined by The Cochrane Collaboration, and detailed in appendix 5c of the Cochrane Handbook; African Index Medicus (February 1998); and LILACS (December 1999). The specific topic search terms used were malaria, qinghaosu, artemisinin, dihydroartemisinin, artesunate, artemether, arteether, co-artemether.</P>
<P>Organisations and individual researchers working in the field were contacted for unpublished data, confidential reports and raw data of published trials. The following drug companies were also contacted: Arenco, Cotec Company, Mepha, Rhone-Poulenc Rorer, Propharma, Novartis, Sanofi Winthrop, Guilin Pharmaceutical Company, Kunming Pharmaceutical Corporation, Thua Thien Hue Pharmaceutical Company, National Pharmaceutical Plant Company (Hanoi).</P>
<P>The reviewer also handsearched conference abstracts and checked the citations of existing reviews on artemisinin drugs (<I>Trans R Soc Trop Med Hyg </I>1994;88 Suppl 1; <I>Jpn J Trop Med Hyg </I>1996;24 Suppl 1; <LINK REF="REF-Woerdenbag-1990" TYPE="REFERENCE">Woerdenbag 1990</LINK>; <LINK REF="REF-Meshnick-1996" TYPE="REFERENCE">Meshnick 1996</LINK>; <LINK REF="REF-de-Vries-1996" TYPE="REFERENCE">de Vries 1996</LINK>) and of all trials identified by the above methods.</P>
<P>The advisory panel supporting this review and the external referees were asked to check the completeness of the search and the efforts made to identify unpublished, on-going and planned trials.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-10-20 10:16:03 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2008-10-20 10:16:03 +0100" MODIFIED_BY="[Empty name]">
<P>The topic was identified as a priority by the Cochrane Infectious Diseases Group Editors, and resources allocated to the reviewer in consultation with the Group's main funders, the Department for International Development, UK.</P>
<P>An advisory panel was established, comprising individuals with relevant methodological and content knowledge, plus a potential user of the review, to advise on content, quality and dissemination of the review, as set out in Editorial Information about the Infectious Diseases Group in <I>The Cochrane Library</I>.</P>
<P>All trials identified were entered in a database register. The inclusion criteria were applied to all identified studies independently by the two reviewers. In the case of disagreement, the opinion of a member of the advisory panel was sought.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-08-05 10:43:31 +0100" MODIFIED_BY="[Empty name]">
<P>Data for the pre-specified outcome measures were abstracted onto collection forms by the first reviewer, and checked independently by the second. Whenever possible investigators were asked to provide additional data for pooled analysis using the pre-specified outcome measures. The primary measure of effectiveness is parasite clearance and clinical cure at day 7. Depending on data available, parasite clearance on day 7 was compared in all patients, counting those with a positive blood smear and those who were not evaluable as failures. Due to increasing loss to follow-up over time, parasite clearance beyond day 7 was compared in evaluable patients, including those lost to follow-up in sensitivity analyses of effects observed in evaluable patients. Analysis of single-drug treatment comparisons was restricted to selected outcomes: parasite clearance at day 7 and end of follow-up, clinical treatment failure and tolerability.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2008-08-04 16:22:26 +0100" MODIFIED_BY="[Empty name]">
<P>The risk of bias in included trials was assessed in terms of allocation concealment, generation of the allocation sequence, and inclusion of all randomised participants according to the Infectious Diseases Group guidelines.</P>
</QUALITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2008-08-04 16:19:30 +0100" MODIFIED_BY="[Empty name]">
<P>Analysis was done in Review Manager (Update Software) pooling data where appropriate. Odds ratios for dichotomous data were first calculated using the Mantel-Haenszel method (fixed effect model); the DerSimonian &amp; Laird method (random effect model) was also used if heterogeneity between studies was evident from the graphical display and the Chi square test for homogeneity. It was not possible to estimate time to parasite clearance and to fever clearance using the Kaplan-Meier procedure, as initially intended, due to lack of data. The mean difference was, therefore, calculated from reported data.</P>
<P>The following comparisons were made:</P>
<SUBSECTION>
<HEADING LEVEL="4">1. Single drug therapy</HEADING>
<P>Artemisinin drug alone versus WHO recommended standard treatment (chloroquine, amodiaquine, sulfadoxine-pyrimethamine, mefloquine, quinine, quinine + tetracycline/doxycycline).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Combination therapy</HEADING>
<P>Artemisinin drug in combination with a longer-acting antimalarial drug (mefloquine, sulfadoxine-pyrimethamine) versus the individual comparator drug.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Comparisons between artemisinin drugs</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3a. Comparisons between derivatives</HEADING>
<P>Any artemisinin derivative in a randomised comparison with any other artemisinin derivative, for each pre-specified outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3b. Comparisons between doses of the same derivative</HEADING>
<P>Includes studies where a different total dose was delivered according to the same time schedule to each treatment group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3c. Comparisons between regimens of the same derivative</HEADING>
<P>Includes studies where the same total dose was delivered differently over time to each treatment group.</P>
<P>Where significant statistical heterogeneity was found within these comparisons, with opposite direction of effect between trials or sub-groups, possible explanations were sought through exploring hypotheses addressing differences in the intervention (dose, duration, formulation/route of administration, regimen), and participants (immunity, level of parasitaemia, symptomatic/asymptomatic).</P>
<P>In comparisons of artemisinin derivatives versus existing antimalarial drugs, the effectiveness of the new drug might be greater in areas where resistance to existing drugs has been demonstrated. We pre-specified that they will be stratified according to the existing level of resistance to the comparator drug in the study area if there is heterogeneity evident in these comparisons to explore the following hypothesis:</P>
<P>The effectiveness of artemisinin drugs compared with existing treatment regimens is greater in areas where resistance to the comparator drug(s) has been demonstrated than in areas where it has not been demonstrated.</P>
<P>We pre-specified that additional appropriate subgroup analyses may be identified only through discussion of the initial tabulations with individuals on the advisory panel, provided justification was clear cut.</P>
<P>In addition to comparisons 1 to 3 above, this review summarises three other important issues (4 to 6 below):</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Effective doses: An overview of cure rates</HEADING>
<P>Although this review primarily examines randomised comparisons, we were able to look at cure rates achieved by individual regimens and draw some conclusions about dosage adequacy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Potentially important effects described in excluded studies</HEADING>
<P>Potentially important effects, such as comparisons between different routes of administration, or with less common but locally recommended standard treatment drugs, were summarised.</P>
</SUBSECTION>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-10-25 18:43:26 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2008-10-20 10:21:29 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Included study code</HEADING>
<P>In this review, each study is given a code name consisting of: 'Name of investigator, Country code, year the study was done'. If the year the study was done is not known, the publication year is given in brackets. Country codes are listed in the footnotes of the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' tables.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Studies identified</HEADING>
<P>One hundred and five potentially eligible studies were identified, of which 41 met the inclusion criteria (see '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'), 53 were excluded (see '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>') and 11 are awaiting assessment (see '<LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK>'). Twenty eight of the included studies are published in English, and one in Portuguese; one unpublished report was obtained from a drug company sponsor, and nine are unpublished data obtained from a principal investigator in Myanmar.</P>
<P>Not all patients reported in those studies included contributed to this review: five of the included studies had treatment groups that were excluded. Groups were excluded because the treatment regimens did not meet the criteria for inclusion (occurred in 4 studies) or patient numbers were questionable (occurred in 1 study).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Location</HEADING>
<P>Thirty-two of the included studies were done in South-East Asia (19 in Thailand, 4 in Viet Nam, 9 in Myanmar), two in China, six in Sub-Saharan African countries and one in South America. Nine studies included adults and children, 29 included only patients over 14 years of age, and three studies included children only.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Artemisinin drugs used</HEADING>
<P>Five different preparations of artemisinin, five of artemether and five of artesunate were reported in the included studies, and two studies used co-artemether (see Notes, Table of Included Studies for details). Ten studies (2 in Thailand, 8 in Myanmar) did not report the source of the drugs used.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Included studies</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Single drug therapy</HEADING>
<P>Eight of the included studies compared an artemisinin drug alone with WHO recommended standard treatment drugs:</P>
<UL>
<LI>Two studies compared an artemisinin derivative with chloroquine (one artesunate comparison, 103 patients; one artemether comparison, 106 patients).</LI>
<LI>Two studies compared rectal artemisinin with oral quinine (60 and 62 patients). One study compared artesunate with quinine-tetracycline (64 patients), and one study compared artesunate and artemether with quinine-tetracycline (144 patients).</LI>
<LI>Four studies compared an artemisinin derivative with mefloquine (three artesunate comparisons, 120, 101 and 85 patients; one artemether comparison, 46 patients).</LI>
<LI>One study (artesunate vs. chloroquine, above) also included a sulfadoxine-pyrimethamine treatment group (53 patients).</LI>
<LI>Two studies compared co-artemether with chloroquine (260 patients) or sulfadoxine-pyrimethamine (287 patients).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Combination therapy</HEADING>
<P>Eighteen included studies compared an artemisinin derivative in combination with mefloquine, versus either drug alone:</P>
<UL>
<LI>There were 11 comparisons with artemisinin derivative alone (one dihydroartemisinin, 50 patients; three artemisinin, 168 patients; four artesunate, 386 patients; three artemether, 347 patients).</LI>
<LI>There were twelve comparisons with mefloquine alone (one artemisinin, 240 patients; ten artesunate, 2141 patients; two artemether, 450 patients).</LI>
<LI>There was also one comparison of artemisinin plus sulfadoxine-pyrimethamine with artemisinin alone in 93 patients.</LI>
<LI>In addition, five trials that compared the same artemisinin drug treatment combined with different doses of mefloquine. One trial studied mefloquine 750 mg vs. 500 mg in combination with artemisinin (76 patients), four trials studied mefloquine 1250 mg vs. 750 mg in combination with artesunate (168, 159, 100 and 27 patients).</LI>
<LI>One other trial studied artesunate combined with mefloquine in the same doses, comparing sequential with concomitant treatment in 36 patients.</LI>
</UL>
<P>The latter two categories address questions relevant to combination therapy with mefloquine and so were included.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparisons between artemisinin derivatives</HEADING>
<P>Five of the included studies compared one artemisinin derivative with another: artemisinin with artesunate (one comparison; 40 patients), artesunate with artemether (four comparisons; 86, 97, 120 and 358 patients. Three of these comparisons included sequential mefloquine given to both groups). Artemisinin drugs were given orally in three studies, and rectally in one.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Dose, regimen</HEADING>
<P>Six studies compared different doses of artemisinin drugs delivered over the same time schedule.</P>
<UL>
<LI>Oral artemether: 360 mg/7 d vs. 640 mg/7 d (46 patients); 500 mg/5 d vs. 750 mg/7 d (111 patients).</LI>
</UL>
<UL>
<LI>Oral artesunate: 1600 mg/7 d vs. 1200 mg/5 d (91 patients); 1200 mg/3 d vs. 800 mg/3 d (34 patients); 1200 mg/5 d vs. 600 mg/5 d (in 16 patients in two arms of a trial with nine treatment groups); 440 mg/5 d vs. 280 mg/3 d (100 patients).</LI>
</UL>
<P>Two studies compared different treatment regimens using the same total dose of artesunate delivered differently over time: 600 mg over 1, 2 or 5 days in 20 patients (in three treatment groups of the nine-arm trial above) and 600 mg daily or twice-daily over 5 days in 59 patients respectively.</P>
</SUBSECTION>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-10-20 10:36:55 +0100" MODIFIED_BY="[Empty name]">
<P>Methodological criteria were graded A, B or C, in descending order, according to the Cochrane Infectious Diseases Group standard guidelines for assessing trial quality.</P>
<SUBSECTION>
<HEADING LEVEL="3">Allocation concealment</HEADING>
<P>Of the 41 included studies, allocation concealment as reported was adequate (Grade A) in only two, inadequate in 9 (alternate allocation) and not clearly described in the other 30.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Blinding</HEADING>
<P>Four studies were reported as double-blind, although in one of these, patients in one group were given treatment daily whereas in the other group it was given twice-a-day. Two studies reported that patients were blinded, yet both compared a 3-day with a 5-day treatment regimen. One study specified that parasitological outcomes were blinded. A further eleven studies were described as open or open-label. The remaining 21 studies did not report on blinding, however, in 19 of these blinding would not be possible because of differences in the drug, regimen or route of administration between the treatment groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Generation of allocation sequence</HEADING>
<P>All 41 studies were reported as randomised; 23 did not specify the method used, 8 reported using either computer generated random numbers or random numbers tables, one reported using a lottery of the first three patients then repeating the same sequence, and nine studies were pseudo-randomised by alternate allocation.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Inclusion of all randomised participants</HEADING>
<P>Thirty-one of the included studies reported on exclusions and/or loss to follow-up. Thirteen reported that less than 10% of enrolled patients were not evaluable for all outcomes (proportionate loss per treatment group differed by more than 10% in four of these studies). In 11 studies 10-15% of enrolled patients were not evaluable at the end of follow-up (with a disproportionate percentage loss per group in three). In six studies, between 16 and 23 % of enrolled patients were not evaluable for all outcomes. One study reported a 73% loss to follow-up at day 28. For eight unpublished studies we have only outcome data and no details on exclusions or loss to follow-up, although these were military hospital studies where losses to follow-up are usually few.</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-10-25 18:43:26 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1. Single drug therapy</HEADING>
<P>This review includes nine studies in which artemisinin drugs alone were compared with WHO recommended standard treatment drugs for uncomplicated falciparum malaria.</P>
<SUBSECTION>
<HEADING LEVEL="4">Parasite clearance</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Chloroquine</HEADING>
<P>Chloroquine was the comparator drug in two studies, each in just over 100 Tanzanian or Nigerian adults and children. Parasite clearance at day 7 was markedly better with artesunate in Nigeria (OR 61.04, 95%CI 7.82, 476.76) and artemether in Tanzania (OR 7.52, 95%CI 2.59, 21.85). The comparative advantage of the artemisinin drugs remained at the end of follow-up, 14 days in one study and 28 days in the other.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Quinine</HEADING>
<P>Artemisinin suppositories (same manufacturer) were compared in two studies with oral quinine in a total of 122 Vietnamese adults and children at the same centre. Adults were given 2800 mg artemisinin over 3 days, whilst children received 600 to 1200 mg based on age. Quinine was given for 14 and 10 days respectively. Parasite clearance at day 7 was better with artemisinin (OR 13.70, 95% CI 1.79, 105.06, fixed effect model). The size of the effect was notably different in the two studies, markedly significant in adults, but not in children. By day 28, there was still no difference in children, however, loss to follow-up exceeded 70% in both treatment groups. In adults the benefit shifted in favour of quinine (OR 0.57, 95% CI 0.18, 1.79, fixed effect model) due to a higher rate of recrudescence in the artemisinin group; this effect was stable to sensitivity analysis counting the 20% loss to follow-up as successes or failures.</P>
<P>One study in Thailand showed no difference in parasite clearance, at day 7 or day 28, between quinine-tetracycline (7 days standard treatment) and 700 mg artesunate over 5 days (in 102 patients) or 800 mg artemether over 5 days (in 89 patients).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Mefloquine</HEADING>
<P>Mefloquine was the comparator drug in five studies, four in South-East Asia and one in Brazil. One comparison in Thailand used oral artemether 700 mg, another used 800 mg, over 5 days. Three comparisons used 600 mg oral artesunate over 5 days, one used 700 mg over 5 days (Thailand and Myanmar), and one used 1000 mg over 4 days (Brazil).</P>
<P>Parasite clearance at day 7 was reported in the two comparisons of artemether with mefloquine in Thailand. No difference was shown overall (OR 1.41, 95% CI 0.05, 42.18), although one study tended to favour artemether and the other mefloquine.</P>
<P>At day 28, artemether was significantly more effective in evaluable patients in one study (OR 10.889, 95% CI 0.99, 119.25), but not when losses to follow-up were counted as failures (OR 2.90, 95% CI 0.63, 13.39). The second study showed no difference in parasite clearance at day 28.</P>
<P>Artesunate was not shown to be better than mefloquine at day 7, nor at day 28 in evaluable patients in three studies (OR 0.98, 95% CI 0.49, 1.95, fixed effect model), nor on intention-to-treat analysis (less than 10% loss to follow-up). The Brazilian study reported parasite clearance at day 35 and also found no difference between the treatment groups (45/50 artesunate, 46/51 mefloquine) (<LINK REF="STD-CardosoBRZ93_x002d_4" TYPE="STUDY">CardosoBRZ93-4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Sulfadoxine-pyrimethamine</HEADING>
<P>this was a comparator drug in one artesunate study in Nigeria. Artesunate was significantly better at clearing parasites by day 7 (OR 21.08, 95% CI 2.67, 166.68) and the comparative advantage remained to the end of the 14 day follow-up.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Clinical treatment failure</HEADING>
<P>In the Nigerian study, four patients were withdrawn from the sulfadoxine-pyrimethamine group after self-administering other antimalarial drugs because of poor clinical improvement within 24-48h of starting treatment in the study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Tolerability</HEADING>
<P>All adverse events reported were mild and transient, none resulted in discontinuation of treatment. Dizziness tended to be more frequent with mefloquine than with artesunate or artemether. Nausea, dizziness and ringing in the ears (tinnitus) was more common in quinine-treated patients, although a few artemether patients also experienced nausea and dizziness. No difference in vomiting was observed between artesunate and mefloquine in three studies. No artemether patient vomited compared to one third of mefloquine-treated patients in one study, whereas the other study comparing these drugs showed no difference. Slowing of the heart rate (bradycardia) was more common with artemether (5/12) than mefloquine (10/34) in one study reporting this outcome. All these studies were in adults.</P>
<P>Itching was more commonly associated with chloroquine than artemisinin drugs. Abdominal pain and diarrhoea affected a similar number of artemether and mefloquine patients. No adverse effect on blood cell count or chemistry was reported with artemether compared with chloroquine or mefloquine.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Summary</HEADING>
<UL>
<LI>Artesunate and artemether clear malaria parasites from the blood more effectively than the standard first-line drugs chloroquine and sulfadoxine-pyrimethamine in Tanzania and Nigeria.</LI>
</UL>
<UL>
<LI>In South-East Asia, artemisinin drugs tend to be more effective by day 7, although different comparator drugs were used in studies with artemisinin (versus quinine), artemether and artesunate (versus mefloquine). On day 28, however, there appears to be no difference between the artemisinin drugs and the comparator drugs. The same was noted in Brazil at day 35 follow-up.</LI>
</UL>
<UL>
<LI>It is worth noting that the day 28 cure rates with artemether and artesunate in the South-East Asian studies between 1989 and 1994, calculated on an intention-to-treat basis, are less than 85%, and varied between 67 and 91% with mefloquine. In contrast, both artesunate and mefloquine were highly effective in Brazil in 1994-5.</LI>
</UL>
<UL>
<LI>Single-agent treatment with artemisinin drugs appears to be well tolerated. Dizziness was notably less common than with mefloquine or quinine.</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">1b. Co-artemether studies</HEADING>
<P>This review includes 2 published studies of co-artemether.</P>
<SUBSECTION>
<HEADING LEVEL="4">Chloroquine</HEADING>
<P>Chloroquine was the comparator drug in one study in 260 children in Tanzania. Parasite clearance at day 7 and day 14 was achieved far more successfully with co-artemether than with chloroquine. However, it is clear that chloroquine was alarmingly ineffective in this trial and therefore, of questionable value as a useful (or ethical) comparator to the new drug in the study area. Co-artemether achieved 84% cure rate by day 7, and 73 to 88% (counting losses to follow-up as failures then as successes) at day 14.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sulfadoxine-pyrimethamine</HEADING>
<P>Sulfadoxine-pyrimethamine was the comparator drug in one study in 287 children in The Gambia. No difference was shown in parasite clearance at day 4 (OR 1.42, 95% CI 0.63, 3.20) based on intention-to-treat analysis. At day 15 there was no difference in parasite clearance in evaluable patients (OR 0.33, 95% CI 0.09, 1.29), nor when all losses to follow-up were included as successes (OR 0.36, 95% CI 0.09, 1.40). When all losses to follow-up were analysed as treatment failures the odds ratio favoured sulfadoxine-pyrimethamine (OR 0.48, 95% CI 0.26, 0.91). Co-artemether cleared parasitaemia faster than sulfadoxine-pyrimethamine (PC50 11.6h, 95% CI 10.8 to 12.3, compared with 21.1h, 95% CI 17.3 to 25.0).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Combination therapy</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">2a. Comparison with mefloquine alone</HEADING>
<P>Eleven studies described 13 comparisons of artemisinin drug-mefloquine combination compared with mefloquine alone: one used artemisinin (240 patients), two artemether (450 patients) and ten artesunate (2141 patients). Nine out of the ten studies were done in South-East Asia, one in Brazil.</P>
<P>Treatment regimens varied considerably between studies. The artemisinin and artemether studies, and 7/10 artesunate studies, gave the same dose of mefloquine to both treatment groups within each study. The other three artesunate studies increased the dose of mefloquine when it was given alone. Mefloquine was given to the combination treatment group at the start of artemisinin drug treatment (concomitant) in four comparisons and on completion of artemisinin drug treatment (sequential) in the other nine. Combination-treated patients received mefloquine before day 7 in all studies. (See Interventions, Table of included studies).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Parasite clearance</HEADING>
<P>Day 7: the artemisinin and artemether studies, and 8 artesunate studies reported parasite clearance at day 7. All favoured combination treatment over mefloquine alone (pooled OR 2.58, 95% CI 1.67, 3.13, fixed effect model).</P>
<P>Day 28: at day 28, parasite clearance was significantly better in patients given artemisinin-mefloquine, based on one study in 228 patients, with less than 5% loss to follow-up.</P>
<P>Artemether with mefloquine was more effective in evaluable patients (OR 19.36, 95% CI 6.81, 55.01) in the largest of the two studies (311 patients), even when the 27% of patients lost to follow-up were counted as failures (OR 3.04, 95% CI 1.89, 4.89). The smaller study (76 patients) showed a non-significant tendency in favour of mefloquine. Pooling the data using a random effect model showed no overall difference between treatments (OR 3.08, 95% CI 0.05, 191.18). The wide confidence interval reflects the marked difference in effect between these studies. Both were conducted in Thailand and used artemether from the same source (Kunming) in equivalent doses. The former study gave artemether over 3 days, the latter over 2 days.</P>
<P>Parasite clearance at day 28 was reported in 9 artesunate comparisons, and at day 35 in the tenth. Loss to follow-up was around 10-20% per group, with none in two studies. Analysis of patients evaluable on day 28 showed a tendency to favour combination therapy in seven out of 9 comparisons, significant in five. The overall odds ratio favours artesunate-mefloquine treatment (OR 4.03, 95%CI 1.58, 10.23, random effect model). The difference is still significant if patients lost to follow-up are included as failures. Two studies tended to favour mefloquine alone, however, the difference between the treatment groups was not significant. The study with 35-day follow-up also favoured mefloquine alone, but again the difference between treatment groups was not significant in 88 evaluable patients nor on intention-to-treat analysis (<LINK REF="STD-CardosoBRZ93_x002d_4" TYPE="STUDY">CardosoBRZ93-4</LINK>). Over all, parasite clearance in patients followed-up for 28 days was significantly better in those treated with a combination of artemisinin drug and mefloquine compared with those given only mefloquine (OR 4.05, 95% CI 1.88, 8.73, random effect model), based on 12 comparisons (2148 patients).</P>
<P>Parasite clearance time: eight out of 11 studies (9 comparisons) reported time to clearance of parasites from the blood. The artemisinin study reported mean and standard deviation, the artemether study reported median and range derived from survival analysis. Four artesunate comparisons reported mean and standard deviation, one reported median and range, two reported percentile ranges, and two did not report this outcome. Our meta-analysis of mean difference in parasite clearance time for all five studies reporting mean and standard deviation shows that parasites are cleared faster when artemisinin or artesunate is combined with mefloquine compared with mefloquine given alone, regardless of variation in the treatment regimen used in different studies (MD -20.70 hours, 95% CI -36.21, -6.48, random effect model). A similar effect was shown in the study using survival analysis (<LINK REF="STD-PriceTHI_x002d_MYA93_x002d_4" TYPE="STUDY">PriceTHI-MYA93-4</LINK>, reported P&lt;0.0001) and the study reporting percentiles (<LINK REF="STD-Nosten_x005b_1_x005d_THI_x002d_MYA92_x002d_3" TYPE="STUDY">Nosten[1]THI-MYA92-3</LINK>; <LINK REF="STD-Nosten_x005b_2_x005d_THI_x002d_MYA92_x002d_3" TYPE="STUDY">Nosten[2]THI-MYA92-3</LINK>, reported P &lt;= 0.001). Only one artesunate study reported the mean time to 50% and 90% parasite clearance, the rate was twice as fast in patients treated with artesunate and mefloquine compared with mefloquine alone.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Fever clearance</HEADING>
<P>Eight out of 11 studies (9 comparisons) reported time to clearance of fever. Data were reported in the different studies as described under parasite clearance time. We present a meta-analysis of mean difference in fever clearance time for all five studies reporting mean and standard deviation. It shows that fever resolves faster when an artemisinin drug is combined with mefloquine compared with mefloquine given alone, regardless of variation in the treatment regimen used in different studies (MD -10.40 hours, 95% CI -18.08, 2.73, random effect model). This pooled MD needs to be interpreted with some caution because the different effect sizes across studies reflect heterogeneity in study design. Furthermore, not all studies reporting mean and standard deviation are explicit about the number of patients evaluated, and there is evidence of a skewed distribution in most of the reported data (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>). Survival analysis is more appropriate for time-to data, one study used it and showed time to fever clearance was significantly faster in patients given artemether or artesunate with mefloquine (<LINK REF="STD-PriceTHI_x002d_MYA93_x002d_4" TYPE="STUDY">PriceTHI-MYA93-4</LINK>). Similarly, the study reporting percentiles showed a faster response when artesunate was given with mefloquine (<LINK REF="STD-Nosten_x005b_1_x005d_THI_x002d_MYA92_x002d_3" TYPE="STUDY">Nosten[1]THI-MYA92-3</LINK>; <LINK REF="STD-Nosten_x005b_2_x005d_THI_x002d_MYA92_x002d_3" TYPE="STUDY">Nosten[2]THI-MYA92-3</LINK>). The remaining study reported the number of patients who's fever had resolved within 48 hours of starting treatment, 98% (259/265) on artesunate-mefloquine and 90% (241/269) on mefloquine only (P = 0.0002) (<LINK REF="STD-LuxemburgerTHI_x002d_MYA91" TYPE="STUDY">LuxemburgerTHI-MYA91</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Clinical treatment failure</HEADING>
<P>Clinical treatment failure was reported in two studies: in the artemisinin study one patient in each group was given alternative treatment within 48 hours because of no clinical improvement under the allocated regimen (<LINK REF="STD-HungVNM93_x002d_4" TYPE="STUDY">HungVNM93-4</LINK>), in one artesunate study one patient on combination treatment took quinine as self-treatment (<LINK REF="STD-LuxemburgerTHI_x002d_MYA91" TYPE="STUDY">LuxemburgerTHI-MYA91</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adherence</HEADING>
<P>One study reported that one patient did not come back for the last of three doses of artesunate in the combination treatment group (<LINK REF="STD-LuxemburgerTHI_x002d_MYA91" TYPE="STUDY">LuxemburgerTHI-MYA91</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Tolerability</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Major adverse effects</HEADING>
<P>Neuropsychiatric effects were reported in three studies conducted in similar populations in the same area. One mefloquine-only treated patient suffered acute psychosis, recovering without additional treatment in one study (<LINK REF="STD-Nosten_x005b_1_x005d_THI_x002d_MYA92_x002d_3" TYPE="STUDY">Nosten[1]THI-MYA92-3</LINK>; <LINK REF="STD-Nosten_x005b_2_x005d_THI_x002d_MYA92_x002d_3" TYPE="STUDY">Nosten[2]THI-MYA92-3</LINK> ); in another study, one artesunate-mefloquine treated patient suffered acute psychosis, and another developed a depressive syndrome, both resolved untreated (<LINK REF="STD-LuxemburgerTHI_x002d_MYA91" TYPE="STUDY">LuxemburgerTHI-MYA91</LINK>); in the third study, one patient suffered anxiety, palpitations and sleep disturbance one week after combination treatment with artesunate-mefloquine, one epileptic patient given artemether-mefloquine experienced fits (first for 10 years) 24 hours after mefloquine treatment, and one patient in the mefloquine-only group suffered psychosis, delusions and hallucinations requiring hospitalisation and sedation (<LINK REF="STD-PriceTHI_x002d_MYA93_x002d_4" TYPE="STUDY">PriceTHI-MYA93-4</LINK>). No other study reported evidence of neurotoxicity.</P>
<P>Severe vomiting was the only adverse event that resulted in discontinuation of treatment. This was reported in four studies. Notably, two studies gave mefloquine sequentially and two concomitantly. The number of events in each study is small (4/834 artesunate-/artemether-mefloquine, 11/657 mefloquine-only), and all tend to favour combination therapy (OR 0.39, 95% CI 0.14, 1.10, fixed effect model).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Mild adverse effects</HEADING>
<P>Vomiting of treatment drugs in patients who tolerated retreatment was reported as an adverse event in 10 studies. Eight reported data that we were able to include in a meta-analysis. All of these studies gave mefloquine sequentially to the combination treatment group. Two reported vomiting when the combination group had been given only the artemisinin drug (early vomiting) compared with mefloquine in the other group, and also vomiting after the combination group had been given both drugs (late vomiting). The other 5 studies simply reported vomiting.</P>
<P>Early vomiting was significantly less common with sequential mefloquine treatment in the larger of the two studies reporting this outcome with either artesunate or artemether (<LINK REF="STD-PriceTHI_x002d_MYA93_x002d_4" TYPE="STUDY">PriceTHI-MYA93-4</LINK>). Late vomiting was similar in both treatment groups. The 5 studies that simply reported vomiting showed no difference between treatment groups. One of the remaining two studies reported that artesunate with concomitant mefloquine made early vomiting less likely compared with mefloquine alone, and that late vomiting was similar in both treatment groups. The last study reported two trials, one using sequential mefloquine (<LINK REF="STD-Nosten_x005b_1_x005d_THI_x002d_MYA92_x002d_3" TYPE="STUDY">Nosten[1]THI-MYA92-3</LINK>) and one concomitant (<LINK REF="STD-Nosten_x005b_2_x005d_THI_x002d_MYA92_x002d_3" TYPE="STUDY">Nosten[2]THI-MYA92-3</LINK>). The study report aggregates the adverse events data for all mefloquine-only treated patients as one group, although the two trials are separate randomised comparisons.</P>
<P>Nausea was reported in 8 studies. Five reported data for pooled analysis that showed a tendency to favour combination treatment (OR 0.67, 95% CI 0.42 to 1.07, random effect model). Two of the other studies reported nausea as a more frequent complaint of patients treated with mefloquine alone, and the third reported no difference between treatment groups.</P>
<P>Dizziness was reported in seven studies, four with data. The data showed no difference between treatment groups. Two other studies reported more dizziness, associated with nausea, in mefloquine-only treated patients. One study stratified patients according to dizziness before treatment and found no difference between them after treatment (<LINK REF="STD-PriceTHI_x002d_MYA93_x002d_4" TYPE="STUDY">PriceTHI-MYA93-4</LINK>).</P>
<P>No difference in diarrhoea or abdominal pain was shown between treatment groups in five studies recording these outcomes. Other adverse effects including headache, rash and arthralgia (joint pain) were reported infrequently and were not shown to be associated with any particular treatment. No abnormalities in haematology or blood chemsitry were reported.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Summary</HEADING>
<P>We can summarise our review of combination artemisinin drug-mefloquine compared with mefloquine alone as follows:</P>
<UL>
<LI>Nine out of 11 studies were done in South-East Asia and one in Brazil between 1991 and 1994, all reported as areas of multidrug resistant falciparum malaria.</LI>
</UL>
<UL>
<LI>No two studies compared the same treatment regimens, either single-agent or combination.</LI>
</UL>
<UL>
<LI>The data are consistent with a conclusion that parasite clearance is achieved earlier and faster, and is better at day 28 or 35 follow-up, with combination regimens compared with mefloquine alone.</LI>
</UL>
<UL>
<LI>Keeping in mind deficiencies in reporting of fever clearance data in some studies and a mixed pattern of effect size across different studies, the available data show that fever clearance is improved by combining mefloquine with an artemisinin derivative.</LI>
</UL>
<UL>
<LI>Neuropsychiatric adverse reactions were suffered by six patients given mefloquine, either alone or in combination with an artemisinin drug. Severe vomiting is less common with combination treatment regimens, although numbers are small. Data on dizziness are inconclusive.</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2b. Comparison with artemisinin drug alone</HEADING>
<P>There were 11 comparisons in 10 studies of artemisinin drug-mefloquine combination compared with artemisinin drug alone, one using dihydroartemisinin (50 patients), three artemisinin (168 patients), four artesunate (386 patients), and three artemether (347 patients). Seven out of the 10 studies were done in South-East Asia, one in China, one in Brazil and one in Tanzania.</P>
<P>In eight out of nine studies, a shorter, lower dose combination regimen was compared with a longer, higher dose single-drug regimen. The treatment regimens used in each study were all different from each other. Mefloquine was given to the combination treatment group concomitantly in 3 studies and sequentially in the other seven. Combination-treated patients received mefloquine before day 5 in all ten studies. (See Interventions, Table of included studies).</P>
<SUBSECTION>
<HEADING LEVEL="4">Parasite clearance</HEADING>
<P>Day 7: parasite clearance at day 7 was reported in one artemisinin study, two artesunate studies and three using artemether. There was no difference between the treatment groups in any study (data not shown).</P>
<P>Day 28: All three artemisinin studies reported parasite clearance at day 28, all favoured combination treatment in evaluable patients (OR 5.96, 95% CI 2.40, 14.76, fixed effect model). Including all losses to follow-up as failures does not affect the direction of the result. Consistent regimens of single-agent artemisinin were used (2500-3000 mg over 3-5 days). However, such doses of single-agent artemisinin, although in line with current WHO recommendations (10 mg/kg/d for 5 days; <LINK REF="REF-WHO-1996" TYPE="REFERENCE">WHO 1996</LINK>), did not achieve adequate cure rates in these studies. In comparison, short-course or single dose artemisinin (1000 or 2000 mg) cleared parasitaemia in all patients at follow-up when combined with 750 mg mefloquine (15 mg/kg) in China and Tanzania. In the Viet Nam study, however, a single dose of 500 mg artemisinin plus 500 mg mefloquine achieved a cure rate of only 85% (<LINK REF="STD-HienVNM_x0028_94_x0029__x005b_1_x005d_" TYPE="STUDY">HienVNM(94)[1]</LINK>).</P>
<P>In the three artesunate studies reporting 28 day follow-up there is a marked difference in the direction of effect in evaluable patients: significantly in favour of combination (<LINK REF="STD-LooareesuwanTHI91" TYPE="STUDY">LooareesuwanTHI91</LINK>; <LINK REF="STD-ThimasarnTHI93_x002d_4" TYPE="STUDY">ThimasarnTHI93-4</LINK>) and non-significantly in favour of artesunate alone [Karbwang THI 92c]. Intention-to-treat analysis (worst and best case) does not change the opposite direction of effect. Consistent regimens of single-agent artesunate were given in these two studies conducted in Thailand and are in line with current WHO recommendations (2 mg/kg/d for 5 days; <LINK REF="REF-WHO-1996" TYPE="REFERENCE">WHO 1996</LINK>). However, very different combination regimens were used; short course (1 day), low dose (300 mg) artesunate plus 750 mg mefloquine is apparently inadequate (<LINK REF="STD-KarbwangTHI92c" TYPE="STUDY">KarbwangTHI92c</LINK>). The Brazilian artesunate study reported a similar finding at day 35 with the combination of 600 mg artesunate over 2 days plus 500 mg mefloquine (<LINK REF="STD-CardosoBRZ93_x002d_4" TYPE="STUDY">CardosoBRZ93-4</LINK>).</P>
<P>With artemether, one study used 700 mg over 5 days single-agent, one used 800 mg over 5 days, and the third tested two doses of artemether in different treatment groups: 500 mg over 5 days and 750 mg over 7 days (<LINK REF="STD-LooareesuwanTHI92b" TYPE="STUDY">LooareesuwanTHI92b</LINK>). The lower dose in the latter study is less than the current WHO recommendation (2 mg/kg/d for 5 days; <LINK REF="REF-WHO-1996" TYPE="REFERENCE">WHO 1996</LINK>) for any adult weighing over 50kg. When we combined all single-agent artemether groups for analysis, combination with mefloquine appeared to be superior to artemether alone (graph not shown). However, separating the high and low dose groups in the Looareesuwan study shows that the difference is due only to the treatment group that received the lower dose in that study (Looareesuwan 500 mg: OR 4.05, 95% CI 1.47, 11.18, fixed effect model; OR 3.47, 95%CI 0.82, 14.78, random effect model). Pooled analysis of only the high dose groups (700, 750 and 800 mg) showed no advantage over combination treatment (Looareesuwan 750 mg: OR 1.66, 95% CI 0.52, 5.25, fixed effect model) in parasite clearance at day 28 follow-up.<BR/>
<BR/>Parasite clearance time: nine studies reported time to clearance of parasites from the blood. One of three studies with artemisinin reported mean and standard deviation, this data was obtained for another study from the investigator, and we estimated a standard deviation in the third study from the reported 95% confidence intervals. Our graph of mean difference in parasite clearance time shows marked heterogeneity between the studies. Parasite clearance was achieved significantly faster in patients treated with artemisinin alone in one study, and with artemisinin-mefloquine combination in another (although time to 50% clearance was similar in both groups), the third artemisinin study showed no difference between the treatment groups in time to 50, 90 or 100% parasite clearance. The treatment regimens used in these studies are diverse (see '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'). There is no evident pattern of effect in relation to sequential or concomitant mefloquine.</P>
<P>One artemether study reported mean and standard deviation, this data was obtained for the other study from the investigator. In the study with two artemether treatment groups (500 and 750 mg) we combined the data from both groups as they were almost identical and used a mean value and the largest standard deviation for analysis. Although neither study showed a significant difference in parasite clearance time, the direction of effect was opposite.</P>
<P>Two of three studies using artesunate reported mean and standard deviation and this data was obtained for the third study from the investigator. These studies show a consistent, but not significant, trend in favour of artesunate-only, although again the treatment regimens vary.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Fever clearance</HEADING>
<P>Nine studies reported time to clearance of fever. Data were reported or obtained for the different studies as described under parasite clearance time. We present a graph of mean difference in fever clearance time using mean and standard deviations. It shows marked heterogeneity between studies which cautions against pooling the data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Clinical treatment failure</HEADING>
<P>No cases of clinical treatment failure were reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Tolerability</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Major adverse effects</HEADING>
<P>No adverse event that resulted in discontinuation of treatment was reported.</P>
<P>Only one neuropsychiatric event was reported, one patient treated with artemisinin-mefloquine developed a psychiatric syndrome including restlessness and sleep disturbance one week after treatment, this resolved two weeks later (<LINK REF="STD-AlinTAZ94" TYPE="STUDY">AlinTAZ94</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Mild adverse effects</HEADING>
<P>Vomiting of treatment drugs was reported as an adverse event in 6 studies that overall showed more vomiting in patients given combination treatment with mefloquine compared with the artemisinin drug alone (OR 1.89, 95% CI 1.07, 3.34). In five of these studies mefloquine was given sequentially to the combination treatment groups, the fifth study is not explicit about this. Vomiting of the first drug was reported only in one artesunate study that showed no difference between treatment groups. Nausea was reported in 2 studies. It was twice as common in the combination treatment group compared with the artemether group in one study, and associated with vomiting in the other.</P>
<P>Diarrhoea was reported in 6 studies. The heterogeneity in direction of effect could be due to the various artemisinin derivatives used. Only one study showed a marked higher incidence in patients treated with artemether for 5 days compared with a single dose of artemether plus mefloquine (<LINK REF="STD-KarbwangTHI93" TYPE="STUDY">KarbwangTHI93</LINK>).</P>
<P>Other adverse effects including headache, rash and arthralgia (joint pain) were reported infrequently and were not shown to be associated with any particular treatment. No abnormalities in haematology or blood chemsitry were reported.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Summary</HEADING>
<P>We can summarise our review of combination artemisinin drug-mefloquine compared with artemisinin drug alone as follows:</P>
<UL>
<LI>Seven out of ten studies were done in South-East Asia, one in Brazil and one in Tanzania between 1991 and 1994; one was done in China in 1982-4. Multidrug resistant falciparum malaria occurs in South-East Asia and Brazil.</LI>
</UL>
<UL>
<LI>No two studies compared the same treatment regimens, either single-agent or combination.</LI>
</UL>
<UL>
<LI>The data are consistent with a conclusion that giving mefloquine with an artemisinin drug does not result in earlier parasite clearance compared with the artemisinin drug alone.</LI>
</UL>
<UL>
<LI>We conclude from the available data that sustained parasite clearance is better when mefloquine is combined with an artemisinin derivative, as long as the dose and duration of combination treatment is adequate.</LI>
</UL>
<UL>
<LI>The available data on fever clearance are inconclusive.</LI>
</UL>
<UL>
<LI>Only one neuropsychiatric adverse reaction was reported in a patient treated with artemisinin-mefloquine.</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Combination mefloquine dose/schedule</HEADING>
<P>In Thailand, a significant advantage in parasite clearance at day 28 was shown when a 300 mg single dose of artemether was combined with 1250 mg mefloquine rather than 750 mg mefloquine (<LINK REF="STD-BunnagTHI92_x002d_4a" TYPE="STUDY">BunnagTHI92-4a</LINK>; <LINK REF="STD-KarbwangTHI93_x002d_4" TYPE="STUDY">KarbwangTHI93-4</LINK>). However, it is worth noting that the author of one of these studies reported a considerably better success rate for the same 750 mg mefloquine-artemether combination in another study (with the same inclusion criteria in the same year) where the combination was shown to be superior to artemether alone (<LINK REF="STD-KarbwangTHI93" TYPE="STUDY">KarbwangTHI93</LINK>). The other 2 studies in Thailand failed to show a difference in parasite clearance at day 28 between 750 mg artemether combined with 500 or 750 mg mefloquine, or between 600 mg artesunate combined with 750 or 1250 mg mefloquine.</P>
<P>In Myanmar, a single 400 mg dose of artesunate combined with either 750 mg or 1250 mg mefloquine achieved only 50% cure rates at day 42 follow-up in 1997.</P>
<P>Only one small Myanmar study (36 patients) compared 600 mg artesunate over 3 days with sequential versus concomitant mefloquine (500 mg) and reported a higher parasitaemia cure rate in the concomitant group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2c. Artemisinin drug in combination with sulfadoxine-pyrimethamine</HEADING>
<P>One study compared a combination of artemisinin (500 mg single dose) and sulfadoxine- pyrimethamine (SP) with artemisinin alone (2500 mg/5 d) in Viet Nam (<LINK REF="STD-HienVNM_x0028_94_x0029__x005b_1_x005d_" TYPE="STUDY">HienVNM(94)[1]</LINK>). At day 28, artemisinin alone tended to be better in terms of parasite clearance than the combination regimen, but the difference was not statistically significant in 74 patients. Parasite and fever clearance times were similar. There were no patient-reported adverse events. More importantly, neither treatment regimen achieved adequate cure rates (even on intention-to-treat analysis counting losses to follow-up as successes).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Comparisons between artemisinin drugs</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">3a. Comparisons between derivatives</HEADING>
<P>Five studies compared one artemisinin derivative with another: oral artemisinin with artesunate; oral artemether with artesunate, both combined with mefloquine; and rectal artemether with artesunate.</P>
<P>Parasite clearance at day 7 and 28 was similar in both groups in all studies. Parasite clearance and fever clearance time was reported in three studies, in one as mean and standard deviation, in another as mean and standard error (we estimated standard deviation as standard error multiplied by square root sample size), and in the third as mean and range. No study showed a significant difference between the artemisinin derivatives used (caution, as described earlier, regarding meta-analysis of this time-to data applies). There were no cases of clinical treatment failure.</P>
<P>Two studies in which patients were treated with artemisinin derivatives only, reported that there were no adverse effects. Three artesunate versus artemether studies in which mefloquine was also given to all patients reported vomiting, nausea and other mild adverse events affecting similar numbers of patients in both treatment groups. In one of these studies, one patient in each treatment group suffered a neuropsychiatric reaction.</P>
<SUBSECTION>
<HEADING LEVEL="5">Summary</HEADING>
<UL>
<LI>The WHO recommended dose of both artemisinin and artesunate monotherapy produced inadequate cure rates in Tanzania.</LI>
</UL>
<UL>
<LI>Both artemether and artesunate (300 mg single dose and 600 mg over 3 days) appear to be effective in Thailand when combined with 1250 mg mefloquine. However, the effectiveness of the single dose of artemisinin drug here is not consistent with other studies using similar regimens (see summary, Artemisinin drug in combination with mefloquine, comparison with artemisinin drug alone, Results, section 2b.).</LI>
</UL>
<UL>
<LI>No study has shown one derivative to be better than the others.</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3b. Comparisons between doses of the same derivative</HEADING>
<P>One study in Thailand compared 1200 mg artesunate with 600 mg over five days (<LINK REF="STD-BunnagTHI89a" TYPE="STUDY">BunnagTHI89a</LINK>). This comparison included only 16 patients and did not show any difference in clinical or parasitological outcome. The only notable adverse event reported was a transient reduction in white blood cell count with the higher dose. A more recent study at the same centre compared 1600 mg/7 days with 1200 mg/5 days showing similar cure rates (over 90% at follow-up) and low incidence of dizziness and nausea in both groups (<LINK REF="STD-LooareesuwanTHI95" TYPE="STUDY">LooareesuwanTHI95</LINK>). In the following year in Myanmar, the cure rate was 80-90% with 800 mg/3 days and 1200 mg/3 days in 34 patients.</P>
<P>In China in 1987, 440 mg artesunate over 5 days was effective, but not when treatment stopped at 280 mg after 3 days.</P>
<P>One study comparing artemether combination with mefloquine alone had two groups treated with artemether alone, 500 mg over 5 days and 750 mg over 7 days by continuing the same treatment schedule for an additional 2 days (<LINK REF="STD-LooareesuwanTHI92b" TYPE="STUDY">LooareesuwanTHI92b</LINK>). Only the higher dose was adequate, resulting in a 98% cure rate at follow-up compared with 74% of patients in the lower dose group.</P>
<P>One study in Myanmar compared oral artemether 360 mg and 640 mg given over 7 days. Both regimens were similarly ineffective, achieving only 60% parasite clearance (<LINK REF="STD-ThanMYA93c" TYPE="STUDY">ThanMYA93c</LINK>).</P>
<P>3c. Comparisons between regimens of the same derivative<BR/>Two studies compared the same total dose of artesunate delivered differently over time. One compared 600 mg given in daily or twice-daily doses over 5 days in 59 patients (<LINK REF="STD-BunnagTHI89b" TYPE="STUDY">BunnagTHI89b</LINK>). The other study compared 600 mg given over 1, 2 or 5 days in three treatment groups (20 patients) of a nine-arm trial (<LINK REF="STD-BunnagTHI89a" TYPE="STUDY">BunnagTHI89a</LINK>). Neither study showed any difference between the treatment groups in any measured outcome of effectiveness or tolerability.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4. Dosage adequacy</HEADING>
<P>Our graphs of parasite clearance show the cure rate achieved in each treatment group in each study at follow-up. Grouping the studies as we have done in this review shows which single-agent and combination treatment regimens appear to be effective and which are not. To achieve at least 90% cure rate at follow-up at least 3 days treatment with an artemisinin derivative is needed when it is combined with a high dose of mefloquine (1250 mg). Shorter regimens with lower doses of mefloquine are not effective. For single-agent treatment with an artemisinin drug, five days treatment is not sufficient to reliably achieve 90% cure rate anywhere in comparative trials with combination therapy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">5. Potentially important effects described in excluded studies</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Oral versus rectal route</HEADING>
<P>One study in 52 children in Thailand showed artesunate given rectally (15 mg/kg/day for 3 days ) was as effective and safe as oral treatment (6 mg/kg/day for 3 days) when both were combined with sequential mefloquine (25 mg/kg). Cure rates were 92-100% at 28 day follow-up (<LINK REF="STD-SabchareonTHI95_x002d_6" TYPE="STUDY">SabchareonTHI95-6</LINK>). Another pharmacokinetic study, in 30 Vietnamese adults, compared oral with rectal artemisinin (2500 mg over 5 days). This showed similar parasite clearance times despite the bioavailability of rectal artemisinin (measured in plasma) being only 30% relative to oral administration (<LINK REF="STD-Ashton-VNM-_x0028_98_x0029_" TYPE="STUDY">Ashton VNM (98)</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other combinations</HEADING>
<P>Two trials in South-East Asia studied combinations of artemisinin drugs with doxycycline and tetracycline with conflicting results. Artesunate (300 mg over 2.5 days) plus doxycycline was only 80% effective, and significantly less effective at 28 day follow-up, than mefloquine (1250 mg) plus doxycycline in Thailand (<LINK REF="STD-Looareesuwan-THI-92a" TYPE="STUDY">Looareesuwan THI 92a</LINK>). Artemether (480 mg over 5 days) combined with either doxycycline or tetracycline was highly effective in Myanmar and produced a cure rate at follow-up similar to artemether plus mefloquine (<LINK REF="STD-Than-MYA-94b" TYPE="STUDY">Than MYA 94b</LINK>).</P>
<P>In Brazil, one study compared artesunate (750 mg over 7days) plus tetracycline with quinine (6000 mg over 3 days) plus tetracycline (<LINK REF="STD-Duarte-BRZ-92_x002d_3" TYPE="STUDY">Duarte BRZ 92-3</LINK>). Both regimens were highly effective at follow-up. Patients treated with artesunate were much less affected by dizziness and tinnitus than those treated with quinine.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-10-20 10:26:29 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="2">Strength of evidence</HEADING>
<P>Around 10,000 patients were enrolled in the trials we identified as potentially eligible for inclusion in this review. After application of our inclusion criteria approximately 5240 have been included in this review. Despite the large amount of clinical research that has been done, variation in study design and quality makes synthesis of the data problematic.</P>
<P>We cannot be assured that the quality of much of this data is good. Randomisation in a trial should involve both generating an unpredicatable allocation sequence and concealing that sequence until allocation occurs; of these, allocation concealment appears to be the most important protector against bias, even more important than blinding which protects the sequence after allocation (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>). Although all of the studies included in this review reported an attempt to randomise allocation of patients to the different treatment groups, only one reported adequate measures to conceal allocation. We therefore have to assume that the twenty-eight studies that were unclearly concealed (did not report on allocation concealment) were potentially open to selection bias.</P>
<P>Most of the included studies reported something about exclusion and, or, loss of randomised patients which allowed us to perform sensitivity analyses on the effect this might have on the results. There is, however, still room for improvement in reporting of patient attrition, the reasons for it and how investigators deal with it (<LINK REF="REF-Begg-1996" TYPE="REFERENCE">Begg 1996</LINK>).</P>
<P>A funnel plot of the primary outcome measure against trial size indicated that publication bias may have influenced the findings in this review (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Applicability</HEADING>
<SUBSECTION>
<HEADING LEVEL="3">Location</HEADING>
<P>Most of the data included in this review are from studies conducted in areas of multidrug resistant falciparum malaria in South-East Asia. This is appropriate because such areas have the greatest need for artemisinin drugs. The Amazon region, where multidrug resistance is also high, is represented by only a few studies in Brazil. The data from Africa comprises a small number of studies in Tanzania and Nigeria comparing the new artemisinin drugs with standard first-line drugs to which resistance is increasing.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Population</HEADING>
<P>Children and adults are represented in the included studies, with blood slide-confirmed uncomplicated falciparum malaria as defined by the investigators. Trials enrolling both children and adults rarely stratify randomisation or report outcome data according to age. It is not clear if some artemisinin drug preparations, such as suppositories, are equally effective in children and adults at the doses used. No study has included pregnant women.</P>
<P>Malaria endemicity and transmission in the study areas or catchment areas is surprisingly not mentioned in some study reports and only in passing in others. The same applies to the immune status of the patients. This restricts decision making to regions and does not allow wider applicabilty of results to be assessed.</P>
<P>The issue of residual levels of other antimalarial drugs in the body is dealt with differently across studies and is not clarified at all in some. Resistance to other antimalarials differs in different regions, areas, populations, and with time, therefore, the potential effect of residual drugs is not constant across studies included in this review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Product</HEADING>
<P>Many formulations of artemisinin drugs are currently available on the market, produced in developed and developing countries. At least 16 different preparations are reported in the included studies. Not all of these drugs has been subject to stringent regulation during development and we cannot assume that they are equivalent in potency or safety.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Regimen</HEADING>
<P>Most data have been generated from studies using artesunate or artemether, there have been significantly fewer studies on artemisinin and very few on dihydroartemisinin. In the majority of studies artemisinin drugs were administered orally, in a few rectally, alone or in combination treatment regimens - mostly with mefloquine.</P>
<P>Differences in treatment regimens cannot be ruled out as a reason for heterogeneity between trials. Regimens vary markedly between studies in terms of dose, schedule, combinations and comparisons. Furthermore, any comparative advantage of one treatment regimen over another reported in any individual study has to be assessed in terms of cure rate which reflects the adequacy of the dose schedules used.</P>
<P>Consecutive and simultaneous studies being conducted in some centres do not appear to follow a logical path of clinical inquiry in terms of the wide range of treatment regimens being tested.</P>
<P>Adherence was hardly ever mentioned in the studies included in this review. Loss to follow-up was either reported without clarification of whether those patients had completed their treatment or not, or with the vague statement that they were lost for "reasons unrelated to their treatment". Some of the treatment regimens used in these studies lasted for a week or more. There are few data to assess how many outpatients actually complete a full treatment course.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Cost</HEADING>
<P>A full cost analysis of artemisinin drugs versus standard treatment is beyond the scope of this review, and can be done better by people developing clinical practice guidelines for national or regional implementation. An example, however, is useful.</P>
<P>The following are approximate retail prices for a full adult treatment course in Viet Nam compared with standard treatment quinine at the time of writing (March 1998) supplied by A Schapira (WHO, Hanoi):</P>
<UL>
<LI>Quinine 10,500 mg/7 d (250 mg tablet x 42) = US $0.97.</LI>
<LI>Artemisinin 3000 mg/5 d (250 mg tablet x 12) = US $ 1.06.</LI>
<LI>Artesunate 600 mg/5 d (50 mg tablet x 12) = US $0.62.</LI>
</UL>
<P>At a rural pharmacy in Lao PDR, drug prices were:</P>
<UL>
<LI>Quinine (as above) = US $1.75.</LI>
<LI>Artesunate (as above) = US $1.25.</LI>
</UL>
<P>Thus in areas of South-East Asia the price of artesunate 5 day treatment is now lower than that of quinine standard 7 day treatment, and a full course of artemisinin costs about the same as quinine.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Benefit and risk</HEADING>
<P>From this review, we can say that artemisinin drugs are effective in areas of multidrug resistance provided that the dose is adequate. Combination with an adequate dose of mefloquine can shorten the overall treatment time. There is no strong evidence from randomised trials that artemisinin drugs are harmful as measured by adverse events within a typical study period of 28 days.</P>
<P>An overview of tolerability and safety data on artemisinin drugs gathered from randomised and non-randomised controlled trials, and studies without control groups, concluded that few side effects have been reported with these compounds (<LINK REF="REF-Ribeiro-1998" TYPE="REFERENCE">Ribeiro 1998</LINK>).</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-10-20 10:20:12 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2008-10-20 10:20:12 +0100" MODIFIED_BY="[Empty name]">
<P>1. Are artemisinin drugs better than existing standard treatment for uncomplicated malaria?</P>
<UL>
<LI>Artemisinin drugs clear parasitaemia more effectively than standard treatment with chloroquine or sulfadoxine-pyrimethamine in Africa.</LI>
</UL>
<UL>
<LI>In South-East Asia and Brazil, there is no difference in sustained parasite clearance between artemisinin drugs used alone and standard treatment with quinine or mefloquine.</LI>
</UL>
<UL>
<LI>Single-agent treatment with artemisinin drugs is well tolerated. Dizziness in particular is less common than with mefloquine and quinine.</LI>
</UL>
<P>2. Do artemisinin drugs have a comparative advantage over other antimalarials in geographical areas where malaria parasites are still sensitive to existing antimalarial drugs, as well as in areas where drug resistance is high?</P>
<UL>
<LI>Data from Tanzania and Nigeria show that artemisinin drugs clear parasitaemia more effectively than standard treatment with chloroquine or sulfadoxine-pyrimethamine in areas where resistance to those drugs is increasing.</LI>
</UL>
<UL>
<LI>Most data are from areas of multidrug resistant falciparum malaria in South-East Asia and Brazil. When used alone, even at WHO recommended doses, artemisinin derivatives do not improve sustained parasite clearance compared with quinine or mefloquine standard treatment in these areas.</LI>
</UL>
<P>3. Should artemisinin derivatives be combined de novo with all first-line treatment regimens using longer-acting antimalarials?</P>
<UL>
<LI>Parasite clearance and fever clearance is achieved earlier if mefloquine is combined with an artemisinin drug compared with mefloquine alone. In areas of mefloquine resistance the combination improves sustained parasite clearance compared with either drug alone.</LI>
</UL>
<UL>
<LI>Neuropsychatric adverse effects have not been reported in patients given only artemisinin derivatives, but have been reported in patients given mefloquine and artemisinin drug combination treatment. Severe vomiting might be less likely with combination treatment compared with mefloquine alone.</LI>
</UL>
<UL>
<LI>There are few data on combination treatment with longer-acting antimalarial drugs other than mefloquine.</LI>
</UL>
<P>4. Is any artemisinin derivative better than the others?</P>
<UL>
<LI>There is no evidence from randomised trials that any artemisinin derivative is better than the others. Most data apply to artesunate and artemether, fewer to artemisinin and very few to dihydroartemisinin.</LI>
</UL>
<P>5. What is the best dose and treatment regimen?</P>
<UL>
<LI>A wide variety of treatment regimens has been tested in randomised trials. The rationale is often not explained in terms of previous clinical or pharmacokinetic findings. Treatment regimens reported as having a comparative advantage in some studies achieve inadequate cure rates. Overall, it appears that if artemisinin drugs are given alone at least 7 days treatment is needed to reliably achieve adequate cure rates; if they are combined with mefloquine at least 3 days treatment is needed with a dose of 1250 mg mefloquine in mefloquine-resistant areas. The treatment regimens recommended in WHO guidelines from 1996 may be inadequate and should be revised as a matter of priority.</LI>
</UL>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>The use of artemisinin derivatives spread before basic questions concerning dose-effect relationship, dose optimisation and standardisation of drug regimens, alone or in combination with other antimalarials, had been addressed. This review highlights the need for clear definition of the clinical questions outstanding and co-ordination of drug trials. </P>
<P>The experience with artemisinin drugs should be useful as researchers encounter more new antimalarial compounds. It is important they get together at an early stage in a collaborative network and agree research questions, methods, outcomes and reporting of results. In addition, careful attention to trial methodology (allocation concealment, for example) should be ensured.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>Heather McIntosh was funded through the Effective Health Care in Developing Countries Project, a grant from the Department for International Development (UK) to the Liverpool School of Tropical Medicine.</P>
<P>We, the reviewers, would like to thank the following members of our advisory panel for their guidance and input throughout the review process: NJ White, S Ebrahim, TE Taylor; also MH Alin, M Liu and P Williamson at the protocol stage. We acknowledge the invaluable contribution of investigators who supplied supplementary data: E Ezedinachi, J Karbwang, Li Guo Qiao, Marlar Than, Kyaw Win; IMPE (Hanoi). Also A Schapira (WHO Hanoi) for assistance in locating Vietnamese studies and Zhou Feng (WCUMS) for Chinese translation. We acknowledge the following drug companies for laudable co-operation: Rhone-Poulec Rorer (JP Helenport), Mepha (M Andrial), Kunming Pharmaceutical Company (Zhang Chu Cheng), Dragon Pharmaceuticals Ltd (GT Williams).</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>We certify that we have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter of the review (e.g. employment, consultancy, stock ownership, honoraria, expert testimony). </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS/>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2008-10-20 10:26:58 +0100" MODIFIED_BY="[Empty name]">
<P>This review was first published in issue 3 1998 of the Cochrane Library. The original review was undertaken to provide a comprehensive assessment of benefit and risk in different epidemiological settings in order to inform drug policy decisions on the rational use of this new class of antimalarial drugs. The clinical questions addressed by the review were based on what needed clarifying at that time.</P>
<P>In April 1998 a conference was held on The Rational use Qinghaosu and its Derivatives (Médicine Tropicale 1998;58(3 suppl). Research findings to date were presented and discussed among representatives of WHO, non-governmental organisations, researchers in the field and the pharmaceutical industry. Our original systematic review served as a working document at that meeting.</P>
<P>The published conclusions relating to treatment of uncomplicated falciparum malaria include the following:</P>
<OL>
<LI>It is clear that artemisinin drugs are fast and effective against uncomplicated <I>Plasmodium falciparum </I>malaria in adults and children in all areas of the world</LI>
<LI>All artemisinin derivatives investigated have comparable efficacy</LI>
<LI>These drugs should be used in combination with a second, longer-acting antimalarial to minimise recrudescence and development of resistance</LI>
<LI>In multidrug resistance areas artemisinin drugs (in combination therapy) should be given for at least 3 days to prevent recrudescence.</LI>
<LI>There have been few studies in areas where there is not multidrug resistance, however, there is a strong theoretical basis for always using longer acting antimalarial drugs concurrently with artemisinin derivatives.</LI>
</OL>
<P>As a result current knowledge and priorities for future research were clarified. The clinical effectiveness of artemisinin drugs is no longer in question and a safety overview showed them to be well tolerated. It is not a priority to continue to review comparisons of artemisinin drugs used alone versus standard non-artemisinin drug treatments; nor whether one derivative is better than the others. The way forward is combination therapy and the main goal is to optimise clinical effectiveness in areas of high and lower parasite resistance to standard antimalarial regimens.</P>
<P>In conclusion, this systematic review has served its intended purpose. Most of the questions addressed have now been answered and research priorities have, as a result, moved forward. The foremost outstanding clinical questions are around artemisinin combination regimens, and these will be managed within separate Cochrane Reviews. It is, therefore, no longer necessary or expedient to update this review in its existing format. It will continue to appear in <I>The Cochrane Library </I>for a limited number of future issues, new trials being added to those awaiting assessment, for information only.<BR/>
</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-10-25 18:47:45 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-10-25 18:47:45 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2008-08-05 10:39:07 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-AlinTAZ94" NAME="AlinTAZ94" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alin MH, Ashton M, Kihamia CM, Mtey GJB, Bjorkman A</AU>
<TI>Clinical efficacy and pharmacokinetics of artemisinin monotherapy and in combination with mefloquine in patients with falciparum malaria</TI>
<SO>J Clin Pharmacol</SO>
<YR>1996</YR>
<VL>41</VL>
<PG>587-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-AlinTAZ96" NAME="AlinTAZ96" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alin MH, Ashton M, Kihamia CM, Mtey GJB, Bjorkman A</AU>
<TI>Multiple dose pharmacokinetics of oral artemisinin and comparison of its efficacy with that of oral artesunate in falciparum malaria patients</TI>
<SO>Trans R Soc Trop Med Hyg</SO>
<YR>1996</YR>
<VL>90</VL>
<NO>1</NO>
<PG>61-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ArnoldVNM89" NAME="ArnoldVNM89" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arnold K, Hien TT, Chinh NT, et al</AU>
<TI>A randomized comparative study of artemisinine (qinghaosu) suppositories and oral quinine in acute falciparum malaria</TI>
<SO>Trans R Soc Trop Med Hyg</SO>
<YR>1990</YR>
<VL>84</VL>
<PG>499-502</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-BunnagTHI89a" NAME="BunnagTHI89a" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bunnag D, Viravan C, Looareesuwan S, Karbwang J, Harinasuta T</AU>
<TI>Clinical trial of artesunate and artemether on multidrug resistant falciparum malaria in Thailand. A preliminary report</TI>
<SO>Southeast Asian J Trop Med Public Health</SO>
<YR>1991</YR>
<VL>22</VL>
<NO>3</NO>
<PG>380-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-BunnagTHI89b" NAME="BunnagTHI89b" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bunnag D, Viravan C, Looareesuwan S, Karbwang J, Harinasuta T</AU>
<TI>Double blind randomised clinical trial of oral artesunate at once or twice daily dose in falciparum malaria</TI>
<SO>Southeast Asian J Trop Med Public Health</SO>
<YR>1991</YR>
<VL>2</VL>
<NO>4</NO>
<PG>539-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-BunnagTHI92_x002d_4a" NAME="BunnagTHI92-4a" YEAR="1992-">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bunnag D, Kanda T, Karbwang J, Thimasarn K, Pungpak S, Harinasuta T</AU>
<TI>Artemether-mefloquine combination in multidrug resistant falciparum malaria</TI>
<SO>Trans R Soc Trop Med Hyg</SO>
<YR>1995</YR>
<VL>89</VL>
<NO>2</NO>
<PG>213-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-BunnagTHI92_x002d_4b" NAME="BunnagTHI92-4b" YEAR="1992-">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bunnag D, Kanda T, Krabwang J, Thimasarn K, Pungpak S, Harinasuta T</AU>
<TI>Artemether or artesunate followed by mefloquine as a possible treatment for multi drug resistant falciparum malaria</TI>
<SO>Trans R Soc Trop Med Hyg</SO>
<YR>1996</YR>
<VL>90</VL>
<NO>4</NO>
<PG>415-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CardosoBRZ93_x002d_4" NAME="CardosoBRZ93-4" YEAR="1993-">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cardoso B da S, Dourado HV, Pinheiro M da C, et al</AU>
<TI>[An efficacy and tolerance study of oral artesunate alone and in combination with mefloquine in the treatment of uncomplicated falciparum malaria in an endemic area of Para, Brazil]. [Portuguese]</TI>
<SO>Rev Soc Bras Med Trop</SO>
<YR>1996</YR>
<VL>29</VL>
<NO>3</NO>
<PG>251-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-EzedinachiNIG92" MODIFIED="2008-08-05 10:33:02 +0100" MODIFIED_BY="[Empty name]" NAME="EzedinachiNIG92" YEAR="1992">
<REFERENCE MODIFIED="2008-08-05 10:33:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ezedinachi E</AU>
<TI>In vivo efficacy of chloroquine, halofantrine, pyrimethamine-sulfadoxine and qinghaosu (artesunate) in the treatment of malaria in Calabar, Nigeria</TI>
<SO>Central African Journal of Medicine</SO>
<YR>1996</YR>
<VL>42</VL>
<NO>4</NO>
<PG>109-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-GuoCHI87" MODIFIED="2008-08-05 10:33:22 +0100" MODIFIED_BY="[Empty name]" NAME="GuoCHI87" YEAR="1987">
<REFERENCE MODIFIED="2008-08-05 10:33:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guo XB, Fu YX, Chen PJ, et al</AU>
<TI>A randomised comparative study on the treatment of falciparum malaria with artesunate tablets and piperaquine. Clinical trial on qinghaosu and its derivatives [Chinese]</TI>
<SO>Sanya Tropical Medicine Institute</SO>
<YR>1990</YR>
<VL>1</VL>
<PG>39-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Guo XB, Fu YX, Chen PQ, et al</AU>
<TI>A randomised comparative study on the treatment of falciparum malaria with artesunate tablets and piperaquine</TI>
<SO>Clinical trials on Qinghaosu and its derivatives [English translation]</SO>
<PG>72-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-HatzTAZ_x0028_98_x0029_" NAME="HatzTAZ(98)" YEAR="199?">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hatz C, Abdulla S, Mull R, Schellenberg D, Gathmann I, Kibatala P, et al</AU>
<TI>Efficacy and safety of CGP 56697 (artemether and benflumetol) compared with chloroquine to treat acute falciparum malaria in Tanzanian children aged 1-5 years</TI>
<SO>Trop Med Int Health</SO>
<YR>1998</YR>
<VL>3</VL>
<NO>6</NO>
<PG>498-504</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Unpublished data property of Novartis not available&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hatz C, Abdulla S, Schellenberg D, Mull R, Gathmann I, Royce C</AU>
<TI>Efficacy and safety of CGP 56697 vs. chloroquine in the treatment of P falciparum malaria in children</TI>
<SO>National Institute for Medical Research 15th Annual joint scientific conference</SO>
<YR>February 1997</YR>
<PG>Abstract</PG>
<CY>Dar es Salaam, Tanzania</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Unpublished data property of Novartis not available&lt;/p&gt;&lt;p&gt;Irion A, Abdullah S, Felger I, Beck HP, Mull R, Hatz C. A comparative trial of CGP 56697 and chloroquine in Tanzanian children with subsequent PCR analysis of recurring parasites [abstract]. In: Fifth International Conference on Travel Medicine: Program and Abstracts; 1997 March 24-27; Geneva. Abstract 107. Data ... property of Novartis, not available before publicaton.&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Irion A, Abdullah S, Felger I, Beck HP, Mull R, Hatz C</AU>
<TI>A comparative trial of CGP 56697 and chloroquine in Tanzanian children with subsequent PCR analysis of recurring parasites</TI>
<SO>Fifth International Conference on Travel Medicine: Program and Abstracts</SO>
<YR>March 24-27 1997</YR>
<PG>Abstract 107</PG>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Irion A, Abdullah S, Felger I, Mull R, Hatz C, Beck HP</AU>
<TI>A comparative trial of CGP 56697 and chloroquine in Tanzanian children with subsequent PCR analysis of recurring parasites</TI>
<SO>British Society for Parasitology 9th malaria meeting</SO>
<YR>September 1997</YR>
<PG>Abstract 4.11</PG>
<CY>Liverpool</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Irion A, Felger I, Abdulla S, Smith T, Mull R, Tanner M, et al</AU>
<TI>Distinction of recrudescences from new infections by PCR-RFLP analysis in a comparative trial of CGP 56697 and chloroquine in Tanzanian children</TI>
<SO>Trop Med Int Health</SO>
<YR>1998</YR>
<VL>3</VL>
<NO>6</NO>
<PG>490-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-HienVNM_x0028_94_x0029__x005b_1_x005d_" NAME="HienVNM(94)[1]" YEAR="19??">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hien TT, Arnold K, Hung NT, Loc PP, Dung NT, Cuong BM, et al</AU>
<TI>Single dose artemisinin-mefloquine treatment for acute uncomplicated falciparum malaria</TI>
<SO>Trans R Soc Trop Med Hyg</SO>
<YR>1994</YR>
<VL>88</VL>
<PG>688-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-HienVNM90" NAME="HienVNM90" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hien TT, Tam DTH, Cuc NTK, Arnold K</AU>
<TI>Comparative effectiveness of artemisinin suppositories and oral quinine in children with acute falciparum malaria</TI>
<SO>Trans R Soc Trop Med Hyg</SO>
<YR>1991</YR>
<VL>85</VL>
<PG>210-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-HungVNM93_x002d_4" NAME="HungVNM93-4" YEAR="1993-">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hung LN, de Vries PJ, Diem LT, et al</AU>
<TI>Single dose artemisinin-mefloquine versus mefloquine alone for uncomplicated falciparum malaria</TI>
<SO>Trans R Soc Trop Med Hyg</SO>
<YR>1997</YR>
<VL>91</VL>
<PG>191-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-KarbwangTHI91" NAME="KarbwangTHI91" YEAR="19??">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karbwang J, Bangchang K, Thanavibul A, Bunnag D, Chongsuphajaisiddhi T, Harinasuta T</AU>
<TI>Comparison of oral artemether and mefloquine in acute uncomplicated falciparum malaria</TI>
<SO>Lancet</SO>
<YR>1992</YR>
<VL>340</VL>
<NO>8830</NO>
<PG>1245-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-KarbwangTHI92a" NAME="KarbwangTHI92a" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karbwang J, Na Bangchang K, Thanavibul A, Back DJ, Bunnag D, Harinasuta T</AU>
<TI>Pharmacokinetics of mefloquine alone or in combination with artesunate</TI>
<SO>Bull WHO</SO>
<YR>1994</YR>
<VL>72</VL>
<NO>1</NO>
<PG>83-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-KarbwangTHI92b" NAME="KarbwangTHI92b" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karbwang J, Na-Bangchang K, Thanavibul A, et al</AU>
<TI>Comparison of oral artesunate and quinine plus tetracycline in acute complicated malaria</TI>
<SO>Bull WHO</SO>
<YR>1994</YR>
<VL>72</VL>
<NO>2</NO>
<PG>233-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-KarbwangTHI92c" NAME="KarbwangTHI92c" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karbwang J, Nabangchang K, Thanavibul A, Dittain M, Bunnag D, Hrinasuta T</AU>
<TI>Comparative clinical trial of artesunate and the combination of artesunate-mefloquine in multidrug resistant falciparum malaria</TI>
<SO>Clin Drug Investig</SO>
<YR>1996</YR>
<VL>11</VL>
<NO>2</NO>
<PG>84-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-KarbwangTHI93" NAME="KarbwangTHI93" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karbwang J, Na-Bangchang K, Thanavibul A, Laothavorn P, Ditta-in M, Harinasuta T</AU>
<TI>A comparative clinical trail of artemether and the sequential regimen of artemether-mefloquine in multidrug resistant falciparum malaria</TI>
<SO>J Antimicrob Chemother</SO>
<YR>1995</YR>
<VL>36</VL>
<PG>1079-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-KarbwangTHI93_x002d_4" NAME="KarbwangTHI93-4" YEAR="1993-">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karbwang J, Na-Bangchang K, Thanavibul A, Ditta-in M, Harinasuta T</AU>
<TI>A comparative clinical trial of two different regimens of artemether plus mefloquine in multidrug resistant falciparum malaria</TI>
<SO>Trans R Soc Trop Med Hyg</SO>
<YR>1995</YR>
<VL>89</VL>
<NO>3</NO>
<PG>296-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-CHI82_x002d_4" NAME="Li CHI82-4" YEAR="1982-">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li GQ, Arnold K, Guo XB, Jian HX, Fu LC</AU>
<TI>Randomised comparative study of mefloquine, qinghaosu, and pyrimethamine-sulfadoxine in patients with falciparum malaria</TI>
<SO>Lancet</SO>
<YR>1984</YR>
<VL>2</VL>
<NO>8416</NO>
<PG>1360-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-LooareesuwanTHI91" NAME="LooareesuwanTHI91" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Looareesuwan S, Viravan C, Vanijanonta S, et al</AU>
<TI>Randomised trial of artesunate and mefloquine alone and in sequence for acute uncomplicated falciparum malaria</TI>
<SO>Lancet</SO>
<YR>1992</YR>
<VL>339</VL>
<NO>8797</NO>
<PG>821-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-LooareesuwanTHI92b" NAME="LooareesuwanTHI92b" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Looareesuwan S, Wilairatana P, Viravan C, Vanijanonta S, Pitisuttithum P, Kyle DE</AU>
<TI>Open randomised trial of oral artemether alone and a sequential combination with mefloquine for acute uncomplicated malaria</TI>
<SO>Am J Trop Med Hyg</SO>
<YR>1997</YR>
<VL>56</VL>
<NO>6</NO>
<PG>613-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-LooareesuwanTHI93" NAME="LooareesuwanTHI93" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Looareesuwan S, Vanijanonta S, Viravan C, Wilairatana P, Charoenlarp P, Andrial M</AU>
<TI>Randomized trial of mefloquine alone and artesunate followed by mefloquine for the treatment of acute uncomplicated falciparum malaria</TI>
<SO>Ann Trop Med Parasitol</SO>
<YR>1994</YR>
<VL>88</VL>
<NO>2</NO>
<PG>131-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-LooareesuwanTHI95" MODIFIED="2008-08-05 10:39:07 +0100" MODIFIED_BY="[Empty name]" NAME="LooareesuwanTHI95" YEAR="1995">
<REFERENCE MODIFIED="2008-08-05 10:39:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Looareesuwan S, Wilairatana P, Vanijanonta S, Pitisuttithum P, Ratanapong Y, Andrial M</AU>
<TI>Monotherapy with sodium artesunate for uncomplicated falciparum malaria: a comparison of 5-day and 7-day regimens</TI>
<SO>Acta Tropica</SO>
<YR>1997</YR>
<VL>67</VL>
<PG>197-205</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-LuxemburgerTHI_x002d_MYA91" NAME="LuxemburgerTHI-MYA91" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luxemburger C, ter Kuile FO, Nosten F, et al</AU>
<TI>Single day mefloquine-artesunate combination in the treatment of multi-drug resistant falciparum malaria</TI>
<SO>Trans R Soc Trop Med Hyg</SO>
<YR>1994</YR>
<VL>88</VL>
<NO>2</NO>
<PG>213-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nosten_x005b_1_x005d_THI_x002d_MYA92_x002d_3" NAME="Nosten[1]THI-MYA92-3" YEAR="1992-">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nosten F, Luxemburger C, ter Kuile FO, et al</AU>
<TI>Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination (study 1)</TI>
<SO>J Infect Dis</SO>
<YR>1994</YR>
<VL>170</VL>
<NO>4</NO>
<PG>971-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nosten_x005b_2_x005d_THI_x002d_MYA92_x002d_3" NAME="Nosten[2]THI-MYA92-3" YEAR="1992-">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nosten F, Luxemburger C, ter Kuile FO, et al</AU>
<TI>Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination (study 2)</TI>
<SO>J Infect Dis</SO>
<YR>1994</YR>
<VL>170</VL>
<NO>4</NO>
<PG>971-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PriceTHI_x002d_MYA93_x002d_4" NAME="PriceTHI-MYA93-4" YEAR="1993-">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Price RN, Nosten F, Luxemburger C, et al</AU>
<TI>Artesunate versus artemether in combination with mefloquine for the treatment of multidrug-resistant falciparum malaria</TI>
<SO>Trans R Soc Trop Med Hyg</SO>
<YR>1995</YR>
<VL>89</VL>
<NO>5</NO>
<PG>523-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-RugemalilaTAZ_x0028_97_x0029_" NAME="RugemalilaTAZ(97)" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Rugemalila JB, Msangeni HA, Akida JA, et al</AU>
<TI>A randomised double blind clinical trial comparing oral B-artemether and chloroquine for the treatment of uncomplicated malaria in Tanzania</TI>
<SO>National Institute for Medical Research 15th annual joint scientific conference Programme and abstracts</SO>
<PG>Abstract 22</PG>
<CY>Dar es Salaam Tanzania</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Rugemalila JB, Msangeni HA</AU>
<TI>Clinical trial of B-artemether for the treatment of malaria in Tanzania</TI>
<SO>Unpublished manuscript</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-ThanMYA90_x002d_91" NAME="ThanMYA90-91" YEAR="1990-">
<REFERENCE NOTES="&lt;p&gt;Unpublished data obtained from the investigator, Marlar Than, Defence Services General Hospital, Myanmar.&lt;/p&gt;" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Than M</AU>
<SO>Unpublished data obtained from the investigator, Defence Services General Hospital, Myanmar</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-ThanMYA91" NAME="ThanMYA91" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Unpublished data obtained from the investigator, Marlar Than, Defence Services General Hospital, Myanmar.&lt;/p&gt;" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Than M</AU>
<SO>Unpublished data obtained from the investigator, Defence Services General Hospital, Myanmar</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-ThanMYA93a" NAME="ThanMYA93a" YEAR="1992-">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Marlar Than, Ma Sabai, Khaing Khaing Gyi, Aye Yu Soe, Khin Mg Aye, Kyaw Win</AU>
<TI>Trial of oral artemisinin (Lactab) alone and in combination with mefloquine in uncomplicated falciparum malaria</TI>
<SO>Second Myanmar Health Research Congress</SO>
<VL>Abstracts</VL>
<PG>29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Unpublished data obtained from the investigator, Marlar Than, Defence Services General Hospital, Myanmar.&lt;/p&gt;" PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Than M</AU>
<SO>Unpublished data obtained from the investigator, Defence Services General Hospital, Myanmar</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-ThanMYA93b" NAME="ThanMYA93b" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Unpublished data obtained from the investigator, Marlar Than, Defence Services General Hospital, Myanmar.&lt;/p&gt;" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Than M</AU>
<SO>Unpublished data obtained from the investigator, Defence Services General Hospital, Myanmar</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-ThanMYA93c" NAME="ThanMYA93c" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marlar Than, Ma Sabai, Khaing Khaing Gyi, Aye Yu Soe, Khin Mg Aye, Kyaw Win</AU>
<TI>Different dosage regimens of oral artemether in uncomplicated falciparum malaria. Second Myanmar Health Research Congress [Abstracts]</TI>
<PG>25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Unpublished data obtained from the investigator, Marlar Than, Defence Services General Hospital, Myanmar.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Than M</AU>
<SO>Unpublished data obtained from the investigator, Defence Services General Hospital, Myanmar</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-ThanMYA94a" NAME="ThanMYA94a" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Unpublished data obtained from the investigator, Marlar Than, Defence Services General Hospital, Myanmar.&lt;/p&gt;" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Than M</AU>
<SO>Unpublished data obtained from the investigator, Defence Services General Hospital, Myanmar</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-ThanMYA96a" NAME="ThanMYA96a" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Unpublished data obtained from the investigator, Marlar Than, Defence Services General Hospital, Myanmar.&lt;/p&gt;" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Than M</AU>
<SO>Unpublished data obtained from the investigator, Defence Services General Hospital, Myanmar</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-ThanMYA97" NAME="ThanMYA97" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Unpublished data obtained from the investigator, Marlar Than, Defence Services General Hospital, Myanmar.&lt;/p&gt;" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Than M</AU>
<SO>Unpublished data obtained from the investigator, Defence Services General Hospital, Myanmar</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ThimasarnTHI93_x002d_4" NAME="ThimasarnTHI93-4" YEAR="1993-">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thimasarn K, Sirichaisinthop J, Chanyakhun P, et al</AU>
<TI>A comparative study of artesunate and artemether in combination with mefloquine on multidrug resistant falciparum malaria in Eastern Thailand</TI>
<SO>S East Asia J Trop Med Pub Health</SO>
<YR>1997</YR>
<VL>28</VL>
<NO>3</NO>
<PG>465-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-vonSeidleinGAM96" NAME="vonSeidleinGAM96" YEAR="1996-">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>A randomized controlled trial of artemether/benflumetol, a new antimalarial and pyrimethamine/sulfadoxine in the treatment of uncomplicated falciparum malaria</AU>
<SO>Am J Trop Med Hyg</SO>
<YR>1998</YR>
<VL>58</VL>
<NO>5</NO>
<PG>638-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-WinMYA94_x002d_5" NAME="WinMYA94-5" YEAR="1994-">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Win Kyaw, Marlar Than, Ye Thwe, et al</AU>
<TI>Efficacy of artemether and artesunate suppositories (Rectocaps) in the treatment of uncomplicated falciparum malaria</TI>
<SO>Jpn J Trop Med Hyg</SO>
<YR>1996</YR>
<VL>24</VL>
<NO>suppl 1</NO>
<PG>55-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-10-25 18:47:45 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Alin-TAZ-93" NAME="Alin TAZ 93" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alin MH, Kihamia CM, Bjorkman A, et al</AU>
<TI>Efficacy of oral and intravenous artesunate in male Tanzanian adults with Plasmodium falciparum malaria and in vitro susceptibility to artemisinin, chloroquine, and mefloquine</TI>
<SO>Am J Trop Med Hyg</SO>
<YR>1995</YR>
<VL>53</VL>
<NO>6</NO>
<PG>639-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Anh-VNM-92b" NAME="Anh VNM 92b" YEAR="1992-">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Anh TK</AU>
<TI>Open randomised studies to compare the efficacy between three regimens of artemisinin and artemisinin-mefloquine in uncomplicated falciparum malaria</TI>
<SO>TDR M20/181/38</SO>
<YR>TDCRC CRH 04/92</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ashton-VNM-_x0028_98_x0029_" NAME="Ashton VNM (98)" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ashton M, Sy ND, van Hong N, et al</AU>
<TI>Artemisinin kinetics and dynamics during oral and rectal treatment of uncomplicated malaria</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1998</YR>
<VL>63</VL>
<NO>4</NO>
<PG>482-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Batty-VNM-96" NAME="Batty VNM 96" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Batty K, Thu LTA, Davis TME, Ilett KF, Mai TX, et al</AU>
<TI>A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria</TI>
<SO>Br J Clin Pharmacol</SO>
<YR>1998</YR>
<VL>45</VL>
<PG>123-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bich-VNM-93" NAME="Bich VNM 93" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nguyen Ngoc Bich, Peter J de Vries, Huyuh Van Thien, Tran Hung Phong, Le Ngoc Hung, Teunis A Eggelte, et al</AU>
<TI>Efficacy and tolerance of artemisinin in short combination regimens for the treatment of uncomplicated falciparum malaria</TI>
<SO>Am J Trop Med Hyg</SO>
<YR>1996</YR>
<VL>55</VL>
<NO>4</NO>
<PG>438-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bunnag-THI-_x0028_97_x0029_" NAME="Bunnag THI (97)" YEAR="19??">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bunnag D, Kanda T, Karbwang J, Pungpak S, Chittamas S, Chalermrut K, et al</AU>
<TI>Standby treatment for multidrug-resistant falciparum malaria: combination of artemether and mefloquine</TI>
<SO>Fifth International Conference on Travel Medicine Program and Abstracts</SO>
<YR>March 24-27 1997</YR>
<PG>Fifth International Conference on Travel Medicine. Program and Abstracts; 1997 March 24-27; Geneva. Abstract 106</PG>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bunnag-THI-89_x002d_90a" NAME="Bunnag THI 89-90a" YEAR="1989-">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bunnag D, Viravan C, Looareesuwan S, Karbwang J, Harinasuta T</AU>
<TI>Double blind randomised clinical trial of two different regimens of oral artesunate in falciparum malaria</TI>
<SO>Southeast Asian J Trop Med Public Health</SO>
<YR>1991</YR>
<VL>22</VL>
<NO>4</NO>
<PG>534-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bunnag-THI-89_x002d_90b" NAME="Bunnag THI 89-90b" YEAR="1989-">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bunnag D, Karbwang J, Harinasuta T</AU>
<TI>Artemether in the treatment of multiple drug resistant falciparum malaria</TI>
<SO>Southeast Asian J Trop Med Public Health</SO>
<YR>1992</YR>
<VL>23</VL>
<NO>4</NO>
<PG>762-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Chen-CHI" NAME="Chen CHI" YEAR="19??">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Chen PO, Guo XB, Li GQN, Song YZ, Wang XH, Pam LT, et al</AU>
<TI>Effect of dihydroartemisinin on the infectivity of gametocytes (PfG) and a randomised comparison with quinine</TI>
<SO>Abstract obtained from Guo Qiao Li</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Duarte-BRZ-92_x002d_3" NAME="Duarte BRZ 92-3" YEAR="1992-">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duarte EC, Fontes CJF, Gyorkos TW, Abrahamowicz M</AU>
<TI>Randomised controlled trial of artesunate plus tetracycline versus standard treatment (quinine plus tetracycline) for uncomplicated malaria in Brazil</TI>
<SO>Am J Trop Med Hyg</SO>
<YR>1996</YR>
<VL>54</VL>
<NO>2</NO>
<PG>197-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Duc-VNM-93" NAME="Duc VNM 93" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Dao Dinh Duc, Pham Thi Yen, Le Nguyen Binh, Nguyen Tien Lam, Le Thanh Nhaun, Nguyen Ba Nen et al</AU>
<TI>In vivo and in vitro study on the activities of artemisinin and artemether on uncomplicated falciparum malaria</TI>
<SO>Obtained from the investigators</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elhassan-SUD-91" MODIFIED="2008-10-25 18:47:45 +0100" MODIFIED_BY="[Empty name]" NAME="Elhassan SUD 91" YEAR="1991">
<REFERENCE MODIFIED="2008-10-25 18:47:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elhassan IM, Satti GHM, Ali A-E, et al</AU>
<TI>The efficacy of artemether in the treatment of Plasmodium falciparum malaria in Sudan</TI>
<SO>Trans R Soc Trop Med Hyg</SO>
<YR>1993</YR>
<VL>87</VL>
<PG>685-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Fu-CHI" NAME="Fu CHI" YEAR="19??">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Fu LC, Li GQN, Guo XB, Wang XH, Chen PQ, Jian HX, Li GQ</AU>
<TI>Dose findings of artesunate treatment of P falciparum malaria</TI>
<SO>Abstract obtained from Li Guo Qiao</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fu-CHI-88_x002d_90" NAME="Fu CHI 88-90" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fu LC, Guo XB, Fu YX, Li GQ</AU>
<TI>Clinical studies on the treatment of falciparum malaria with artesunate im injection and a randomly controlled study on artesunate and piperaquine. Clinical trials on Qinghaosu and its derivatives [English translation]</TI>
<SO>Sanya Tropical Medicine Institute</SO>
<YR>1990</YR>
<VL>volume1</VL>
<PG>66-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guo-CHI-_x0028_90_x0029_" NAME="Guo CHI (90)" YEAR="19??">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Guo XB, Fu LQ, Li GQ</AU>
<TI>Clinical trials of intramuscular artemether for falciparum malaria treatment [Chinese]</TI>
<SO>Clinical trials on qinghaosu and its derivatives Sanya Tropical Medicine Institute</SO>
<YR>1990</YR>
<VL>1</VL>
<PG>85-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guo-CHI-86a" NAME="Guo CHI 86a" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guo XB, Fu LC, Li GQ</AU>
<TI>Comparative study of im artemether versus oral piperaquine phosphate</TI>
<SO>J New Drugs</SO>
<YR>1989</YR>
<VL>8</VL>
<PG>248-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guo-CHI-86b" NAME="Guo CHI 86b" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Guo XB, Fu LC, Li GQ</AU>
<TI>Comparative study of im artemether versus oral pyronaridine complex</TI>
<SO>Clinical trials on Qinghaosu and its derivatives [English translation] Sanya Tropical Medicine Institute</SO>
<YR>1990</YR>
<PG>12-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hien-VNM-_x005b_2_x002d_4_x005d_-_x0028_94_x0029_" NAME="Hien VNM [2-4] (94)" YEAR="19??">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hien TT, Arnold K, Hung NT, Loc PP, Dung NT, Cuong BM, et al</AU>
<TI>Single dose artemisinin-mefloquine treatment for acute uncomplicated falciparum malaria</TI>
<SO>Trans R Soc Trop Med Hyg</SO>
<YR>1994</YR>
<VL>88</VL>
<PG>688-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Irion-GAM_x0028_98_x0029_" NAME="Irion GAM(98)" YEAR="199?">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Irion A, Abdullah S, Felger I, Beck HP, Mull R, Hatz C</AU>
<TI>A comparative trial of CGP 56697 and chloroquine in Tanzanian children with subsequent PCR analysis of recurring parasites</TI>
<SO>Fifth International Conference on Travel Medicine Program and Abstracts</SO>
<YR>March 24-27 1997</YR>
<PG>Abstract 107</PG>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Irion A, Abdullah S, Felger I, Mull R, Hatz C, Beck HP</AU>
<TI>A comparative trial of CGP 56697 and chloroquine in Tanzanian children with subsequent PCR analysis of recurring parasites</TI>
<SO>British Society for Parasitology 9th malaria meeting</SO>
<YR>September 1997</YR>
<PG>Abstract 4</PG>
<CY>Liverpool</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Irion A, Felger I, Abdulla S, Smith T, Mull R, Tanner M, et al</AU>
<TI>Distinction of recrudescences from new infections by PCR-RFLP analysis in a comparative trial of CGP 56697 and chloroquine in Tanzanian children</TI>
<SO>Trop Med Int Health</SO>
<YR>1998</YR>
<VL>3</VL>
<NO>6</NO>
<PG>490-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jiang-CHI-80" NAME="Jiang CHI 80" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jiang JB, Guo XB, Li GQ, Kong YC</AU>
<TI>Antimalarial activity of mefloquine and qinghaosu</TI>
<SO>Lancet</SO>
<YR>1982</YR>
<VL>2</VL>
<NO>8293</NO>
<PG>258-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jiao-CHI-_x0028_97_x0029_" NAME="Jiao CHI (97)" YEAR="19??">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Jiao XQ, Liu EY, Shan CQ, Shan CQ, Dal P, Gathmann I, et al</AU>
<TI>A double-blind comparative trial of benflumetol, a novel antimalarial, and CGP 56697, a combination of benflumetol and artemether, in the treatment of acute P. falciparum malaria in adults in China</TI>
<SO>Fifth International Conference on Travel Medicine Program and Abstracts</SO>
<YR>March 24-27 1997</YR>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-CHI-_x0028_82_x0029_" NAME="Li CHI (82)" YEAR="19??">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li GQ, et al</AU>
<TI>Clinical study on use of artemether in treatment of pernicious malaria [Chinese]</TI>
<SO>Chinese Med J</SO>
<YR>1982</YR>
<VL>62</VL>
<NO>5</NO>
<PG>293-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-CHI-_x0028_90_x0029_" NAME="Li CHI (90)" YEAR="19??">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Li GQ, Guo XB, Fu LJ, et al</AU>
<TI>Clinical report of artesunate intramuscular injection for malaria treatment [Chinese]</TI>
<SO>Clinical trials on qinghaosu and its derivatives Sanya Tropical Medicine Institute</SO>
<YR>1990</YR>
<PG>80-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-CHI-_x0028_95_x0029_" NAME="Li CHI (95)" YEAR="19??">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li X, Yang C</AU>
<TI>A comparative clinical trial of dihydroarteannuin tablet for 5 day and 7 day course of treatment of falciparum and vivax malaria [Chinese]</TI>
<SO>J Practical Parasitic Diseases</SO>
<YR>1995</YR>
<VL>3</VL>
<NO>2</NO>
<PG>66-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-CHI-85" NAME="Li CHI 85" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Li GQ, Guo XB, Fu LC</AU>
<TI>A randomised comparative study of artesunate versus quinine dihydrochloride in the treatment of falciparum malaria</TI>
<SO>Clinical trials on Qinghaosu and its derivatives [English translation] Sanya Tropical Medicine Institute</SO>
<YR>1990</YR>
<PG>50-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Li-CHI-a" NAME="Li CHI a" YEAR="19??">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Li GQ, Chen, Li GQN, Wang XH, Trinh KA, Pahm LT, et al</AU>
<TI>Effect of artesunate on the infectivity of P falciparum gametocytes and a randomised comparative study with quinine</TI>
<SO>Abstract obtained from Li Guo Qiao</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Li-CHI-b" NAME="Li CHI b" YEAR="19??">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Li GQN, Wang XH, Guo XB, Fu LC, Jian HX, Li GQ</AU>
<TI>Dose findings of dihydroartemisinin in treatment of falciparum malaria</TI>
<SO>Abstract obtained from Li Guo Qiao</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Li-VNM-_x0028_95_x0029_" NAME="Li VNM (95)" YEAR="19??">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Li GQ, Wang XH, Guo XB, Jian HX, Anh TK, Thinh PL, et al</AU>
<TI>Dose findings of dihydroartemisinin on treatment of falciparum malaria and a randomized comparative study with artesunate</TI>
<SO>Symposium on Tropical Medicine China</SO>
<YR>1995</YR>
<PG>10-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Looareesuwan-THI-92a" NAME="Looareesuwan THI 92a" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Looareesuwan S, Viravan C, Vanijanonta S, et al</AU>
<TI>Randomized trial of mefloquine-doxycycline, and artesunate-doxycycline for treatment of acute uncomplicated falciparum malaria</TI>
<SO>Am J Trop Med Hyg</SO>
<YR>1994</YR>
<VL>50</VL>
<NO>6</NO>
<PG>784-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Looareesuwan-THI-94" NAME="Looareesuwan THI 94" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Looareesuwan S, Viravan C, Vanijanonta S, Wilairatana P, Pitisuttithum P, Andrial M</AU>
<TI>Comparative clinical trial of artesunate followed by mefloquine in the treatment of acute uncomplicated falciparum malaria: two- and three-day regimens</TI>
<SO>Am J Trop Med Hyg</SO>
<YR>1996</YR>
<VL>54</VL>
<NO>2</NO>
<PG>210-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-LuxemburgerTHI_x002d_MYA93" NAME="LuxemburgerTHI-MYA93" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luxemburger C, Nosten F, Shotar D, Raimond D, Chongsuphajaisiddhi T, White NJ</AU>
<TI>Oral artesunate in the treatment of uncomplicated hyperparasitaemic falciparum malaria</TI>
<SO>Am J Trop Med Hyg</SO>
<YR>1995;53(5)</YR>
<VL>522-5</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Na_x002d_BangchangTHI_x0028_96_x0029_a" NAME="Na-BangchangTHI(96)a" YEAR="19??">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Na-Bangchang K, Kanda T, Tipawangso P, Thanavibul A, Suprakob K, Ibrahim M, Wattanagoon Y, Karbwang J</AU>
<TI>Activity of artemether-azithromycin versus artemether-doxycycline in the treatment of multiple drug resistant falciparum malaria</TI>
<SO>SE Asian J Trop Med Pub Health</SO>
<YR>1996</YR>
<VL>27</VL>
<NO>3</NO>
<PG>522-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Na_x002d_BangchangTHI_x0028_96_x0029_b" NAME="Na-BangchangTHI(96)b" YEAR="19??">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Na-Bangchang K, Tipwangso P, Thanavibul A, Tan-ariya P, Suprakob K, Kanda T, Karbwang J</AU>
<TI>Artemether-pyrimethamine in the treatment of pyrimethamine-resistant falciparum malaria</TI>
<SO>SE Asian J Trop Med Pub Health</SO>
<YR>1996</YR>
<VL>27</VL>
<NO>1</NO>
<PG>19-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Nigeria-1988" NAME="Nigeria 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Federal Ministry of Health Republic of Nigeria</AU>
<SO>National Malaria Vector Control Division</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pang-CHI-_x0028_87_x0029_" NAME="Pang CHI (87)" YEAR="19??">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pang XJ, et al</AU>
<TI>Combined use of artemether with other antimalarials in treatment of falciparum malaria [Chinese]</TI>
<SO>Chinese Med J</SO>
<YR>1987</YR>
<VL>67</VL>
<NO>3</NO>
<PG>137-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Price-THI-93_x002d_5" NAME="Price THI 93-5" YEAR="1993-">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Price R, Luxemburger C, van Vugt M, Nosten F, Kham A, et al</AU>
<TI>Artesunate and mefloquine in the treatment of uncomplicated multidrug-resistant hyperparasitaemic falciparum malaria</TI>
<SO>Trans R Soc Trop Med Hyg</SO>
<YR>1998</YR>
<VL>92</VL>
<PG>207-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-QACRG-CHI-75" NAME="QACRG CHI 75" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Qinghaosu Antimalaria Co-ordinating Research Group</AU>
<TI>Antimalaria studies on qinghaosu</TI>
<SO>Chinese Med J</SO>
<YR>1979</YR>
<VL>92</VL>
<NO>12</NO>
<PG>815</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SabchareonTHI95_x002d_6" NAME="SabchareonTHI95-6" YEAR="1995-">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sabchareon A, Attanath P, Chanthavanich P, Phanuaksook P, Prarinyanupharb V, Poonpanich Y et al</AU>
<TI>Comparative clinical trial of artesunate suppositories and oral artesunate in combination with mefloquine in the treatment of children with acute falciparum malaria</TI>
<SO>Am J Trop Med Hyg</SO>
<YR>1998</YR>
<VL>58</VL>
<NO>1</NO>
<PG>11-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sabchareon A, Teja-Isavadharm P, Brewer TG, et al</AU>
<TI>Clinical and pharmacokinetic comparison of oral versus rectal artesunate in children with uncomplicated falciparum malaria. Program and abstracts of the 45th annual meeting of the American Society for Tropical Medicine and Hygiene</TI>
<SO>Am J Trop Med Hyg</SO>
<YR>1996</YR>
<VL>55</VL>
<NO>Suppl 2</NO>
<PG>97</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shen-1989" NAME="Shen 1989" YEAR="19??">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Shen Jiaxiang (editor)</AU>
<TI>Phase III trials of artemisinin and its derivatives. Antimalarial drug development in China</TI>
<SO>Papers presented at a meeting of the Scientific Working Group on the Chemotherapy of Malaria</SO>
<YR>April 1989</YR>
<PB>The National Institute of Pharmaceutical Research and Development Beijing, on behalf of the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR)</PB>
<CY>Beijing</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shwe-MYA-_x0028_98_x0029_" NAME="Shwe MYA (98)" YEAR="19??">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tin Shwe, Myint Lwin, Soe Aung</AU>
<TI>Efficacy of artesunate + mefloquine over artesunate alone in community-based treatment of non-severe falciparum malaria in Myanmar</TI>
<SO>Bull WHO</SO>
<YR>1998</YR>
<VL>76</VL>
<NO>2</NO>
<PG>in press</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simooya-ZIM-91" NAME="Simooya ZIM 91" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simooya O, Mutetwa S, Chandiwana S, et al</AU>
<TI>A comparative study of the schizontocidal efficacy and safety of artemether versus chloroquine in uncomplicated malaria</TI>
<SO>Central African Journal Medicine</SO>
<YR>1992</YR>
<VL>38</VL>
<NO>7</NO>
<PG>257-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sowunmi-NIG-93" NAME="Sowunmi NIG 93" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sowunmi A, Oduola AMJ, Ilesanmi AO, Salako LA</AU>
<TI>Open comparison of artemether and mefloquine in uncomplicated Plasmodium falciparum hyperparasitaemia in children</TI>
<SO>Ann Trop Paed</SO>
<YR>1996</YR>
<VL>16</VL>
<PG>5-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sowunmi-NIG-94_x002d_7" MODIFIED="2008-08-05 10:40:50 +0100" MODIFIED_BY="[Empty name]" NAME="Sowunmi NIG 94-7" YEAR="94-7">
<REFERENCE MODIFIED="2008-08-05 10:40:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sowunmi A, Oduola AMJ, Ogundahunsi OAT, et al</AU>
<TI>Randomised trial of artemether versus artemether and mefloquine for the treatment of chloroquine/sulfadoxine-pyrimethamine-resistant falciparum malaria during pregnancy</TI>
<SO>Journal of Obstetrics and Gynaecology</SO>
<YR>1998</YR>
<VL>18</VL>
<NO>4</NO>
<PG>322-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Than-MYA-94b" NAME="Than MYA 94b" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Than M</AU>
<SO>Unpublished data obtained from the investigator, Defence Services General Hospital, Myanmar</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-ThanMYA95" NAME="ThanMYA95" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Than M</AU>
<SO>Unpublished data obtained from the investigator, Defence Services General Hospital, Myanmar</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-ThanMYA96b" NAME="ThanMYA96b" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Than M</AU>
<SO>Unpublished data obtained from the investigator, Defence Services General Hospital, Myanmar</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Thwe-MYA-93" NAME="Thwe MYA 93" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Thwe Y, Htun YY, Tun KS, Nyunt HH, Yee H, Aung S</AU>
<TI>Artemether capsule and mefloquine; monotherapies compared to combination therapy</TI>
<SO>Fourth Myanmar Military Medical Conference</SO>
<YR>1994</YR>
<PG>12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Vugt-THI-95_x002d_6" NAME="van Vugt THI 95-6" YEAR="1995-">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Vugt M, Brockman A, Gemperli B, Luxemburger C, Gathmann I, et al</AU>
<TI>Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1998</YR>
<VL>42</VL>
<PG>135-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-CHI-_x0028_81_x0029_" NAME="Wang CHI (81)" YEAR="19??">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang TY, et al</AU>
<TI>Clinical observation of treatment of malignant malaria with derivatives of qinghaosu "224" and "242" [Chinese]</TI>
<SO>Chinese J Internal Med</SO>
<YR>1981</YR>
<VL>20</VL>
<NO>11</NO>
<PG>673-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Wang-CHI-_x0028_95_x0029_" NAME="Wang CHI (95)" YEAR="19??">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Wang XH, Guo XB, Jian HX, Fu LC, Li GQ, Anh TK</AU>
<TI>Randomized comparative study of compound artemisinin and mefloquine + artesunate in treatment of falciparum malaria</TI>
<SO>Symposium on Tropical Medicine China</SO>
<YR>1995</YR>
<PG>13-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-CHI-79_x002d_80" NAME="Wang CHI 79-80" YEAR="1979-">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang Tongin, Xu Ruchang</AU>
<TI>Clinical studies of treatment of falciparum malaria with artemether, a derivative of qinghaosu</TI>
<SO>Journal of Traditional Chinese Medicine [Chinese]</SO>
<YR>1985</YR>
<VL>5</VL>
<NO>4</NO>
<PG>240-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-CHI-94" NAME="Wang CHI 94" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Wang XH, Fu LC, Jian HX, Guo XB, Li GQ, Thinh PL, et al</AU>
<TI>Randomised comparative study of compound artemisinin tablet and Fansimef in treatment of P falciparum malaria</TI>
<SO>Clinical trials on Qinghaosu and its derivatives [English translation] Sanya Tropical Medicine Institute</SO>
<YR>1990</YR>
<PG>12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Yen-VNM-96" NAME="Yen VNM 96" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;funded by WHO CTD/MAL&lt;/p&gt;&lt;p&gt;Pham Thi Yen. Final report on the study on efficacy and effectiveness of standard artemisinin 5 day treatment [funded by WHO CTD/MAL]. Hanoi, Viet Nam: Institute of Malariology, Parasitology and Entomology (IMPE), (1996). Unpublished report.&lt;/p&gt;" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Pham Thi Yen</AU>
<TI>Final report on the study on efficacy and effectiveness of standard artemisinin 5 day treatment</TI>
<SO>Institute of Malariology, Parasitology and Entomology (IMPE) Viet Nam</SO>
<YR>1996</YR>
<PG>Institute of Malariology, Parasitology and Entomology (IMPE), (1996). Unpublished report</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Anh-VNM-92a" NAME="Anh VNM 92a" YEAR="1992-">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Anh TK</AU>
<TI>Open randomised comparison of the efficacy of artemisinin in oral and in suppository formulation versus oral quinine</TI>
<SO>TDR M20/181/38</SO>
<YR>TDCRC CRH 04/92</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Bunnag-THI-_x0028_97_x0029_b" NAME="Bunnag THI (97)b" YEAR="19??">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bunnag D, Kanda T, Karbwang J, Pungpak S, Cittamas S, Chalermrut K, et al</AU>
<TI>Proposed standby treatment for multidrug-resistant falciparum malaria: combination of artemether or artesunate with mefloquine</TI>
<SO>Fifth International Conference on Travel Medicine Program and Abstracts</SO>
<YR>March 24-27 1997</YR>
<PG>Fifth International Conference on Travel Medicine. Program and Abstracts; 1997 March 24-27; Geneva. Abstract 275</PG>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bunnag D, Kanda T, Karbwang J, Thimasarn K, Pungpak S, Harinasuta T</AU>
<TI>Two doses of artemether/mefloquine or artesunate/mefloquine combination for multidrug-resistant falciparum malaria</TI>
<SO>S E Asian J Trop Med Pub Health</SO>
<YR>1997</YR>
<VL>28</VL>
<NO>4</NO>
<PG>727-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Coker-NIG" NAME="Coker NIG" YEAR="19??">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Coker HAB, Fagbenro-Beyioku AF, Akinwande JA, Akintonwa A</AU>
<TI>The efficacy of artemether on normal and chloroquine resistant strains of Plasmodium falciparum in Lagos state of Nigeria</TI>
<SO>Dragon Pharmaceuticals, UK, unpublished manuscript</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Doherty-GAM-_x0028_99_x0029_" NAME="Doherty GAM (99)" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Doherty JF, Sadiq AD, Bayo L, Alloueche A, Olliaro P, Milligan P, et al</AU>
<TI>A randomized safety and tolerability trial of artesunate plus sulfadoxine-pyrimethamine versus sulfadoxine-pyrimethamine alone for the treatment of uncomplicated malaria in Gambian children</TI>
<SO>Trans R Soc Trop Med Hyg</SO>
<YR>1999</YR>
<VL>93</VL>
<NO>5</NO>
<PG>543-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hamisi-THI-_x0028_97_x0029_" NAME="Hamisi THI (97)" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Hamisi MI, Tipangkosol P, Na-Bangchang K, Wattanagorn Y, Thanavibul A, Suprakob K, et al</AU>
<TI>Dose finding of the combination artemether + benflumetol in the treatment of acute uncomplicated falciparum malaria</TI>
<SO>National Institute for Medical Research 15th Annual Joint Scientific Conference Programme and Abstracts</SO>
<YR>18-21 February 1997</YR>
<PG>Abstract 24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Honrado-THI-94_x002d_5" NAME="Honrado THI 94-5" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Honrado ER, Fungladda W, Kamoiratanaku P, Kitayaporn D, Karbwang J, Thimasarn K, et al</AU>
<TI>Cost-effectiveness analysis of artesunate and quinine + tetracycline for the treatment of uncomplicated falciparum malaria in Chanthaburi, Thailand</TI>
<SO>Bull WHO</SO>
<YR>1999</YR>
<VL>77</VL>
<NO>3</NO>
<PG>235-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-LooareesuwanTHI_x0028_99_x0029_" NAME="LooareesuwanTHI(99)" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Looareesuwan S, Wilairatana P, Chokejindachai W, Chalermrut K, Wernsdorfer W</AU>
<TI>A randomized, double-blind, comparative trial of a new oral combination of artemether and benflumetol (CGP 56697) with mefloquine in the treatment of acute Plasmodium falciparum malaria in Thailand</TI>
<SO>Am J Trop Med Hyg</SO>
<YR>1999</YR>
<VL>60</VL>
<NO>2</NO>
<PG>238-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Novartis-CHI" NAME="Novartis CHI" YEAR="199?">
<REFERENCE NOTES="&lt;p&gt;This unpublished study, conducted in Chinese children aged 5-14 years, comparing artemether monotherapy with co-artemether (artemether-benflumetol/lumefantrine) is mentioned in the discussion section of two published reports of co-artemether trials [Hatz TAZ (98), vonSeidlein GAM 96]. The reviewers have been unable to obtain unpublished data from Novartis Pharma A.G., the manufacturer of co-artemether.&lt;/p&gt;" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>This unpublished study, conducted in Chinese children aged 5-14 years, comparing artemether monotherapy with co-artemether (artemether-benflumetol/lumefantrine) is mentioned in the discussion section of two published reports of co-artemether trials (Hatz TAZ (98), vonSeidlein GAM 96)</AU>
<TI>The reviewers have been unable to obtain unpublished data from Novartis Pharma A.G</TI>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Price-THI-_x0028_98_x0029_" NAME="Price THI (98)" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Price R, van Vugt M, Nosten F, Luxemburger C, Brockman A, Phaipun L, et al</AU>
<TI>Artesunate versus artemether for the treatment of recrudescent multidrug-resistant falciparum malaria</TI>
<SO>Am J Trop Med Hyg</SO>
<YR>1998</YR>
<VL>59</VL>
<NO>6</NO>
<PG>883-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salcedo-BRZ-_x0028_97_x0029_" NAME="Salcedo BRZ (97)" YEAR="19??">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salcedo JMV, Camargo LMA, Braga MFV, Vanize PSM, Macedo VO</AU>
<TI>Avaliacao da eficacia do artesunato associado a tetraciclina na terapeutica da malaria falciparum</TI>
<SO>Revista da Sociedade Brasileira de Medicina Tropical</SO>
<YR>1997</YR>
<VL>30</VL>
<NO>3</NO>
<PG>215-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Villalobos-_x0028_97_x0029_" NAME="Villalobos (97)" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Villalobos SJM, Aranha CLM, De FVB, Soares DMP, De OMV</AU>
<TI>Effectiveness evaluation of artesunate associated with tetracycline in falciparum malaria therapy</TI>
<SO>Revista Da Sociedade Brasileira De Medicina Tropical</SO>
<YR>1997</YR>
<VL>30</VL>
<NO>3</NO>
<PG>215-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-10-20 10:35:37 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-10-20 10:35:37 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Altman-1996" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecting skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Begg-1996" MODIFIED="2008-08-05 10:47:30 +0100" MODIFIED_BY="[Empty name]" NAME="Begg 1996" TYPE="JOURNAL_ARTICLE">
<AU>Begg C, Cho M, Eastwood S, Horton R, Moher D, Ingram O, et al</AU>
<TI>Improving the quality of reporting of randomized controlled trials. The CONSORT statement</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>276</VL>
<NO>8</NO>
<PG>637-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brewer-1994" NAME="Brewer 1994" TYPE="JOURNAL_ARTICLE">
<AU>Brewer TG, Peggins JO, Grate SJ, Petras JM, Levine BS, Weina PJ et al</AU>
<TI>Neurotoxicity in animals due to arteether and artemether</TI>
<SO>Trans R Soc Trop Med Hyg</SO>
<YR>1984</YR>
<VL>88 suppl 1</VL>
<PG>33-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CCRGQ-1982" NAME="CCRGQ 1982" TYPE="JOURNAL_ARTICLE">
<AU>China Co-operative Group on Qinghaosu and its Derivatives as Antimalarials</AU>
<TI>Clinical studies on the treatment of malaria with qinhaosu and its derivatives</TI>
<SO>J Trad Chin Med</SO>
<YR>1982</YR>
<VL>2</VL>
<NO>1</NO>
<PG>49-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-Vries-1996" NAME="de Vries 1996" TYPE="JOURNAL_ARTICLE">
<AU>de Vries PJ, Dien TK</AU>
<TI>Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria</TI>
<SO>Drugs</SO>
<YR>1996</YR>
<VL>52</VL>
<NO>6</NO>
<PG>818-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hien-1993" NAME="Hien 1993" TYPE="JOURNAL_ARTICLE">
<AU>Hien TT, White NJ</AU>
<TI>Qinghaosu</TI>
<SO>The Lancet</SO>
<YR>1993</YR>
<VL>341</VL>
<PG>603-608</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hien-1994" NAME="Hien 1994" TYPE="JOURNAL_ARTICLE">
<AU>Hein TT</AU>
<TI>An overview of the clinical use of artemisinin and its derivatives in the treatment of falciparum malaria in Viet Nam</TI>
<SO>Trans R Soc Trop Med Hyg</SO>
<YR>1994</YR>
<VL>88 suppl 1</VL>
<PG>7-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Looareesuwan-1994" NAME="Looareesuwan 1994" TYPE="JOURNAL_ARTICLE">
<AU>Looareesuwan S</AU>
<TI>Overview of clinical studies on artemisinin derivatives in Thailand</TI>
<SO>Trans R Soc Trop Med Hyg</SO>
<YR>1994</YR>
<VL>88 suppl 1</VL>
<PG>9-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meshnick--1993" NAME="Meshnick  1993" TYPE="JOURNAL_ARTICLE">
<AU>Meshnick SR, Yang YZ, Lima V, Kuypers F, Kamchonwongpaisan S, Yuthavong Y</AU>
<TI>Iron-dependent free radical generation and the antimalarial artemisinin (qinghaosu)</TI>
<SO>Antimicrob Agents Chemother</SO>
<YR>1993</YR>
<VL>37</VL>
<PG>1108-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meshnick-1996" NAME="Meshnick 1996" TYPE="JOURNAL_ARTICLE">
<AU>Meshnick SR, Taylor TE, Kamchonwongpaisan S</AU>
<TI>Artemisinin and the antimalarial endoperoxidases: from herbal remedy to targeted chemotherapy</TI>
<SO>Microbiol Rev</SO>
<YR>1996</YR>
<VL>60</VL>
<NO>2</NO>
<PG>301-315</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Miller-1997" NAME="Miller 1997" TYPE="JOURNAL_ARTICLE">
<AU>Miller LG, Panosian CB</AU>
<TI>Ataxia and slurred speech after artesunate treatment for falciparum malaria [Letter]</TI>
<SO>N Eng Med J</SO>
<YR>1997</YR>
<VL>336</VL>
<NO>18</NO>
<PG>1328</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nosten-1994" NAME="Nosten 1994" TYPE="JOURNAL_ARTICLE">
<AU>Nosten F</AU>
<TI>Artemisinin: large community studies</TI>
<SO>Trans R Soc Trop Med Hyg</SO>
<YR>1994</YR>
<VL>88 suppl 1</VL>
<PG>45-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Olliaro-1995" NAME="Olliaro 1995" TYPE="JOURNAL_ARTICLE">
<AU>Olliaro PL, Trigg PI</AU>
<TI>Status of antimalarial drugs under development</TI>
<SO>Bull WHO</SO>
<YR>1995</YR>
<VL>73</VL>
<NO>5</NO>
<PG>565-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Olliaro-1996" NAME="Olliaro 1996" TYPE="JOURNAL_ARTICLE">
<AU>Olliaro P, Cattani J, Writh D</AU>
<TI>Malaria, the submerged disease</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>275</VL>
<NO>3</NO>
<PG>230-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-PRISM-1996" NAME="PRISM 1996" TYPE="JOURNAL_ARTICLE">
<AU>Unit for Policy Research in Science and Medicine</AU>
<TI>Malaria Research: an audit of international activity. PRISM, 1996</TI>
<PG>an audit of international activity. PRISM, 1996. Report No 7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-QARCG-1979" NAME="QARCG 1979" TYPE="JOURNAL_ARTICLE">
<AU>Qinghaosu Antimalarial Co-ordinating Research Group</AU>
<TI>Antimalarial studies on qinghaosu</TI>
<SO>Chin Med J</SO>
<YR>1979</YR>
<VL>92</VL>
<PG>811-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ribeiro-1998" NAME="Ribeiro 1998" TYPE="JOURNAL_ARTICLE">
<AU>Ribeiro IR, Olliaro P</AU>
<TI>Safety of artemisinin and its derivatives. A systematic review of published and unpublished clinical trials</TI>
<SO>Médecine Tropicale</SO>
<YR>1998</YR>
<VL>58</VL>
<NO>suppl 3</NO>
<PG>50-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Warrell-1990" NAME="Warrell 1990" TYPE="JOURNAL_ARTICLE">
<AU>Warrell DA, Molyneux ME, Beales PF (eds)</AU>
<TI>Severe and complicated malaria.</TI>
<SO>Trans R Soc Trop Med Hyg</SO>
<YR>1990</YR>
<VL>84</VL>
<NO>suppl 2</NO>
<PG>1-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wernsdorfer-1994" NAME="Wernsdorfer 1994" TYPE="JOURNAL_ARTICLE">
<AU>Wernsdorfer WH</AU>
<TI>Epidemiology of drug resistance in malaria</TI>
<SO>Acta Tropica</SO>
<YR>1994</YR>
<VL>56</VL>
<PG>143-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-White-1994" NAME="White 1994" TYPE="JOURNAL_ARTICLE">
<AU>White NJ</AU>
<TI>Artemisinin: current status</TI>
<SO>Trans R Soc Trop Med Hyg</SO>
<YR>1994</YR>
<VL>88 suppl 1</VL>
<PG>3-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1973" MODIFIED="2008-10-20 10:35:37 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 1973" TYPE="JOURNAL_ARTICLE">
<AU>World Health Organization</AU>
<TI>Chemotherapy of malaria and resistance to antimalarials</TI>
<SO>Technical Report Series</SO>
<YR>1973</YR>
<VL>529</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1988" MODIFIED="2008-10-20 10:35:07 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 1988" TYPE="BOOK">
<AU>World Health Organization</AU>
<SO>Guidelines for developing national drug policies</SO>
<YR>1988</YR>
<PB>World Health Organization</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1990" MODIFIED="2008-10-20 10:34:38 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 1990" TYPE="JOURNAL_ARTICLE">
<AU>World Health Organization</AU>
<TI>Practical chemotherapy of malaria. Geneva: WHO, 1990</TI>
<SO>Technical Report Series</SO>
<YR>1990</YR>
<VL>805</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1994" MODIFIED="2008-10-20 10:33:57 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 1994" TYPE="BOOK">
<AU>World Health Organization</AU>
<SO>Antimalarial drug policies. Report of an informal consultation, Geneva, 14-18 March 1994</SO>
<YR>1994</YR>
<PB>World Health Organization</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1995" MODIFIED="2008-10-20 10:33:30 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 1995" TYPE="BOOK">
<AU>World Health Organization</AU>
<SO>The world health report 1995: bridging the gaps</SO>
<YR>1995</YR>
<PB>World Health Organization</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1996" MODIFIED="2008-10-20 10:33:04 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 1996" TYPE="BOOK">
<AU>World Health Organization, Division of control of tropical diseases</AU>
<SO>Management of uncomplicated malaria and the use of antimalarial drugs for the protection of travellers; Report of an informal consultation, Geneva, 18-21 September 1995.</SO>
<YR>1995</YR>
<PB>World Health Organization</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Woerdenbag-1990" NAME="Woerdenbag 1990" TYPE="JOURNAL_ARTICLE">
<AU>Woerdenbag HJ, Lugt CB, Pras N</AU>
<TI>Artemisia annua L.:a source of novel antimalarial drugs</TI>
<SO>Pharm Weekbl [Sci]</SO>
<YR>1990</YR>
<VL>12</VL>
<NO>5</NO>
<PG>169-81</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES>
<REFERENCE ID="REF-IHM-1998" NAME="IHM 1998" TYPE="JOURNAL_ARTICLE">
<TI>Artemisinin drugs for treating malaria</TI>
<SO>International Health Matters. Department for International Development. Suitable health Benefits from Applied Research: Malaria</SO>
<YR>1998</YR>
<NO>3</NO>
<PG>10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McIntosh-1998" NAME="McIntosh 1998" TYPE="JOURNAL_ARTICLE">
<AU>McIntosh HM, Olliaro P</AU>
<TI>Treatment of uncomplicated malaria with Artemisinin derivatives. A systematic review of randomised controlled trials</TI>
<SO>Médecine Tropicale</SO>
<YR>1998</YR>
<VL>58</VL>
<NO>suppl 3</NO>
<PG>57-8</PG>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-10-25 18:47:10 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-10-25 18:47:10 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-10-25 18:45:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-AlinTAZ94">
<CHAR_METHODS MODIFIED="2008-08-05 09:19:05 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, method not specified; open</P>
<P>Follow-up 28 days</P>
<P>No exclusions reported</P>
<P>Loss to follow-up day 28: ART = 1/18 (5%), ART+MQ = 3/20 (15%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-25 18:45:26 +0100" MODIFIED_BY="[Empty name]">
<P>38 adults, male and female, 18 to 25 years; febrile, <I>Plasmodium falciparum</I> &gt;1000/µl</P>
<P>Excluded: severe/cerebral malaria; recent antimalarial treatment; pregnancy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-05 11:36:33 +0100" MODIFIED_BY="[Empty name]">
<P>ARTpo vs ARTpo + MQ15 (C)<BR/>ART 3000 mg/5 d (500 mg x 2 on d1, 250 mg x 2 on days 2 to 5)<BR/>ART 2000 mg/2 d (500 + 750 mg on d1, 250 mg x 3 on d2) + MQ 750 mg (250 mg x 3 on d1)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinical: FCT<BR/>Parasitological: PCT, PC50, recrudescence<BR/>Adverse events<BR/>Pharmacokinetics</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-04 16:57:35 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: B, B, C</P>
<P>ART (capsules) from Institute Materia Medica, Hanoi</P>
<P>Holoendemic area, drug resistance not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-20 10:40:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-AlinTAZ96">
<CHAR_METHODS MODIFIED="2008-08-05 09:19:06 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, method not specified</P>
<P>Follow-up 28 days</P>
<P>No exclusions reported</P>
<P>Loss to follow-up day 28: ART = 0/20, AS = 1/20 (5%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-20 10:40:17 +0100" MODIFIED_BY="[Empty name]">
<P>40 male and female, 14 to 50 years; febrile, Pf&gt;1000/µl</P>
<P>Excluded: severe malaria; recent antimalarials; pregnancy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-05 11:36:42 +0100" MODIFIED_BY="[Empty name]">
<P>ARTpo vs ASpo<BR/>ART 3000 mg/6 d (500 mg on d1, 2 x 250 mg on days 2 to 5, 500 mg on d6)<BR/>AS 600 mg/6 d (100 mg on day 1, 2 x 50 mg on days 2 t6)<BR/>Treatment supervised</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinical: FCT<BR/>Parasitological: PCT, PC50, recrudescence<BR/>Pharmacokinetics<BR/>Adverse events: clinical observation and patient reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 08:44:01 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: B, B, A</P>
<P>ART (capsules) from Institute of Materia Medica, Viet Nam; AS (tablets) from Guilin Pharmaceutical Works, China</P>
<P>Holoendemic area, drug resistance not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-20 10:40:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ArnoldVNM89">
<CHAR_METHODS MODIFIED="2008-08-05 09:19:07 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised using table of random numbers, allocation concealment not reported</P>
<P>Follow-up 28 days</P>
<P>No exclusions reported</P>
<P>Loss to follow-up day 28: ART = 5/32 (16%), QNN = 8/30 (27%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-20 10:40:17 +0100" MODIFIED_BY="[Empty name]">
<P>62 adults, male and female, 17 to 56 years; Pf asexual 1000 to 150,000/µl; negative Dill-Glazko and lignin urine test.</P>
<P>Excluded: antimalarials for current illness; confusion; coma; pregnancy; heart, liver, kidney disease; PfPv</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-05 08:41:55 +0100" MODIFIED_BY="[Empty name]">
<P>ARTpr vs QNNpo<BR/>ART 2800 mg (600 mg at 0 and 6 h, 400 mg at 24, 32, 48 and 56 h)<BR/>QNN 21,000 mg (500 mg x 3, daily for 14 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinical: FCT<BR/>Parasitological: PCT, PC50; recrudescence<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 08:42:11 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: B, A, C</P>
<P>ART supplied by Prof. Li Guo Qiao, Sanya Tropical Medicine Institute, China</P>
<P>Endemic catchment area, drug resistance not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-20 10:37:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-BunnagTHI89a">
<CHAR_METHODS MODIFIED="2008-08-05 11:36:56 +0100" MODIFIED_BY="[Empty name]">
<P>Random allocation reported, method not specified</P>
<P>Follow-up 28 days</P>
<P>No exclusions reported</P>
<P>Loss to follow-up at day 28: AS600/1 d = 0/5, AS600/2 d = 0/5, AS600/5 d = 1/10, AS1200 = 1/6 (17%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-20 10:37:45 +0100" MODIFIED_BY="[Empty name]">
<P>26 male, &gt;14 years</P>
<P>Excluded: PfPv; Pf &gt; 100,000/µl; concurrent disease; recent antimalarials; urine positive for sulfonamides/4-aminoquinolines</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-04 16:33:57 +0100" MODIFIED_BY="[Empty name]">
<P>ASpo dose/regimens<BR/>AS1200 mg vs 600 mg over 5 days<BR/>AS 600 mg over 1, 2 or 5 days<BR/>150 mg CLQ base if Pv detected during follow-up</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinical: FCT<BR/>Parasitological: PCT, cure, recrudescence<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 08:51:37 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: B, B, C</P>
<P>AS (50 mg tablet) supplied by Prof. Li Guo Qiao, Sanya Tropical Medicine Institute, China</P>
<P>Five treatment groups excluded: AS 650 mg over 5 days; AMim; ASiv; ASpo200+CLQ; ASpo200+SP (total 21 patients)</P>
<P>Endemicity and drug resistance not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-05 11:37:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-BunnagTHI89b">
<CHAR_METHODS MODIFIED="2008-08-05 09:19:15 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, method not specified; double blind</P>
<P>Follow-up 28 days</P>
<P>No exclusions reported</P>
<P>Loss to follow-up: 9/59 (15%) total</P>
<P>Evaluated: AS daily = 25, twice daily = 25</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-05 10:17:44 +0100" MODIFIED_BY="[Empty name]">
<P>59 adults, male and= female, 15 to 52 years; acute uncomplicated malaria, Pf asexual &lt; 5%</P>
<P>Excluded: history of liver/kidney disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-05 11:37:05 +0100" MODIFIED_BY="[Empty name]">
<P>ASpo daily vs twice daily dose<BR/>AS600 mg/5 d (200 mg on day 1, 100 mg on days 2 to 5)<BR/>AS600 mg/5 d (100 mg at 0 and 12h, then 8 x 50 mg at 12 h intervals)<BR/>Treatment supervised; 150 mg CLQ base if Pv detected during follow-up</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinical: FCT<BR/>Parasitological: PCT, cure, recrudescence<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 08:53:09 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: B, B, C</P>
<P>AS (from Atlantic Laboratories Corp. Ltd, Thailand?)</P>
<P>Endemicity not reported, 67% of patients from multidrug resistant areas</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-05 08:57:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-BunnagTHI92_x002d_4a">
<CHAR_METHODS MODIFIED="2008-08-05 08:53:34 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, method not specified, double blind</P>
<P>Follow-up 42 days</P>
<P>No exclusions reported</P>
<P>Loss to follow-up: MQ25 = 10/80 (12%), MQ15 = 6/79 (8%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-05 08:53:56 +0100" MODIFIED_BY="[Empty name]">
<P>159 male adults, 15 to 65 years; acute uncomplicated malaria, Pf asexual &lt; 5%</P>
<P>Excluded: history of liver/kidney disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-05 08:57:12 +0100" MODIFIED_BY="[Empty name]">
<P>ASpo + MQ15 vs ASpo + MQ25<BR/>AS300 mg (singles dose) + MQ 750 mg at 24 h, 500 mg at 30 h<BR/>AS300 mg (singles dose) + MQ 750 mg at 24 h, placebo at 30 h<BR/>300 mg CLQ if Pv detected during follow-up</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-05 08:57:21 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical: Fever clearance within 24 and 48 h<BR/>Parasitological: Parasite clearance within 24 and 48 h, cure, recrudescence<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 08:57:33 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: B, B, B</P>
<P>Source of AS: not reported</P>
<P>Endemicity not reported, mentions high resistance to CLQ, SP, increasing resistance to QNN and MQ in Thailand</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-05 10:23:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-BunnagTHI92_x002d_4b">
<CHAR_METHODS MODIFIED="2008-08-05 09:01:23 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, method not specified</P>
<P>Follow-up 42 days</P>
<P>No exclusions reported</P>
<P>Loss to follow-up day 42: AM = 2/60 (3%), AS = 3/60 (5%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-05 10:23:25 +0100" MODIFIED_BY="[Empty name]">
<P>120 male, 15 to 57 years; acute uncomplicated malaria; Pf asexual &lt; 5%</P>
<P>Excluded: history of liver/kidney disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-05 08:58:28 +0100" MODIFIED_BY="[Empty name]">
<P>AMpo + MQ25 vs ASpo + MQ25 (S)<BR/>AM 300 mg (single dose) + MQ 1250 mg (750 mg at 24 h, 500 mg at 30 h)<BR/>AS 300 mg (single dose) + MQ 1250 mg (as before)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-05 08:58:46 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical: Fever clearance within 24 and 48 h<BR/>Parasitological: Parasite clearance within 24 and 48 h, cure, recrudescence<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 08:59:00 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: B, B, A</P>
<P>AM (50 mg tablet) from Arenco, Belgium; AS (50 mg tablet) from Guilin Pharmaceuticals, China</P>
<P>Endemicity not reported, multidrug resistance</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-05 11:37:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-CardosoBRZ93_x002d_4">
<CHAR_METHODS MODIFIED="2008-08-05 09:01:58 +0100" MODIFIED_BY="[Empty name]">
<P>First 3 patients allocated by lottery, followed by sequential application of the same numbers; open</P>
<P>Follow-up 35 days </P>
<P>Excluded: AS = 1/51 (2%) </P>
<P>Loss to follow-up day 35: AS+MQ = 9/51 (18%), AS = 5/50 (10%), MQ = 5/51 (10%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-05 10:18:08 +0100" MODIFIED_BY="[Empty name]">
<P>103 male and female, 14 to 60 years; signs and symptoms of uncomplicated malaria; Pf asexual.</P>
<P>Excluded: &lt; 12 years; heart, liver, kidney disease; pregnancy; antimalarials in previous 15 days; PfPv; serious associated infection; unable to remain in study area for 35 days</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-05 11:37:15 +0100" MODIFIED_BY="[Empty name]">
<P>ASpo vs ASpo + MQ10(S) vs MQ20<BR/>AS 1000 mg/4 d (200 mg at 0 and12 h; 100 mg x 2 on days 2 to 4)<BR/>AS 600 mg/2 d (200 mg at 0, 12 and 24 h) + MQ 500 mg (at 36 h)<BR/>MQ 1000 mg (500 mg at 0 and 8h)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinical: FCT<BR/>Parasitological: PCT, cure, recrudescence<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 09:03:02 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: B, B, C</P>
<P>AS: Plasmotrim Lactab (50 mg), Mepha, Switzerland</P>
<P>High transmission area; CQ, QNN resistance</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-05 10:18:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-EzedinachiNIG92">
<CHAR_METHODS MODIFIED="2008-08-05 09:03:23 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, method not specified</P>
<P>Follow-up 14 days</P>
<P>Excluded: SP = 4/52 (8%)</P>
<P>Loss to follow-up not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-05 10:18:09 +0100" MODIFIED_BY="[Empty name]">
<P>155 adults and children; Pf parasitaemia; no other visible disease</P>
<P>Excluded: unable to take oral medication; concomitant illness</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-05 09:04:32 +0100" MODIFIED_BY="[Empty name]">
<P>ASpo vs CLQpo vs SPpo<BR/>AS 550 mg (100 mg at 0 h, 50 mg every 12 h for 5 days)<BR/>CLQ 75 mg/kg (25 mg/kg for 3 days)<BR/>SP (age-adjusted single dose)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinical: symptom clearance rate per group according to a defined scoring system<BR/>Parasitological: PCT<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 10:18:11 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: B, B, B</P>
<P>AS from Guilin Pharmaceutical (sic), Guangxi, China</P>
<P>Symptom score: 1 point for each case of fever, headache, bitter mouth, aches and pains, malaise</P>
<P>One treatment group excluded: Halfan po 72 mg/kg (24 mg/kg at 6, 12, 18 h), 53 patients</P>
<P>Endemicity, drug resistance not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-20 10:37:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-GuoCHI87">
<CHAR_METHODS MODIFIED="2008-08-05 09:05:31 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, random number table set up by coin tossing; patients blind</P>
<P>Follow-up 28 days</P>
<P>No exclusions reported</P>
<P>Loss to follow-up day 28: AS280 = 9/50 (18%), AS440 = 5/50 (10%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-20 10:37:46 +0100" MODIFIED_BY="[Empty name]">
<P>100 male and female, 9 to 60 years; symptoms of malaria; Pf asexual &gt;1000/µl with illness &lt; 5 days or Pf asexual &gt; 5000/µl with illness of &gt; 5days</P>
<P>Excluded: serious gastrointestinal symptoms</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-05 11:37:31 +0100" MODIFIED_BY="[Empty name]">
<P>ASpo 280 mg/3 d vs ASpo 440 mg/5 d<BR/>(80 mg at 0 h, 40 mg at 6 h on day 1, then 80 mg/day for 2 to 4 days; equivalent dose adjusted for age)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinical: FCT<BR/>Parasitological: PCT, cure, recrudescence<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 09:06:22 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: B, B, C</P>
<P>AS (20 mg tablet) from Guilin Pharmaceutical Factory, China</P>
<P>One treatment group excluded: piperaquine, 50 patients</P>
<P>Endemicity, drug resistance not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-20 10:37:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-HatzTAZ_x0028_98_x0029_">
<CHAR_METHODS MODIFIED="2008-08-05 09:14:51 +0100" MODIFIED_BY="[Empty name]">
<P>Random allocation in blocks of 6, sequence generation not specified;open</P>
<P>Follow-up 14 days for major outcomes reported, follow-up also at day 28</P>
<P>Exclusions/Loss to follow-up at day 7: Co-AM = 14/130 (11%); CLQ = 34/130 (26%); at day 14: Co-AM = 20/130 (15%); CLQ = 33/130 (25%); Total premature discontinuation: Co-AM = 24/130 (18.5%), CLQ = 94/130 (72.3%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-20 10:37:47 +0100" MODIFIED_BY="[Empty name]">
<P>260 children 1 to 5 years; febrile; &gt;5kg; acute uncomplicated malaria; Pf &gt; 5000/µl</P>
<P>Excluded: intolerance of oral medication; signs of severe malaria; malnutrition; antimalarials in previous 48 h; sensitivity to chloroquine; underlying chronic disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-05 11:37:48 +0100" MODIFIED_BY="[Empty name]">
<P>Co-AMpo vs CLQpo<BR/>Co-AM/2 d: 5 to10 kg body weight given AM40 mg + Lumifantrine 240 mg;10 to15 kg given x 2 dose; 15 to 20 kg given x 3 dose; 20 to 25 kg given x 4 dose (4 equal doses at 0, 8, 24 and 48 h)<BR/>25 Co-AM and 93 CLQ patients received other antimalarials in the 28 day study period (118 discontinued prematurely<BR/>All received paracetamol 250 mg x 2/d in first 3 to 4 days; 2 CLQ patients received cotrimoxazole; 183/260 had other medication for pneumonia, anaemia, ulcers, rash<BR/>CLQ 25 mg/kg/3 d (10, 5, 5, 5 mg/kg)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-05 09:10:25 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical: fever at 48 h; Hb<BR/>Parasitological: cure at 7 d and 14 d; % parasite reduction on days 1, 2 and 3; gametocytaemia on days 0, 1, 2, 3 and 7<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 09:10:14 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: B, B, C</P>
<P>Co-AM (CGP56697) from Novartis Pharma A.G.</P>
<P>Permanent transmission area</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-20 10:37:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-HienVNM_x0028_94_x0029__x005b_1_x005d_">
<CHAR_METHODS MODIFIED="2008-08-05 09:16:20 +0100" MODIFIED_BY="[Empty name]">
<P>Computer generated block randomisation table, allocation concealed in sealed envelopes; open</P>
<P>Follow-up 28 days</P>
<P>No exclusions reported</P>
<P>Loss to follow-up ART = 9/45 (20%), ART+MQ = 5/45 (11%), ART+SP = 10/48 (21%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-20 10:37:48 +0100" MODIFIED_BY="[Empty name]">
<P>138 adults, 16 to 62 years; acute uncomplicated malaria; Pf asexual 1000 to 500,000/µl; no underlying disease</P>
<P>Excluded: PfPv; pregnancy; severe or complicated malaria</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-05 09:16:39 +0100" MODIFIED_BY="[Empty name]">
<P>ARTpo vs ARTpo + MQ10 vs ARTpo + SP<BR/>ART 2500 mg (500 mg/d for 5 days)<BR/>ART 500 mg (single dose) + MQ 500 mg (single dose at 6 h)<BR/>ART 500 mg (as before) + SP 1.5 g/75 mg (single dose at 6 h)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinical: FCT<BR/>Parasitological: PCT (50, 90, 100%), recrudescence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 09:17:00 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: A, A, C</P>
<P>Source of ART not reported (Roche?)</P>
<P>No local transmission, mentions CLQ, SP resistance and increasing resistance to QNN in Viet Nam</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-20 10:37:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-HienVNM90">
<CHAR_METHODS MODIFIED="2008-08-05 09:17:28 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, method not specified</P>
<P>Follow-up 28 days</P>
<P>No exclusions reported</P>
<P>Loss to follow-up day 28: ART = 21/30 (70%), QNN = 23/30 (77%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-20 10:37:49 +0100" MODIFIED_BY="[Empty name]">
<P>60 children, male and female, 4 to 13 years; Pf asexual 1000 to 150,000/µl; negative Dill-Glazko and lignin urine test</P>
<P>Excluded: antimalarials for current illness; confusion; coma; pregnancy; heart, liver, kidney disease; PfPv</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-05 11:38:04 +0100" MODIFIED_BY="[Empty name]">
<P>ARTpr vs QNNpo<BR/>ART 600 to1200 mg/3 d adjusted for age (100 to 600 mg at 0 h, 100 to 400 mg at 4h, 100 to 300 mg on day 2 and day 3)<BR/>QNN 300 mg/kg (10 mg/kg every 8 h for 10 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinical: FCT<BR/>Parasitological: PCT (50, 90, 100%); recrudescence<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 09:21:33 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: B, B, C</P>
<P>ART supplied by Prof. Li Guo Qiao, Sanya Tropical Medicine Institute, China</P>
<P>Endemic area, drug resistance not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-20 10:37:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-HungVNM93_x002d_4">
<CHAR_METHODS MODIFIED="2008-08-05 09:21:50 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, method not specified; double blind</P>
<P>Follow-up 28 days</P>
<P>Excluded: ART+MQ = 5/122 (4%), MQ = 4/118 (3%)</P>
<P>Loss to follow-up day 28: 2/117 (2%), 2/114 (2%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-20 10:37:49 +0100" MODIFIED_BY="[Empty name]">
<P>240, adults and children, male and female, 6 to 59 years; Pf 1000 to 100,000/µl</P>
<P>Excluded: complicated malaria; PfPv; pregnancy; lactation; unable to take oral drug; known allergy to treatment; recent ART, QNN, MQ, Tc, Dox</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-05 09:22:14 +0100" MODIFIED_BY="[Empty name]">
<P>ARTpo + MQ10 vs MQ10 (S)<BR/>ART 500 mg (single dose) + MQ 500 mg (at 2 h)<BR/>Placebo + MQ 500 mg (at 2 h)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinical: FCT<BR/>Parasitological: PCT, cure, recrudescence<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 09:22:25 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: B, B, A</P>
<P>ART from ACF-Chemie, The Netherlands</P>
<P>Endemic area, mentions CLQ and SP resistance in Viet Nam</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-05 11:38:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-KarbwangTHI91">
<CHAR_METHODS MODIFIED="2008-08-05 09:22:44 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, method not specified; open</P>
<P>Follow-up AM 28 days, MQ 42 days</P>
<P>No exclusions reported</P>
<P>Loss to follow-up: AM (day 28) = 4/34 (12%), MQ (day 42) = 1/12 (8%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-05 09:22:58 +0100" MODIFIED_BY="[Empty name]">
<P>46 adult male, 17 to 48 years; febrile, acute uncomplicated malaria; Pf &lt; 5% asexual</P>
<P>Excluded: liver/kidney disease; antimalarials for current illness</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-05 11:38:15 +0100" MODIFIED_BY="[Empty name]">
<P>AMpo vs MQ25<BR/>AM 700 mg/5 d (200 mg at 0 and 6 h; 100 mg on days 2 to 5)<BR/>MQ 1250 mg (750 mg at 0 h, 500 mg at 6 h)<BR/>Treatment supervised; 150 mg CLQ base if Pv detected during follow-up</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinical: FCT<BR/>Parasitological: PCT, PC50, cure, recrudescence<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 09:23:25 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: B, B, B</P>
<P>AM supplied by United Medical Ltd, Bangkok</P>
<P>No local transmission, mentions multidrug resistance in Thailand</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-05 10:20:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-KarbwangTHI92a">
<CHAR_METHODS MODIFIED="2008-08-05 09:23:37 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, method not specified</P>
<P>Follow-up 42 days</P>
<P>Excluded: 2/22 (9%) total</P>
<P>No loss to follow-up reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-05 10:20:27 +0100" MODIFIED_BY="[Empty name]">
<P>20 adult male, 17 to 48 years; acute uncomplicated Pf malaria; Pf asexual &lt; 5%</P>
<P>Excluded: history of liver/kidney disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-05 09:23:57 +0100" MODIFIED_BY="[Empty name]">
<P>ASpo + MQ25 (S) vs MQ25<BR/>AS (200 mg single dose) + MQ 1250 mg (750 mg at 6 h, 500 mg at 12 h)<BR/>MQ 1250 mg (as before)<BR/>Treatment supervised</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinical: FCT<BR/>Parasitological: PCT, cure, recrudescence<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 09:24:04 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: B, B, B</P>
<P>AS supplied by Atlantic Co. Ltd, Thailand</P>
<P>Patients with CLQ resistant malaria</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-05 11:38:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-KarbwangTHI92b">
<CHAR_METHODS MODIFIED="2008-08-05 09:24:19 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, method not specified; open</P>
<P>Follow-up 28 days</P>
<P>No exclusions reported</P>
<P>Loss to follow-up day 28: AS = 1/31 (3%), QNN+Tc = 3/33 (9%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-05 09:28:02 +0100" MODIFIED_BY="[Empty name]">
<P>64 male adults, 15 to 35 years; acute uncomplicated malaria, Pf asexual &lt; 5%</P>
<P>Excluded: severe malaria (<LINK REF="REF-WHO-1990" TYPE="REFERENCE">WHO 1990</LINK>); history of liver/kidney disease; antimalarials for current episode</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-05 11:38:21 +0100" MODIFIED_BY="[Empty name]">
<P>ASpo vs QNN+Tc po<BR/>AS 700 mg/5 d (200 mg at 0 h, 100 mg at 12 h then daily for 4 d)<BR/>QNN 600 mg 8 hourly + Tc 250 mg 6 hourly for 7 d</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinical: FCT<BR/>Parasitological: PCT, cure, recrudescence<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 09:28:39 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: B, B, B</P>
<P>AS (50 mg tablet) China</P>
<P>Mentions multidrug resistance in Thailand</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-05 11:38:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-KarbwangTHI92c">
<CHAR_METHODS MODIFIED="2008-08-05 09:29:05 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, method not specified</P>
<P>Follow-up AS 28 days, AS+MQ 42 days</P>
<P>No exclusions reported</P>
<P>Loss to follow-up: AS (day 28) = 1/32 (3%), AS+MQ (day 42) = 6/34 (18%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-05 10:23:47 +0100" MODIFIED_BY="[Empty name]">
<P>66 male, 15 to 58 years; acute uncomplicated malaria, Pf asexual &lt; 5%</P>
<P>Excluded: history of liver/kidney disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-05 11:38:28 +0100" MODIFIED_BY="[Empty name]">
<P>ASpo vs ASpo + MQ15 (S)<BR/>AS 700 mg/5 d (200 mg at 0 h, 100 mg at 12 h, 100 mg on days 2 to 5)<BR/>AS 300 mg/1 d (200 mg at 0 h, 100 mg at 12 h) + MQ 750 mg (at 24 h)<BR/>300 mg CLQ base if Pv detected during follow-up</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinical: FCT<BR/>Parasitological: PCT, cure, recrudescence<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 09:29:53 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: B, B, C</P>
<P>AS: China (50 mg tablet)</P>
<P>CLQ resistant malaria</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-05 11:38:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-KarbwangTHI93">
<CHAR_METHODS MODIFIED="2008-08-05 09:30:08 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, method not specified</P>
<P>Follow-up AM 28 days, AM+MQ 42 days</P>
<P>No exclusions reported</P>
<P>Loss to follow-up: AM+MQ = 6/56 (11%), AM = 3/53 (6%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-05 09:30:22 +0100" MODIFIED_BY="[Empty name]">
<P>109 male, 13 to 47 years; febrile; Pf &lt; 5%</P>
<P>Excluded: history of liver/kidney disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-05 11:38:33 +0100" MODIFIED_BY="[Empty name]">
<P>AMpo vs AMpo + MQ15 (S)<BR/>AM 700 mg/5 d (300 mg on day 1, 100 mg on days 2 to 5)<BR/>AM 300 mg (single dose) + MQ 750 mg (at 24 h)<BR/>300 mg CLQ base if Pv detected during follow-up</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinical: FCT <BR/>Parasitological: PCT, recrudescence<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 09:31:05 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: B, B, B</P>
<P>AM: Artenam, Arenco, Belgium</P>
<P>Mentions multidrug resistant malaria in Thailand</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-05 09:31:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-KarbwangTHI93_x002d_4">
<CHAR_METHODS MODIFIED="2008-08-05 09:31:17 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, method not specified</P>
<P>Follow-up 42 days</P>
<P>No exclusions reported</P>
<P>Loss to follow-up day 42: MQ25 = 2/30 (7%), MQ15 = 0/27</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-05 09:31:32 +0100" MODIFIED_BY="[Empty name]">
<P>57 male adults, 13 to 47 years; acute uncomplicated malaria, Pf asexual &lt; 5%</P>
<P>Excluded: history of liver/kidney disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-05 09:31:38 +0100" MODIFIED_BY="[Empty name]">
<P>AM + MQ15 (S) vs AM + MQ25 (S)<BR/>AM 300 mg/sd + MQ 750 mg at 24 h<BR/>AM 300 mg/sd + MQ 750 mg at 24 h, 500 mg at 30 h</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinical: FCT<BR/>Parasitological: PCT, cure, recrudescence<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 09:31:52 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: B, B, B</P>
<P>AM: Artenam, Profarma n.v., Belgium</P>
<P>Mentions multidrug resistant malaria in Thailand</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-20 10:37:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-CHI82_x002d_4">
<CHAR_METHODS MODIFIED="2008-08-05 09:34:10 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, random number table set up by coin tossing </P>
<P>Follow-up 28 days</P>
<P>No exclusions reported</P>
<P>Loss to follow-up day 28: ART = 3/20 (15%), ART+MQ = 0/20</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-20 10:37:51 +0100" MODIFIED_BY="[Empty name]">
<P>40 male and female, 8 to 60 years; febrile; clinical diagnosis of malaria; Pf asexual &gt; 1000/µl (or &gt; 5000/µl if febrile &gt; 5 days)</P>
<P>Excluded: treated; other serious disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-05 11:39:07 +0100" MODIFIED_BY="[Empty name]">
<P>ARTpo vs ARTpo + MQ15<BR/>ART 3000 mg/3 d (1000 mg/day)<BR/>ART 1000 mg (single dose) + MQ 750 mg<BR/>Treatment supervised</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinical: FCT<BR/>Parasitological: PCT, PC95, cure, recrudescence<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 09:34:52 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: B, B, C</P>
<P>ART produced by Institute for Chinese Pharmacy, Academy of Traditional Chinese Medicine</P>
<P>Endemicity not reported, chloroquine resistance</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-20 10:37:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-LooareesuwanTHI91">
<CHAR_METHODS MODIFIED="2008-08-05 09:35:02 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, method not specified; open label</P>
<P>Follow-up 28 days</P>
<P>Excluded after treatment: MQ = 2/43 (5%)</P>
<P>Loss to follow-up day 28: AS+MQ = 3/42 (7%), AS 2/42 (5%), MQ = 4/41 (10%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-20 10:37:51 +0100" MODIFIED_BY="[Empty name]">
<P>127 male and female, 16 to 60 years; febrile; acute uncomplicated malaria; Pf asexual 100 to 200,000/µl</P>
<P>Excluded: severe malaria; pregnancy; antimalarials in previous week</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-05 11:39:13 +0100" MODIFIED_BY="[Empty name]">
<P>ASpo vs ASpo + MQ25(S) vs MQ25<BR/>AS 600 mg/5 d (100 mg at 0 h, 50 mg every 12 h for 5 days)<BR/>AS (as before) + MQ 1250 mg (750 mg 12 h after last dose of AS, 500 mg 6 h later)<BR/>MQ25 (750 mg at 0 h, 500 mg at 6 h)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinical: FCT<BR/>Parasitological: PCT, cure, recrudescence<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 09:35:44 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: B, B, B</P>
<P>AS (tablet) from Atlantic Pharmaceutical Co. Ltd, Thailand</P>
<P>No local transmission, multidrug resistance, 24/127 (19%) patients with first attack of malaria</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-20 10:37:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-LooareesuwanTHI92b">
<CHAR_METHODS MODIFIED="2008-08-05 09:37:09 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, method not specified; open label</P>
<P>Follow-up 28 days</P>
<P>Enrollment to AM5d stopped early when cure rate fell below 80%, so only partially randomised</P>
<P>No exclusions reported</P>
<P>Loss to follow-up day 28: AM5d = 2/40 (5%), AM7d = 9/58 (16%), AM+MQ = 9/53 (17%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-20 10:37:52 +0100" MODIFIED_BY="[Empty name]">
<P>151, male and female, 16 to 50 years; acute uncomplicated malaria; Pf 1000 to 200,000/µl</P>
<P>Excluded: severe malaria; pregnancy; lactating; MQ in previous 2 weeks</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-05 11:39:26 +0100" MODIFIED_BY="[Empty name]">
<P>AMpo vs AMpo + MQ25<BR/>AM500 mg/5 d (100 mg, then 50 mg every 12 h for 5 days)<BR/>AM750 mg/7 d (100 mg, then 50 mg every 12 h for 7 days)<BR/>AM600 mg/1 d (200 mg at 0, 8 and 16 h) + MQ 1250 mg (at 24 h, 2 doses 6 h apart)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinical: FCT<BR/>Parasitological: PCT, cure, recrudescence<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 09:38:01 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: B, B, C</P>
<P>AM (50 mg capsule) from Kunming Pharmaceutical Factory, China</P>
<P>No local transmission, multidrug resistance</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-05 11:39:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-LooareesuwanTHI93">
<CHAR_METHODS MODIFIED="2008-08-05 09:38:12 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, method not specified; open label</P>
<P>Follow-up 28 days</P>
<P>No exclusions reported</P>
<P>Loss to follow-up day 28: AS+MQ = 12/62 (19%), MQ 6/63 (10%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-05 10:18:16 +0100" MODIFIED_BY="[Empty name]">
<P>125 male and female, 16 to 60 years; acute uncomplicated malaria</P>
<P>Excluded: severe malaria; pregnancy; antimalarials in previous week</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-05 11:39:31 +0100" MODIFIED_BY="[Empty name]">
<P>ASpo + MQ15 (S) vs MQ25<BR/>AS 800 mg/2 d (200 mg every 12 h) + MQ 750 mg (6 h later)<BR/>MQ 1250 mg (750 mg at 0 h, 500 mg at 6 h)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinical: FCT<BR/>Parasitological: PCT, cure, recrudescence<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 09:38:46 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: B, B, C</P>
<P>AS: Plasmotrim Lactab, Mepha, Switzerland</P>
<P>Endemicity, transmission not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-20 10:37:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-LooareesuwanTHI95">
<CHAR_METHODS MODIFIED="2008-08-05 09:38:57 +0100" MODIFIED_BY="[Empty name]">
<P>Computer generated randomisation in blocks of ten; open label</P>
<P>Follow-up 28 days</P>
<P>No exclusions reported</P>
<P>Loss to follow-up day 28: AS1200 = 3/45 (7%), AS1600 = 6/46 (13%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-20 10:37:53 +0100" MODIFIED_BY="[Empty name]">
<P>91 male and female, 16 to 60 years; acute uncomplicated malaria (65/91 first attack of malaria); Pf 500 to 200,000/µl</P>
<P>Excluded: severe malaria; pregnancy; antimalarials in previous 2 weeks</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-05 11:39:39 +0100" MODIFIED_BY="[Empty name]">
<P>ASpo1200 vs 1600<BR/>AS 1200 mg/5 d (200 mg x 2 on day 1, 200 mg on days 2 to 5)<BR/>AS 1600 mg/7 d (200 mg x 2 on day 1, 200 mg on days 2 to 7)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinical: FCT<BR/>Parasitological: PCT (50, 90, 100%), cure, recrudescence<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 09:40:08 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: B, A, B</P>
<P>AS: Plasmotrim, Lactab, Mepha, Switzerland</P>
<P>Endemicity, transmission not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-05 09:49:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-LuxemburgerTHI_x002d_MYA91">
<CHAR_METHODS MODIFIED="2008-08-05 09:40:22 +0100" MODIFIED_BY="[Empty name]">
<P>Patients allocated at random in pairs, method not specified; open</P>
<P>Follow-up 28 days</P>
<P>Excluded: AS+MQ 4/274 (1%), MQ = 5/278 (2%)</P>
<P>Loss to follow-up day 28: 59/270 (22%), 47/273 (17%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-05 09:41:13 +0100" MODIFIED_BY="[Empty name]">
<P>552 adults &gt; 15 years and children &lt; 6 years; febrile or history of fever; Pf asexual positve</P>
<P>Excluded: severe malaria; concomitant disease; antimalarials in previous week; pregnancy; children &lt; 6 kg; history of neuropsychiatric disorder</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-05 09:49:33 +0100" MODIFIED_BY="[Empty name]">
<P>ASpo + MQ15 (C) vs MQ25<BR/>AS 10 mg/kg (3 doses at 8 h intervals) + MQ 750 mg (single dose)<BR/>MQ 1250 mg (single dose)<BR/>Treatment supervised, drugs given after temperature reduced by paracetamol and tepid sponging</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-05 09:49:47 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical: number afebrile at 24 and 48 h; symptomatic treatment failure<BR/>Parasitological: asymptomatic treatment failure<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 09:49:59 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: B, B, C</P>
<P>AS (tablet) from Guilin No.1 Factory, China</P>
<P>Seasonal unstable transmission, multidrug resistance</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-05 10:21:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nosten_x005b_1_x005d_THI_x002d_MYA92_x002d_3">
<CHAR_METHODS MODIFIED="2008-08-05 09:50:19 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised in pairs, method not specified</P>
<P>Follow-up 28 days</P>
<P>Excluded: AS+MQ = 5/151 (3%), MQ = 2/153 (1%)</P>
<P>Loss to follow-up day 28: 27/146 (18%), 31/151 (20%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-05 10:21:05 +0100" MODIFIED_BY="[Empty name]">
<P>304 adults and children, 6 months to 88 years; slide positive Pf</P>
<P>Excluded: severe malaria; pregnancy; children &lt; 5kg; antimalarials in previous month</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-04 16:35:23 +0100" MODIFIED_BY="[Empty name]">
<P>ASpo + MQ25 (C) vs MQ25<BR/>AS 4 mg/kg (single dose) + MQ 1250 mg (concomitant single dose)<BR/>MQ 1250 mg (single dose)<BR/>Treatment supervised; patients with high temperature cooled and given acetaminophen before mefloquine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinical: % patients febrile at each follow-up; haematological recovery<BR/>Parasitological: % patients parasitaemic at each follow-up; failure rate; recrudescence<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 09:50:55 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: B, B, C</P>
<P>AS (tablet) from Guilin Pharmaceutical Factory No1, China</P>
<P>Seasonal hypoendemic to mesoendemic, multidrug resistance</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-05 11:39:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nosten_x005b_2_x005d_THI_x002d_MYA92_x002d_3">
<CHAR_METHODS MODIFIED="2008-08-05 09:51:10 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, method not specified</P>
<P>Follow-up 63 days</P>
<P>No exclusions reported</P>
<P>Loss to follow-up day 28: AS+MQ = 26/179 (14%), MQ = 15/169 (9%); day 63: 71/179 (40%), 40/169 (24%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-05 10:18:18 +0100" MODIFIED_BY="[Empty name]">
<P>348 adults and children, 4 months to 58 years; slide positive Pf</P>
<P>Excluded: severe malaria; pregnancy; children &lt; 5kg; antimalarials in previous month</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-05 11:39:52 +0100" MODIFIED_BY="[Empty name]">
<P>ASpo + MQ25 (S) vs MQ25<BR/>AS 10 mg/kg/3 d (4 mg/kg initially, then 2 mg/kg once daily (n = 112) or 1 mg/kg twice daily (n = 67)) + MQ 1250 mg (on day 2)<BR/>MQ 1250 mg<BR/>Treatment supervised; patients with high temperature cooled and given acetaminophen before mefloquine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinical: % patients febrile at each follow-up; haematological recovery<BR/>Parasitological: % patients parasitaemic at each follow-up; failure rate; recrudescence<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 09:57:58 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: B, B, C</P>
<P>AS (tablet) from Guilin Pharmaceutical Factory No1, China</P>
<P>Seasonal hypoendemic to mesoendemic, multidrug resistance</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-05 10:18:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-PriceTHI_x002d_MYA93_x002d_4">
<CHAR_METHODS MODIFIED="2008-08-05 09:58:52 +0100" MODIFIED_BY="[Empty name]">
<P>Patients randomised in blocks of three using a random number generator; open-label</P>
<P>Follow-up 63 days</P>
<P>Excluded: AM+MQ = 4/178 (2%), AS+MQ = 5/180 (3%), MQ = 1/182 (&lt; 1%)</P>
<P>Loss to follow-up day 28: 17%, 15%, 10%; d63: 37%, 30%, 24%</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-05 10:18:18 +0100" MODIFIED_BY="[Empty name]">
<P>540 adults and children; slide positive Pf</P>
<P>Excluded: severe disease; pregnancy; children &lt; 5kg; antimalarials in last 63 days; concomitant disease; history of neuropsychiatric disorder</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-05 09:59:22 +0100" MODIFIED_BY="[Empty name]">
<P>AMpo + MQ25 (S) vs ASpo + MQ25 (S) vs MQ25<BR/>AM 12 mg/kg (4 mg/kg/d for 3 d) + MQ 1250 mg (single dose on day 2)<BR/>AS 12 mg/kg (4 mg/kg/d for 3 d) + MQ 1250 mg (single dose on day 2)<BR/>MQ 1250 mg (single dose)<BR/>Treatment supervised, drugs given after temperature reduced by paracetamol and tepid sponging</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinical: % patients febrile at each follow-up; haematological recovery<BR/>Parasitological: % patients parasitaemic at each follow-up; failure rate; recrudescence<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 09:59:40 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: B, B, C</P>
<P>AS from Guilin No.1 factory; AM from Kunming</P>
<P>Pharmaceutical factory, China</P>
<P>Seasonal low transmission, multidrug resistance</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-05 10:18:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-RugemalilaTAZ_x0028_97_x0029_">
<CHAR_METHODS MODIFIED="2008-08-05 10:00:01 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised using random numbers, allocation concealment not specified; patients and assessors reported as blind (however, 5 d vs 3 d regimen), nurses giving drug not blinded</P>
<P>Follow-up 28 days</P>
<P>No exclusions reported</P>
<P>Loss to follow-up day 28: AM = 13/52 (25%), CLQ = 11/54 (20%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-05 10:18:19 +0100" MODIFIED_BY="[Empty name]">
<P>106 adults and children; Pf parasitaemia</P>
<P>Excluded: &lt; 5 years; pregnancy; lactation; antimalarials in previous 14 days; positive Dill-Glazko urine test; concurrent illness</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-05 10:00:58 +0100" MODIFIED_BY="[Empty name]">
<P>AMpo vs CLQpo<BR/>AM 9.6 mg/kg if &lt; 15 years (3.2 mg/kg on day 1, 1.6 mg/kg on days 2 to 5), 700 mg if &gt;15y (300 mg on day 1, 100 mg on days 2 to 5)<BR/>CLQ 25 mg/kg over 3 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-05 10:02:08 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical: proportion of febrile patients examined on days 0, 3, 7, 14, 21 and 28; prevalence rate of malaria-related symptoms</P>
<P>Parasitological: proportion of examined patients cleared of parasitaemia on days 2 to 7, 14, 21 and 28</P>
<P>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-04 16:35:32 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: B,A,C<BR/>AM: Artenam (tablet, 50 mg B-artemether)<BR/>Holoendemic area, 13% CLQ and 15% MQ resistance in vivo</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-05 11:40:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ThanMYA90_x002d_91">
<CHAR_METHODS MODIFIED="2008-08-05 10:02:15 +0100" MODIFIED_BY="[Empty name]">
<P>Alternate allocation</P>
<P>Follow-up 28 days</P>
<P>No exclusions or loss to follow-up reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>120 adults, military hospital</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-05 11:40:05 +0100" MODIFIED_BY="[Empty name]">
<P>ASpo vs MQ20<BR/>AS 600 mg/5 d</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Parasitological: parasite clearance at day 7 and 28</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 10:45:12 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: C, B, C</P>
<P>Source of AS: not reported</P>
<P>One treatment group excluded: Halofantran, 60 patients</P>
<P>Endemicity, transmission not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-05 11:40:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ThanMYA91">
<CHAR_METHODS MODIFIED="2008-08-05 10:03:28 +0100" MODIFIED_BY="[Empty name]">
<P>Alternate allocation</P>
<P>Follow-up 28 days</P>
<P>No exclusions or loss to follow-up reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>118 adults, military hospital</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-05 11:40:08 +0100" MODIFIED_BY="[Empty name]">
<P>ASpo + MQ20 vs MQ20<BR/>AS 600 mg/5 d</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Parasitological: parasite clearance at day 7 and 28</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 10:45:19 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: C, B, C</P>
<P>Source of AS: not reported</P>
<P>Endemicity, transmission not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-20 10:37:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ThanMYA93a">
<CHAR_METHODS MODIFIED="2008-08-05 10:03:48 +0100" MODIFIED_BY="[Empty name]">
<P>Alternate allocation; parasitological outcomes blinded</P>
<P>Follow-up 28 days</P>
<P>No exclusions reported</P>
<P>Loss to follow-up: ART = 2/10 (20%), ART+MQ15 = 2/33 (6%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-20 10:37:53 +0100" MODIFIED_BY="[Empty name]">
<P>76 male adults, military hospital, 18 to 50 years; febrile; Pf asexual &gt; 500 &lt; 100,000/µl</P>
<P>Excluded: severe malaria symptoms; PfPv; concomitant systemic illness; antimalarials in previous 2 weeks</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-05 10:04:56 +0100" MODIFIED_BY="[Empty name]">
<P>ART + MQ10 vs ART + MQ15 (C)<BR/>ART 750 mg (250 mg at 0 h, 4 h and 24h) + MQ 500 mg (at 0 h)<BR/>ART 750 mg (as before) + MQ 750 mg (at 0 h)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinical: FCT<BR/>Parasitologcal: PCT, cure rate, recrudescence<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 10:05:04 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: C, B, C</P>
<P>ART: Lactab (250 mg) Mepha, Switzerland</P>
<P>Endemicity, transmission not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-05 10:05:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ThanMYA93b">
<CHAR_METHODS MODIFIED="2008-08-05 10:05:13 +0100" MODIFIED_BY="[Empty name]">
<P>Alternate allocation</P>
<P>Follow-up 28 days</P>
<P>No exclusions or loss to follow-up reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>36 adults, military hospital</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-05 10:05:20 +0100" MODIFIED_BY="[Empty name]">
<P>AS + MQ10 (C) vs AS + MQ10 (S)<BR/>AS 600 mg/3 d</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Parasitological: parasite clearance at day 7 and 28</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 10:05:35 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: C, B, C</P>
<P>Source of AS: not reported</P>
<P>Endemicity, transmission not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-05 10:06:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ThanMYA93c">
<CHAR_METHODS MODIFIED="2008-08-05 10:05:40 +0100" MODIFIED_BY="[Empty name]">
<P>Alternate allocation</P>
<P>Follow-up 28 days</P>
<P>No exclusions or loss to follow-up reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>46 Burmese adults, military hospital</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-05 10:06:08 +0100" MODIFIED_BY="[Empty name]">
<P>AMpo dose<BR/>AM 360 mg/7 d (80 mg at 0 h, 40 mg at 12 h, then 40 mg/d); 20 patients<BR/>AM 640 mg/7 d (80 mg at 0 h and 12 h, then 80 mg/d): 26 patients</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Parasitological: parasite clearance at day 7 and 28</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 10:06:53 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: C, B, C</P>
<P>Source of AM: not reported</P>
<P>Two treatment groups excluded, uneven numbers (alternate allocation):<BR/>AM 480 mg/5 d (80 mg at 0 h and 12h, then 80 mg/d); 24 patients<BR/>AM 960 mg/5 d (160 mg at 0 h, 80 mg every 12 h); 40 patients</P>
<P>Patients from areas of varying resistance, all CLQ resistant</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-05 10:07:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ThanMYA94a">
<CHAR_METHODS MODIFIED="2008-08-05 10:06:59 +0100" MODIFIED_BY="[Empty name]">
<P>Alternate allocation</P>
<P>Follow-up 28 days</P>
<P>No exclusions or loss to follow-up reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>50 adults, military hospital</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-05 10:07:03 +0100" MODIFIED_BY="[Empty name]">
<P>DHApo vs DHApo + MQ20<BR/>DHA 360 mg/5 d</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Parasitological: parasite clearance at day 7 and 28</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 10:07:10 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assesment: C, B, C</P>
<P>Source of DHA: not reported</P>
<P>Endemicity, transmission not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-05 10:07:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ThanMYA96a">
<CHAR_METHODS MODIFIED="2008-08-05 10:07:25 +0100" MODIFIED_BY="[Empty name]">
<P>Alternate allocation</P>
<P>Follow-up 28 days</P>
<P>No exclusions or loss to follow-up reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>34 adults, military</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-04 16:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>ASpo dose<BR/>AS 800 mg/3 days + MQ25<BR/>AS 1200 mg/3 days + MQ25</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Parasitological: parasite clearance at day 7 and 28</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 10:07:35 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: C, B, C</P>
<P>Source of AS: not reported</P>
<P>Endemicity, transmission not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-05 10:07:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ThanMYA97">
<CHAR_METHODS MODIFIED="2008-08-05 10:07:39 +0100" MODIFIED_BY="[Empty name]">
<P>Alternate allocation</P>
<P>Follow-up 28 days</P>
<P>No exclusions or loss to follow-up reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>100 adults, military hospital</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-04 16:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>ASpo + MQ15 vs ASpo + MQ25<BR/>AS 400 mg both groups</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Parasitological: parasite clearance at day 7 and 42</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 10:07:49 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: C, B, C</P>
<P>Source of AS: not reported</P>
<P>Endemicity, transmission not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-20 10:37:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ThimasarnTHI93_x002d_4">
<CHAR_METHODS MODIFIED="2008-08-05 10:08:48 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, method not specified; no blinding</P>
<P>Follow-up 28 days</P>
<P>12/394 excluded due to treatment error</P>
<P>Loss to follow-up day 7: AS = 7/55 (13%); AM = 8/42 (19%); AS+MQ(1) = 2/80 (2%); AS+MQ(2) = 4/68 (6%); AM+MQ = 5/45 (11%); MQ = 2/45 (4%); QNN+Tc = 6/47 (13%)</P>
<P>Loss to follow-up day 28: AS = 8/55 (14%); AM = 11/42 (26%); AS+MQ(1) = 5/80 (6%); AS+MQ(2) = 6/68 (9%); AM+MQ = 10/45 (22%); MQ = 4/45 (9%); QNN+Tc = 8/47 (17%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-20 10:37:54 +0100" MODIFIED_BY="[Empty name]">
<P>394 Thai and Cambodian male and female 15 to 70 years; febrile; uncomplicated malaria; Pf 500 to 400,000/µl</P>
<P>Excluded: complications; pregnancy; antimalarials in previous 2 weeks</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-05 10:10:42 +0100" MODIFIED_BY="[Empty name]">
<P>ASpo vs AMpo vs ASpo+MQ vs AMpo+MQ vs MQ vs QNN+Tc<BR/>AS 700 mg/5 d (300 mg day 1, 100 mg days 2 to 5)<BR/>AM 800 mg/5 d (320 mg day 1, 120 mg days 2 to 5)<BR/>AS 600 mg/2 d+MQ25 (AS 300 mg + MQ750 mg at 6 h on day 1, AS 300 mg + MQ500 mg at 6 h on day 2)<BR/>AS 600 mg/2 d+MQ15 (AS 300 mg + MQ750 mg at 1 h on day 1, AS 300 mg on day 2)<BR/>AM 640 mg/2 d+MQ25 (AM 320 mg + MQ750 mg at 6 h on day 1, AM 320 mg + MQ500 mg at 6 h on day 2)<BR/>MQ25/2 d (750 mg on day 1, 500 mg on day 2)<BR/>QNN+Tc/7 d (QNN 600 mg 3 x daily + Tc 500 mg x 2 daily)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-05 10:10:49 +0100" MODIFIED_BY="[Empty name]">
<P>Parasitological: Parasitaemia on day 7 and day 28<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 10:11:06 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: B, B, C</P>
<P>AS 50 mg tablet from Guilin Co., China</P>
<P>AM40 mg capsule from Kunming Co., China</P>
<P>MQ 250 mg tablet from Hoffman La Roche</P>
<P>Endemic area, MDR Pf</P>
<P>4 centre trial</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-20 10:37:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-vonSeidleinGAM96">
<CHAR_METHODS MODIFIED="2008-08-05 10:11:48 +0100" MODIFIED_BY="[Empty name]">
<P>Computer generated block (size 4) randomisation, investigators blind to treatment code</P>
<P>Double-dummy placebo blinded</P>
<P>Follow-up 15 days (passive follow-up to day 29)</P>
<P>Excluded: at day 4 Co-AM = 7/144 (5%), SP = 2/143 (1%), at day 15 Co-AM = 8/144 (6%), SP = 8/143 (6%)</P>
<P>Loss to follow-up: at day 4 Co-AM = 4/144 (3%), SP = 4/143 (3%), at day 15 Co-AM = 17/144 (12%), SP = 7/143 (5%)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-20 10:37:55 +0100" MODIFIED_BY="[Empty name]">
<P>287 children 1 to 5 years; history of fever; Pf &gt; 5000/µl</P>
<P>Excluded: required parenteral treatment; SP in previous 2 weeks; PCV &lt; 25%; malnutrition; chronic disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-05 10:12:56 +0100" MODIFIED_BY="[Empty name]">
<P>Co-AMpo vs SPpo<BR/>Co-AM/2 d: AM 80 mg/kg+Lumefantrine 480 mg/kg given for body weight &lt; 15 kg; x 2 dose given to body weight &gt; 15 kg (4 equal doses at 0 h, 8 h, 24 h and 48 h)<BR/>SP single dose:S 250 mg+ P 12.5 mg given to body weight &lt; 15 kg; x 2 dose given to body weight &gt; 15kg<BR/>Paracetamol 15 mg/kg/6 h while febrile</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-05 10:29:02 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical: episodes of malaria in 29 days; new infections vs recrudescence by genotyping; PCV<BR/>Parasitological: PCT; cure rate at day 4 and day 15; gametocytaemia<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 10:13:16 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: A, A, C</P>
<P>Co-AM (CGP56697) from Novartis Pharma A.G.</P>
<P>Seasonal transmission</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-10-20 10:37:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-WinMYA94_x002d_5">
<CHAR_METHODS MODIFIED="2008-08-05 10:13:28 +0100" MODIFIED_BY="[Empty name]">
<P>Alternate allocation; double blind</P>
<P>Follow-up 28 days</P>
<P>Excluded: AM = 2/43 (5%), AS = 3/43 (7%)</P>
<P>No loss to follow-up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-20 10:37:56 +0100" MODIFIED_BY="[Empty name]">
<P>86 adult male, 15 to 50 years; uncomplicated Pf malaria; Pf asexual &gt; 500/µl</P>
<P>Excluded: concomitant illness; severe manifestations; mixed infection; antimalarial in previous 14 days; diarrhoea</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-04 16:35:53 +0100" MODIFIED_BY="[Empty name]">
<P>AMpr vs ASpr<BR/>AM 600 mg (200 mg/d for 3 days)<BR/>AS 600 mg (200 mg/d for 3 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinical: FCT<BR/>Parasitological: PCT, S/R<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-05 10:13:51 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment: C, B, B</P>
<P>AM, AS: Rectocaps (200 mg), Mepha, Switzerland</P>
<P>Malaria free study area</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Study code: Name of investigator, COUNTRY CODE, year the study was done (study publication date in brackets if the year the study was done is not known).<BR/>Small letters a, b code studies done in the same year chronologically.<BR/>Numbers [1], [2] code separate randomised controlled trials reported in one study.</P>
<P>BRZ-Brazil; CHI-China; MYA-Myanmar; NIG-Nigeria; TAZ-Tanzania; THI-Thailand; VNM-Viet Nam; ART-artemisinin; AS-artesunate; AM-artemether; DHA-dihydroartemisinin; MQ-mefloquine; CLQ-chloroquine; SP-sulfadoxine-pyrimethamine; MQ10 = 500 mg; MQ15 = 750 mg; MQ20 = 1000 mg; MQ25 = 1250 mg; (S)-sequential MQ; (C)-concomitant MQ; MDR-multidrug resistant; <I>Pf-Plasmodium falciparum</I>; Pv-<I>Plasmodium vivax</I>; po-per; os pr-per rectum; PCT-parasite clearance time; FCT-fever clearance time; PC50/90/95-time to 50%/90%/95% reduction in parasitaemia; S/R-sensitive/resistant; (<LINK REF="REF-WHO-1973" TYPE="REFERENCE">WHO 1973</LINK>).</P>
<P>Quality assessment: the risk of bias in the trials was assessed using the Cochrane Infectious Diseases Group standard guidelines in terms of 1) allocation concealment, 2) generation of allocation sequence, 3) inclusion of all randomised participants. Graded A, B, C, in descending order of quality.<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-08-05 11:41:53 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Alin-TAZ-93">
<CHAR_REASON_FOR_EXCLUSION>
<P>Artesunate given by intravenous infusion.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Anh-VNM-92b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Although this study is titled an open randomised comparison the data we have suggest that it is comparing data from three different regimens tested in patients at one site which was collected from three individual studies comparing the same three regimens at three different sites.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-05 11:40:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ashton-VNM-_x0028_98_x0029_">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-05 11:40:57 +0100" MODIFIED_BY="[Empty name]">
<P>RCT comparing oral with rectal administration of artemisinin (500 mg/d/5 days). Comparison does not fit the inclusion criteria. Outcomes reported: pharmacokinetics and fever clearance time.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Batty-VNM-96">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intravenous route of administration does not meet the inclusion criteria, although relevant outcomes reported (fever and 50% parasite clearance time).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bich-VNM-93">
<CHAR_REASON_FOR_EXCLUSION>
<P>Treatment regimens do not fit the inclusion criteria: ART + QNN vs AS + doxycycline vs QNN</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-04 16:35:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bunnag-THI-_x0028_97_x0029_">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-04 16:35:58 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment regimens do not fit the inclusion criteria: AM 150 mg + MQ15 at 0h, followed by either AM 100 mg + MQ10 at 6h [Group A] or AM 100 mg + MQ10 at 24h [Group B]</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-05 11:41:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bunnag-THI-89_x002d_90a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-05 11:41:19 +0100" MODIFIED_BY="[Empty name]">
<P>Using placebo in the middle of a treatment regimen, as in this trial, would not be done in clinical practice.<BR/>AS600 mg/5 d (200 mg on day 1, 100 mg on day 2, placebo on day 3 and day 4, 100 mg on days 5 to 7)<BR/>AS 600 mg/7 d (200 mg on d1, 100 mg on days 2 to 5, placebo on days 6 and 7)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bunnag-THI-89_x002d_90b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of two different doses of artemether given by intramuscular injection.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chen-CHI">
<CHAR_REASON_FOR_EXCLUSION>
<P>Reported as randomised comparison of dihydroartemisinin and quinine. Only outcome reported is gametocyte infectivity.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Duarte-BRZ-92_x002d_3">
<CHAR_REASON_FOR_EXCLUSION>
<P>Treatment regimens do not fit the inclusion criteria: AS + tetracycline vs. QNN + tetracycline, concomitant treatments.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Duc-VNM-93">
<CHAR_REASON_FOR_EXCLUSION>
<P>Artemether given by intramuscular injection compared with oral chloroquine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Elhassan-SUD-91">
<CHAR_REASON_FOR_EXCLUSION>
<P>Artemether versus quinine both given by intramuscular injection.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fu-CHI">
<CHAR_REASON_FOR_EXCLUSION>
<P>Investigators unable to provide data or details concerning design, conduct and analysis of the trial (personal communication).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fu-CHI-88_x002d_90">
<CHAR_REASON_FOR_EXCLUSION>
<P>Artesunate given by intramuscular injection compared with oral piperaquine, used only in China; also intramuscular AS dose comparison, different dose given over a different time period in each treatment group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Guo-CHI-_x0028_90_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of non-randomised treatment groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Guo-CHI-86a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Artemether given by intramuscular injection compared with oral piperaquine, used only in China.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Guo-CHI-86b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Artemether given by intramuscular injection compared with oral pyronaridine (+ sulfadoxine pyrimethamine) used only in China.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hien-VNM-_x005b_2_x002d_4_x005d_-_x0028_94_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>Treatment regimens do not fit the inclusion criteria:<BR/>Study [2]: ART + MQ vs. Fansimef vs. QNN + SP<BR/>Study [3]: ART + MQ vs. Fansimef<BR/>Study [4]: ART + MQ vs. Fansimef vs. ART + SP</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Irion-GAM_x0028_98_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>Same study as included study Hatz GAM(98). Reports only on distinction of new infections from recrudescences as determined by PCR-RFLP analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jiang-CHI-80">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients were not allocated randomly to the two treatment groups (personal communication).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jiao-CHI-_x0028_97_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>Treatment regimens do not meet the inclusion criteria: benflumetol vs. CGP 56697 (co-artemether).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Li-CHI-_x0028_82_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>No comparator group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Li-CHI-_x0028_90_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised comparison of groups treated at different study sites.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Li-CHI-_x0028_95_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>Report does not mention randomisation (DHA 5d vs. 7d).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Li-CHI-85">
<CHAR_REASON_FOR_EXCLUSION>
<P>Artesunate given by intravenous infusion.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Li-CHI-a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Outcome measured (gametocyte infectivity) does not fit inclusion criteria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Li-CHI-b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Investigator unable to provide data or details concerning design, conduct and analysis of the trial (personal communication).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Li-VNM-_x0028_95_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>Investigator unable to provide details concerning design, conduct and analysis of the trial (personal communication).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Looareesuwan-THI-92a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Treatment regimens do not fit the inclusion criteria: MQ + doxycycline vs. AS + doxycycline, both concomitant.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Looareesuwan-THI-94">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients were not randomly assigned to the two treatment groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-LuxemburgerTHI_x002d_MYA93">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of oral AM+MQ vs. intravenous QNN+MQ in patients with hyperparasitaemia.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Na_x002d_BangchangTHI_x0028_96_x0029_a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Treatment regimens do not fit inclusion criteria: artemether-doxycycline vs. artemether-azithromycin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Na_x002d_BangchangTHI_x0028_96_x0029_b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Treatment regimens do not fit the inclusion criteria: three different regimens of artemether-pyrimethamine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nigeria-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>AM versus CLQ both given by intramuscular injection.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pang-CHI-_x0028_87_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised comparison.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Price-THI-93_x002d_5">
<CHAR_REASON_FOR_EXCLUSION>
<P>Hyperparasitaemic falciparum malaria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-QACRG-CHI-75">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to obtain detailed information on this study from 1975 summarised in a review of antimalarial studies on qinghaosu by the Qinghaosu Antimalaria Co-ordinating Research Group [China]. Design not specified; 18 patients treated with qinghaosu tablets, 18 with oral chloroquine; PCT and recrudescence at day 28 reported.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-04 16:36:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-SabchareonTHI95_x002d_6">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-04 16:36:01 +0100" MODIFIED_BY="[Empty name]">
<P>Compares artesunate suppositories vs. oral.<BR/>ASpr 45(30-57) mg/kg over 48h + MQ25 (S) 6h apart (total 3 days)<BR/>ASpo 18(15-21) mg/kg over 48h+ MQ25(S) 6h apart (total 3 days)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shen-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Retrospective comparison of separate study groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shwe-MYA-_x0028_98_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>Report of three community based studies:<BR/>1. Retrospective study to characterise current use of artemisinin derivatives<BR/>2. Random cohort study on use of subsidised mefloquine with artesunate<BR/>3. Double blind study of compliance and effectiveness of combined packaging (artesunate 5 days + MQ vs. artesunate 5 days + paracetamol placebo) at six health centres, two selling intervention, four placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Simooya-ZIM-91">
<CHAR_REASON_FOR_EXCLUSION>
<P>Artemether given by intramuscular injection vs. oral chloroquine.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sowunmi-NIG-93">
<CHAR_REASON_FOR_EXCLUSION>
<P>Artemether given by intramuscular injection vs. oral mefloquine in hyperparasitaemic falciparum malaria.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sowunmi-NIG-94_x002d_7">
<CHAR_REASON_FOR_EXCLUSION>
<P>Artemether given by intramuscular injection.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-05 11:41:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Than-MYA-94b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-05 11:41:45 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment regimens do not fit the inclusion criteria.<BR/>Alternate allocation. Outcomes: (cure rate d7 and 28).<BR/>AM 480 mg/5 d + Dox 200 mg/7 d; 30 patients (30/30; 29/30)<BR/>AM 480 mg/5 d + Tc 1000 mg/7d; 28 patients (28/28, 27/28)<BR/>AM 480/5 d + MQ20; 30 patients (30/30; 30/30).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-ThanMYA95">
<CHAR_REASON_FOR_EXCLUSION>
<P>Treatment groups treated with different artesunate regimens and different mefloquine schedules (sequential or concomitant). AS600/2+MQ20(S) vs. AS600/3+MQ20(C).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-05 11:41:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ThanMYA96b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-05 11:41:53 +0100" MODIFIED_BY="[Empty name]">
<P>Unexplained uneven group numbers in a study supposedly using alternate allocation. Dihydroartemisinin (Cotexin) regimen comparison: 480 mg/3 d (32 patients) vs. 480 mg/7 d (21 patients).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Thwe-MYA-93">
<CHAR_REASON_FOR_EXCLUSION>
<P>Investigators unable to provide data or details concerning design, conduct and analysis of the trial (personal communication, Kyaw Win).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-van-Vugt-THI-95_x002d_6">
<CHAR_REASON_FOR_EXCLUSION>
<P>Compares co-artemether (AM + lumefantrine/benflumetol) vs AS + MQ. Does not meet the inclusion criteria as both the artemisinin derivative and the combination drug differ between the treatment groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wang-CHI-_x0028_81_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>Observational study, no comparator group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wang-CHI-_x0028_95_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>Investigator unable to provide details concerning design, conduct and analysis of the trial (personal communication).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wang-CHI-79_x002d_80">
<CHAR_REASON_FOR_EXCLUSION>
<P>Patients were not allocated randomly to the three treatment groups (personal communication).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wang-CHI-94">
<CHAR_REASON_FOR_EXCLUSION>
<P>Investigator unable to provide details concerning design, conduct and analysis of the trial (personal communication).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-05 10:32:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yen-VNM-96">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-05 10:32:28 +0100" MODIFIED_BY="[Empty name]">
<P>Pseudorandomisation of patients (choosing a closed odd-even ticket) with uncomplicated falciparum malaria to supervised versus unsupervised treatment with artemisinin at one study site and artesunate at another site.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2008-10-20 10:28:29 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2008-10-20 10:28:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anh-VNM-92a">
<CHAR_METHODS MODIFIED="2008-10-20 10:28:00 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-20 10:28:04 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-20 10:28:05 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-20 10:28:05 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-20 10:28:06 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2008-10-20 10:28:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bunnag-THI-_x0028_97_x0029_b">
<CHAR_METHODS MODIFIED="2008-10-20 10:28:09 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-20 10:28:09 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-20 10:28:09 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-20 10:28:09 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-20 10:28:09 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2008-10-20 10:28:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Coker-NIG">
<CHAR_METHODS MODIFIED="2008-10-20 10:28:13 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-20 10:28:13 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-20 10:28:13 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-20 10:28:13 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-20 10:28:13 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2008-10-20 10:28:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Doherty-GAM-_x0028_99_x0029_">
<CHAR_METHODS MODIFIED="2008-10-20 10:28:14 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-20 10:28:14 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-20 10:28:14 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-20 10:28:14 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-20 10:28:14 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2008-10-20 10:28:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hamisi-THI-_x0028_97_x0029_">
<CHAR_METHODS MODIFIED="2008-10-20 10:28:18 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-20 10:28:18 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-20 10:28:18 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-20 10:28:18 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-20 10:28:18 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2008-10-20 10:28:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Honrado-THI-94_x002d_5">
<CHAR_METHODS MODIFIED="2008-10-20 10:28:19 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-20 10:28:19 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-20 10:28:19 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-20 10:28:19 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-20 10:28:19 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2008-10-20 10:28:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-LooareesuwanTHI_x0028_99_x0029_">
<CHAR_METHODS MODIFIED="2008-10-20 10:28:23 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-20 10:28:23 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-20 10:28:23 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-20 10:28:23 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-20 10:28:23 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2008-10-20 10:28:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Novartis-CHI">
<CHAR_METHODS MODIFIED="2008-10-20 10:28:24 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-20 10:28:24 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-20 10:28:24 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-20 10:28:24 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-20 10:28:24 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2008-10-20 10:28:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Price-THI-_x0028_98_x0029_">
<CHAR_METHODS MODIFIED="2008-10-20 10:28:28 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-20 10:28:28 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-20 10:28:28 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-20 10:28:28 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-20 10:28:28 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2008-10-20 10:28:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Salcedo-BRZ-_x0028_97_x0029_">
<CHAR_METHODS MODIFIED="2008-10-20 10:28:29 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-20 10:28:29 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-20 10:28:29 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-20 10:28:29 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-10-20 10:28:29 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Villalobos-_x0028_97_x0029_">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-08-05 10:17:07 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-08-05 10:17:07 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-10-25 18:57:35 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2008-10-25 18:49:53 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Single drug</NAME>
<DICH_OUTCOME CHI2="44.095090940112435" CI_END="5.299814209128792" CI_START="1.7887488578630286" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="OR" EFFECT_SIZE="3.0789668094127576" ESTIMABLE="YES" EVENTS_1="497" EVENTS_2="401" I2="77.32173857270993" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.7242606451924042" LOG_CI_START="0.25254936946583834" LOG_EFFECT_SIZE="0.4884050073291212" METHOD="MH" MODIFIED="2008-10-25 18:49:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="3.164706047442678E-6" P_Q="0.0" P_Z="4.9356562343333154E-5" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="2.336128980241085" TOTALS="SUB" TOTAL_1="538" TOTAL_2="502" WEIGHT="800.0" Z="4.058653135902506">
<NAME>Parasite clearance at day 7</NAME>
<GROUP_LABEL_1>Artemisinin drug</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ctrl</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Expt</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="476.74256788138126" CI_START="7.816181078070628" DF="0" EFFECT_SIZE="61.043478260869556" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="23" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="2.6782839313913227" LOG_CI_START="0.8929946121610642" LOG_EFFECT_SIZE="1.7856392717761935" NO="1" P_CHI2="1.0" P_Z="8.829345979878329E-5" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="50" WEIGHT="100.0" Z="3.9206963536539057">
<NAME>Artesunate vs chloroquine</NAME>
<DICH_DATA CI_END="476.74256788138126" CI_START="7.816181078070628" EFFECT_SIZE="61.04347826086956" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="23" LOG_CI_END="2.6782839313913227" LOG_CI_START="0.8929946121610642" LOG_EFFECT_SIZE="1.7856392717761935" ORDER="160" O_E="0.0" SE="1.0486877834405106" STUDY_ID="STD-EzedinachiNIG92" TOTAL_1="53" TOTAL_2="50" VAR="1.0997460671373713" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="21.854348790608476" CI_START="2.5876039840776004" DF="0" EFFECT_SIZE="7.519999999999998" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="30" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="1.3395378700405465" LOG_CI_START="0.4128978111427378" LOG_EFFECT_SIZE="0.8762178405916421" NO="2" P_CHI2="1.0" P_Z="2.1003635962520297E-4" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="54" WEIGHT="100.0" Z="3.7066288979860937">
<NAME>Artemether vs chloroquine</NAME>
<DICH_DATA CI_END="21.854348790608476" CI_START="2.5876039840776004" EFFECT_SIZE="7.52" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="30" LOG_CI_END="1.3395378700405465" LOG_CI_START="0.4128978111427378" LOG_EFFECT_SIZE="0.8762178405916422" ORDER="161" O_E="0.0" SE="0.5443129575388417" STUDY_ID="STD-RugemalilaTAZ_x0028_97_x0029_" TOTAL_1="52" TOTAL_2="54" VAR="0.2962765957446809" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0584493364181011" CI_END="98.0450409950275" CI_START="1.1499927336527396" DF="1" EFFECT_SIZE="10.618431367907721" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="80" I2="5.522166664669993" ID="CMP-001.01.03" LOG_CI_END="1.9914256324458284" LOG_CI_START="0.06069509622796934" LOG_EFFECT_SIZE="1.0260603643368988" NO="3" P_CHI2="0.3035695003787403" P_Z="0.03723371126616845" STUDIES="3" TAU2="0.14366542585527314" TOTAL_1="92" TOTAL_2="90" WEIGHT="100.0" Z="2.0831921620754303">
<NAME>Artemisinin vs quinine</NAME>
<DICH_DATA CI_END="519.6556177155713" CI_START="1.5873817299420951" EFFECT_SIZE="28.72093023255814" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="21" LOG_CI_END="2.7157156265701974" LOG_CI_START="0.2006813774619982" LOG_EFFECT_SIZE="1.458198502016098" ORDER="162" O_E="0.0" SE="1.4773435675464743" STUDY_ID="STD-ArnoldVNM89" TOTAL_1="32" TOTAL_2="30" VAR="2.182544016570944" WEIGHT="55.29294483508073"/>
<DICH_DATA CI_END="79.22786759281833" CI_START="0.12142837665097087" EFFECT_SIZE="3.1016949152542375" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="29" LOG_CI_END="1.8988779671075169" LOG_CI_START="-0.9156798109309462" LOG_EFFECT_SIZE="0.4915990780882853" ORDER="163" O_E="0.0" SE="1.6532851711054914" STUDY_ID="STD-HienVNM90" TOTAL_1="30" TOTAL_2="30" VAR="2.733351856997314" WEIGHT="44.70705516491926"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="30" EVENTS_2="30" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="164" O_E="0.0" SE="0.0" STUDY_ID="STD-KarbwangTHI92b" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.709407600016897" CI_START="0.38820214850302254" DF="0" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="40" I2="0.0" ID="CMP-001.01.04" LOG_CI_END="0.5693045574354224" LOG_CI_START="-0.41094206534017286" LOG_EFFECT_SIZE="0.07918124604762482" NO="4" P_CHI2="1.0" P_Z="0.751517175716343" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="47" WEIGHT="100.0" Z="0.31663948010331855">
<NAME>Artesunate vs quinine</NAME>
<DICH_DATA CI_END="3.709407600016897" CI_START="0.38820214850302254" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="40" LOG_CI_END="0.5693045574354224" LOG_CI_START="-0.41094206534017286" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="165" O_E="0.0" SE="0.5758017185174242" STUDY_ID="STD-ThimasarnTHI93_x002d_4" TOTAL_1="55" TOTAL_2="47" VAR="0.33154761904761904" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2627851101735534" CI_START="0.2444615973531719" DF="0" EFFECT_SIZE="0.74375" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="40" I2="0.0" ID="CMP-001.01.05" LOG_CI_END="0.3546433122856519" LOG_CI_START="-0.6117893548124399" LOG_EFFECT_SIZE="-0.128573021263394" NO="5" P_CHI2="1.0" P_Z="0.6020168169230645" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="47" WEIGHT="100.0" Z="0.5215024277199382">
<NAME>Artemether vs quinine</NAME>
<DICH_DATA CI_END="2.2627851101735534" CI_START="0.2444615973531719" EFFECT_SIZE="0.74375" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="40" LOG_CI_END="0.3546433122856519" LOG_CI_START="-0.6117893548124399" LOG_EFFECT_SIZE="-0.128573021263394" ORDER="166" O_E="0.0" SE="0.5676873325722753" STUDY_ID="STD-ThimasarnTHI93_x002d_4" TOTAL_1="42" TOTAL_2="47" VAR="0.3222689075630252" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.155827179532362" CI_END="42.177629334962695" CI_START="0.04705910999388777" DF="1" EFFECT_SIZE="1.4088441000179674" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="99" I2="75.93740170609004" ID="CMP-001.01.06" LOG_CI_END="1.6250821658331056" LOG_CI_START="-1.3273562906831267" LOG_EFFECT_SIZE="0.14886293757498942" NO="6" P_CHI2="0.041491625896984186" P_Z="0.8433235416221506" STUDIES="2" TAU2="4.644425421097396" TOTAL_1="115" TOTAL_2="105" WEIGHT="100.0" Z="0.19764408340899797">
<NAME>Artesunate vs mefloquine</NAME>
<DICH_DATA CI_END="183.0545799459353" CI_START="0.507362393318779" EFFECT_SIZE="9.63716814159292" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="56" LOG_CI_END="2.2625805992124386" LOG_CI_START="-0.29468172666772835" LOG_EFFECT_SIZE="0.9839494362723552" ORDER="167" O_E="0.0" SE="1.5021485488746793" STUDY_ID="STD-ThanMYA90_x002d_91" TOTAL_1="60" TOTAL_2="60" VAR="2.256450262886305" WEIGHT="43.584564135961614"/>
<DICH_DATA CI_END="1.6188234962536943" CI_START="0.06283620900898582" EFFECT_SIZE="0.31893687707641194" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="43" LOG_CI_END="0.2091994992896241" LOG_CI_START="-1.201790024398174" LOG_EFFECT_SIZE="-0.496295262554275" ORDER="168" O_E="0.0" SE="0.8288222307249996" STUDY_ID="STD-ThimasarnTHI93_x002d_4" TOTAL_1="55" TOTAL_2="45" VAR="0.6869462901439646" WEIGHT="56.415435864038386"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.645582710713892" CI_END="8.515005702368114" CI_START="0.056917771907623836" DF="1" EFFECT_SIZE="0.696171783656523" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="52" I2="78.47417509769558" ID="CMP-001.01.07" LOG_CI_END="0.9301849431390399" LOG_CI_START="-1.2447521090649771" LOG_EFFECT_SIZE="-0.1572835829629686" NO="7" P_CHI2="0.031133635156734507" P_Z="0.7768127311304758" STUDIES="2" TAU2="2.561833646140196" TOTAL_1="76" TOTAL_2="57" WEIGHT="100.00000000000001" Z="0.2834750161200705">
<NAME>Artemether vs mefloquine</NAME>
<DICH_DATA CI_END="13.307581392773026" CI_START="0.4696570936168911" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="9" LOG_CI_END="1.124099131115624" LOG_CI_START="-0.3282191137715489" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="169" O_E="0.0" SE="0.8530989261379818" STUDY_ID="STD-KarbwangTHI91" TOTAL_1="34" TOTAL_2="12" VAR="0.7277777777777777" WEIGHT="49.616255670452794"/>
<DICH_DATA CI_END="0.9923489366270833" CI_START="0.03937644746564685" EFFECT_SIZE="0.19767441860465115" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="43" LOG_CI_END="-0.0033355913482819937" LOG_CI_START="-1.4047634683823056" LOG_EFFECT_SIZE="-0.7040495298652938" ORDER="170" O_E="0.0" SE="0.8232056721496582" STUDY_ID="STD-ThimasarnTHI93_x002d_4" TOTAL_1="42" TOTAL_2="45" VAR="0.6776675786593707" WEIGHT="50.38374432954722"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="166.67480198055932" CI_START="2.666341728121266" DF="0" EFFECT_SIZE="21.081081081081077" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="37" I2="0.0" ID="CMP-001.01.08" LOG_CI_END="2.2218699478305908" LOG_CI_START="0.4259158094163795" LOG_EFFECT_SIZE="1.3238928786234854" MODIFIED="2008-10-25 18:49:53 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Z="0.0038574893853134807" STUDIES="1" TAU2="0.0" TOTAL_1="53" TOTAL_2="52" WEIGHT="100.0" Z="2.8895864387519663">
<NAME>Artesunate vs sulfadoxine-pyrimethamine</NAME>
<DICH_DATA CI_END="166.67480198055932" CI_START="2.666341728121266" EFFECT_SIZE="21.08108108108108" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="37" LOG_CI_END="2.2218699478305908" LOG_CI_START="0.4259158094163795" LOG_EFFECT_SIZE="1.3238928786234854" ORDER="171" O_E="0.0" SE="1.054952351020871" STUDY_ID="STD-EzedinachiNIG92" TOTAL_1="53" TOTAL_2="52" VAR="1.1129244629244628" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.456794370925328" CI_END="1.7276324695256737" CI_START="0.5793017987344988" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0004102144362317" ESTIMABLE="YES" EVENTS_1="272" EVENTS_2="251" I2="17.226318945791373" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.2374513576834705" LOG_CI_START="-0.2370951230126734" LOG_EFFECT_SIZE="1.7811733539853646E-4" METHOD="MH" NO="2" P_CHI2="0.2940408241092788" P_Q="0.0" P_Z="0.9988260612882989" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.1412744094137343" TOTALS="SUB" TOTAL_1="313" TOTAL_2="290" WEIGHT="500.0" Z="0.0014713145144019332">
<NAME>Parasite clearance at day 28</NAME>
<GROUP_LABEL_1>Artemisinin drug</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ctrl</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Expt</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.786650299957849" CI_START="0.18371446664867105" DF="0" EFFECT_SIZE="0.5729166666666666" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.2520395566127254" LOG_CI_START="-0.7358566437033747" LOG_EFFECT_SIZE="-0.2419085435453246" NO="1" P_CHI2="1.0" P_Z="0.3371144730032012" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="22" WEIGHT="100.00000000000001" Z="0.9598822887458545">
<NAME>Artemisinin vs quinine</NAME>
<DICH_DATA CI_END="1.786650299957849" CI_START="0.18371446664867105" EFFECT_SIZE="0.5729166666666666" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.2520395566127254" LOG_CI_START="-0.7358566437033747" LOG_EFFECT_SIZE="-0.2419085435453246" ORDER="172" O_E="0.0" SE="0.5802951182307363" STUDY_ID="STD-ArnoldVNM89" TOTAL_1="27" TOTAL_2="22" VAR="0.3367424242424243" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="38.41882574949713" CI_START="0.38248031161225127" DF="0" EFFECT_SIZE="3.8333333333333335" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="36" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="1.5845440867540148" LOG_CI_START="-0.4173909154861164" LOG_EFFECT_SIZE="0.5835765856339492" NO="2" P_CHI2="1.0" P_Z="0.2531700244314984" STUDIES="1" TAU2="0.0" TOTAL_1="47" TOTAL_2="39" WEIGHT="100.0" Z="1.1426835424561883">
<NAME>Artesunate vs quinine</NAME>
<DICH_DATA CI_END="38.41882574949713" CI_START="0.38248031161225127" EFFECT_SIZE="3.8333333333333335" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="36" LOG_CI_END="1.5845440867540148" LOG_CI_START="-0.4173909154861164" LOG_EFFECT_SIZE="0.5835765856339492" ORDER="173" O_E="0.0" SE="1.1759465300539365" STUDY_ID="STD-ThimasarnTHI93_x002d_4" TOTAL_1="47" TOTAL_2="39" VAR="1.3828502415458936" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="25.29851018610755" CI_START="0.24705012089732195" DF="0" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="36" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="1.403094946590702" LOG_CI_START="-0.6072149292466269" LOG_EFFECT_SIZE="0.3979400086720376" NO="3" P_CHI2="1.0" P_Z="0.4377796250062199" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="39" WEIGHT="99.99999999999999" Z="0.7759481206148765">
<NAME>Artemether vs quinine</NAME>
<DICH_DATA CI_END="25.29851018610755" CI_START="0.24705012089732195" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="36" LOG_CI_END="1.403094946590702" LOG_CI_START="-0.6072149292466269" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="174" O_E="0.0" SE="1.1808659722612234" STUDY_ID="STD-ThimasarnTHI93_x002d_4" TOTAL_1="31" TOTAL_2="39" VAR="1.3944444444444444" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1359621295212583" CI_END="1.9483518337742904" CI_START="0.49498740154536963" DF="2" EFFECT_SIZE="0.9820435894073603" ESTIMABLE="YES" EVENTS_1="126" EVENTS_2="118" I2="0.0" ID="CMP-001.02.04" LOG_CI_END="0.2896673846111858" LOG_CI_START="-0.30540585461987696" LOG_EFFECT_SIZE="-0.0078692350043456" NO="4" P_CHI2="0.5666685136859955" P_Z="0.958658542785089" STUDIES="3" TAU2="0.0" TOTAL_1="147" TOTAL_2="138" WEIGHT="100.0" Z="0.051837038460438946">
<NAME>Artesunate vs mefloquine</NAME>
<DICH_DATA CI_END="5.68351377166692" CI_START="0.4693888120896282" EFFECT_SIZE="1.6333333333333333" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="30" LOG_CI_END="0.7546169166666828" LOG_CI_START="-0.32846726604898036" LOG_EFFECT_SIZE="0.21307482530885122" ORDER="175" O_E="0.0" SE="0.6362090102803518" STUDY_ID="STD-LooareesuwanTHI91" TOTAL_1="40" TOTAL_2="37" VAR="0.40476190476190477" WEIGHT="30.186753857740857"/>
<DICH_DATA CI_END="1.937060616316622" CI_START="0.3554596319702597" EFFECT_SIZE="0.8297872340425532" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="47" LOG_CI_END="0.28714321128179504" LOG_CI_START="-0.4492097131002316" LOG_EFFECT_SIZE="-0.08103325090921827" ORDER="176" O_E="0.0" SE="0.43253735278776406" STUDY_ID="STD-ThanMYA90_x002d_91" TOTAL_1="60" TOTAL_2="60" VAR="0.18708856155664666" WEIGHT="65.30836459683007"/>
<DICH_DATA CI_END="9.421597209276863" CI_START="0.014806167886155743" EFFECT_SIZE="0.37349397590361444" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="41" LOG_CI_END="0.9741245334059664" LOG_CI_START="-1.8295573304895691" LOG_EFFECT_SIZE="-0.4277163985418012" ORDER="177" O_E="0.0" SE="1.6468966053012926" STUDY_ID="STD-ThimasarnTHI93_x002d_4" TOTAL_1="47" TOTAL_2="41" VAR="2.712268428552921" WEIGHT="4.504881545429073"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.4691069080003363" CI_END="80.17392018212503" CI_START="0.04572273024185074" DF="1" EFFECT_SIZE="1.9146202038312916" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="49" I2="71.17413713328251" ID="CMP-001.02.05" LOG_CI_END="1.9040331193693882" LOG_CI_START="-1.33986784447169" LOG_EFFECT_SIZE="0.2820826374488492" NO="5" P_CHI2="0.06252517551976855" P_Z="0.7332025883755233" STUDIES="2" TAU2="5.205329244935561" TOTAL_1="61" TOTAL_2="52" WEIGHT="100.0" Z="0.3408684890362145">
<NAME>Artemether vs mefloquine</NAME>
<DICH_DATA CI_END="119.24346151158878" CI_START="0.9917996634851651" EFFECT_SIZE="10.875" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="8" LOG_CI_END="2.0764345746531294" LOG_CI_START="-0.003576043399779477" LOG_EFFECT_SIZE="1.036429265626675" ORDER="178" O_E="0.0" SE="1.2218085332628934" STUDY_ID="STD-KarbwangTHI91" TOTAL_1="30" TOTAL_2="11" VAR="1.492816091954023" WEIGHT="54.207054701653384"/>
<DICH_DATA CI_END="6.22133845843913" CI_START="0.009646663888601036" EFFECT_SIZE="0.24497991967871485" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="41" LOG_CI_END="0.7938838288356839" LOG_CI_START="-2.015622853005622" LOG_EFFECT_SIZE="-0.6108695120849693" ORDER="179" O_E="0.0" SE="1.6503181321959524" STUDY_ID="STD-ThimasarnTHI93_x002d_4" TOTAL_1="31" TOTAL_2="41" VAR="2.723549937454737" WEIGHT="45.792945298346616"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="17.262699126383023" CI_END="1.4173583050357315" CI_START="0.21926480762191308" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5574735833068509" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="45" I2="65.2429787713206" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.1514796528087024" LOG_CI_START="-0.65903106773919" LOG_EFFECT_SIZE="-0.2537757074652437" METHOD="MH" NO="3" P_CHI2="0.008364771954683548" P_Q="0.0" P_Z="0.21969009204979928" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.141792839800586" TOTALS="SUB" TOTAL_1="339" TOTAL_2="270" WEIGHT="200.0" Z="1.227352665852024">
<NAME>Adverse events (artemisinin drug vs mefloquine)</NAME>
<GROUP_LABEL_1>Artemisinin drug</GROUP_LABEL_1>
<GROUP_LABEL_2>Comparator</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Expt</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Ctrl</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.904240993036809" CI_END="2.3040345363174115" CI_START="0.277440162799574" DF="3" EFFECT_SIZE="0.7995196788395791" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="19" I2="49.18906590130616" ID="CMP-001.03.01" LOG_CI_END="0.3624889846555422" LOG_CI_START="-0.5568306693634284" LOG_EFFECT_SIZE="-0.09717084235394315" NO="1" P_CHI2="0.11636343528021786" P_Z="0.6786316582080223" STUDIES="4" TAU2="0.5494413991346093" TOTAL_1="218" TOTAL_2="169" WEIGHT="100.00000000000001" Z="0.4143310773974116">
<NAME>Vomiting</NAME>
<DICH_DATA CI_END="4.372194054797335" CI_START="0.2400111611356967" EFFECT_SIZE="1.024390243902439" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6406994293658113" LOG_CI_START="-0.6197685620094814" LOG_EFFECT_SIZE="0.010465433678164977" ORDER="180" O_E="0.0" SE="0.7404051375510322" STUDY_ID="STD-CardosoBRZ93_x002d_4" TOTAL_1="45" TOTAL_2="46" VAR="0.5481997677119629" WEIGHT="26.56732980588989"/>
<DICH_DATA CI_END="0.5590476162579439" CI_START="0.0013404969876951317" EFFECT_SIZE="0.027375201288244767" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="-0.25255119998947445" LOG_CI_START="-2.8727341576071383" LOG_EFFECT_SIZE="-1.5626426787983063" ORDER="181" O_E="0.0" SE="1.539108439419435" STUDY_ID="STD-KarbwangTHI91" TOTAL_1="34" TOTAL_2="12" VAR="2.3688547882921287" WEIGHT="9.992609733643349"/>
<DICH_DATA CI_END="3.6992179794618" CI_START="0.39584133093428236" EFFECT_SIZE="1.2100840336134453" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.5681099232289382" LOG_CI_START="-0.40247886182350046" LOG_EFFECT_SIZE="0.08281553070271887" ORDER="182" O_E="0.0" SE="0.5701286568317743" STUDY_ID="STD-LooareesuwanTHI91" TOTAL_1="42" TOTAL_2="43" VAR="0.325046685340803" WEIGHT="33.34681787645857"/>
<DICH_DATA CI_END="4.4294517998468566" CI_START="0.3496238463103233" EFFECT_SIZE="1.2444444444444445" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.6463499801658256" LOG_CI_START="-0.456398953704112" LOG_EFFECT_SIZE="0.09497551323085675" ORDER="183" O_E="0.0" SE="0.6477601824504606" STUDY_ID="STD-ThimasarnTHI93_x002d_4" TOTAL_1="97" TOTAL_2="68" VAR="0.419593253968254" WEIGHT="30.093242584008202"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.058166956216133" CI_END="1.1438846999804602" CI_START="0.021923197489640556" DF="2" EFFECT_SIZE="0.1583591177768109" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="26" I2="71.66403100965756" ID="CMP-001.03.02" LOG_CI_END="0.058382251130235645" LOG_CI_START="-1.6590961038904635" LOG_EFFECT_SIZE="-0.8003569263801139" NO="2" P_CHI2="0.029331827240262065" P_Z="0.06774280449582341" STUDIES="3" TAU2="2.163204013855658" TOTAL_1="121" TOTAL_2="101" WEIGHT="100.0" Z="1.8267138516145005">
<NAME>Dizziness</NAME>
<DICH_DATA CI_END="0.41549679261992245" CI_START="0.006494875891054256" EFFECT_SIZE="0.05194805194805195" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="14" LOG_CI_END="-0.3814323243536256" LOG_CI_START="-2.187429143335413" LOG_EFFECT_SIZE="-1.2844307338445193" ORDER="184" O_E="0.0" SE="1.060851471298336" STUDY_ID="STD-CardosoBRZ93_x002d_4" TOTAL_1="45" TOTAL_2="46" VAR="1.125405844155844" WEIGHT="30.94891260584219"/>
<DICH_DATA CI_END="0.618838025960188" CI_START="0.005935470071488133" EFFECT_SIZE="0.06060606060606061" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="-0.20842300790530868" LOG_CI_START="-2.226544880522504" LOG_EFFECT_SIZE="-1.2174839442139063" ORDER="185" O_E="0.0" SE="1.1854547778397244" STUDY_ID="STD-KarbwangTHI91" TOTAL_1="34" TOTAL_2="12" VAR="1.4053030303030303" WEIGHT="28.52142305755332"/>
<DICH_DATA CI_END="2.3172614042904467" CI_START="0.2294449934708947" EFFECT_SIZE="0.7291666666666666" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.36497502819538485" LOG_CI_START="-0.639321414246008" LOG_EFFECT_SIZE="-0.1371731930253116" ORDER="186" O_E="0.0" SE="0.5899287016376411" STUDY_ID="STD-LooareesuwanTHI91" TOTAL_1="42" TOTAL_2="43" VAR="0.348015873015873" WEIGHT="40.52966433660449"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2008-10-25 18:56:18 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Co-artemether vs standard treatment</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="242" EVENTS_2="162" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-10-25 18:56:11 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="274" TOTAL_2="273" WEIGHT="0.0" Z="0.0">
<NAME>Parasite clearance at day 4 or day 7</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ctrl</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Expt</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="133" EVENTS_2="128" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2008-10-25 18:50:16 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="144" TOTAL_2="143" WEIGHT="0.0" Z="0.0">
<NAME>Co-artemether vs sulfadoxine-pyrimethamine (day 4)</NAME>
<DICH_DATA CI_END="3.2010147215584452" CI_START="0.627180892725171" EFFECT_SIZE="1.4169034090909092" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="128" LOG_CI_END="0.5052876714814943" LOG_CI_START="-0.20260718104814704" LOG_EFFECT_SIZE="0.15134024521667364" ORDER="187" O_E="0.0" SE="0.41582094051194535" STUDY_ID="STD-vonSeidleinGAM96" TOTAL_1="144" TOTAL_2="143" VAR="0.1729070545682388" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="109" EVENTS_2="34" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="130" TOTAL_2="130" WEIGHT="0.0" Z="0.0">
<NAME>Co-artemether vs chloroquine (day 7)</NAME>
<DICH_DATA CI_END="26.951776561477494" CI_START="7.969143383270016" EFFECT_SIZE="14.655462184873949" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="34" LOG_CI_END="1.4305873975530725" LOG_CI_START="0.9014116408549626" LOG_EFFECT_SIZE="1.1659995192040176" ORDER="188" O_E="0.0" SE="0.31084045894671136" STUDY_ID="STD-HatzTAZ_x0028_98_x0029_" TOTAL_1="130" TOTAL_2="130" VAR="0.09662179091820215" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="206" EVENTS_2="135" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-10-25 18:56:18 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="229" TOTAL_2="225" WEIGHT="0.0" Z="0.0">
<NAME>Parasite clearance at day 14/15</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ctrl</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Expt</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="111" EVENTS_2="125" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2008-10-25 18:50:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="119" TOTAL_2="128" WEIGHT="0.0" Z="0.0">
<NAME>Co-artemether vs sulfadoxine-pyrimethamine</NAME>
<DICH_DATA CI_END="1.2861919271248519" CI_START="0.08621497123518793" EFFECT_SIZE="0.333" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="125" LOG_CI_END="0.10930577937508616" LOG_CI_START="-1.0644173123624463" LOG_EFFECT_SIZE="-0.4775557664936801" ORDER="189" O_E="0.0" SE="0.6894507541096335" STUDY_ID="STD-vonSeidleinGAM96" TOTAL_1="119" TOTAL_2="128" VAR="0.4753423423423423" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="95" EVENTS_2="10" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="110" TOTAL_2="97" WEIGHT="0.0" Z="0.0">
<NAME>Co-artemether vs chloroquine</NAME>
<DICH_DATA CI_END="129.09153080956338" CI_START="23.518274056868542" EFFECT_SIZE="55.1" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="10" LOG_CI_END="2.1108977508386606" LOG_CI_START="1.3714054468649097" LOG_EFFECT_SIZE="1.741151598851785" ORDER="190" O_E="0.0" SE="0.4343814399001223" STUDY_ID="STD-HatzTAZ_x0028_98_x0029_" TOTAL_1="110" TOTAL_2="97" VAR="0.18868723532970355" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2008-10-20 10:31:20 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Combination with mefloquine vs mefloquine alone</NAME>
<DICH_OUTCOME CHI2="12.445443981951163" CI_END="2.953602863566285" CI_START="1.7231834081682291" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="OR" EFFECT_SIZE="2.256014062193672" ESTIMABLE="YES" EVENTS_1="1192" EVENTS_2="1061" I2="35.71944872676385" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.4703521004016256" LOG_CI_START="0.23633150432921207" LOG_EFFECT_SIZE="0.3533418023654189" METHOD="MH" NO="1" P_CHI2="0.13240834893927644" P_Q="0.0" P_Z="3.2469260427894166E-9" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1279" TOTAL_2="1240" WEIGHT="300.0" Z="5.918600486381095">
<NAME>Parasite clearance at day 7</NAME>
<GROUP_LABEL_1>Combination</GROUP_LABEL_1>
<GROUP_LABEL_2>MQ alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ctrl</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Expt</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.7809744088209674" CI_START="0.5676018545084434" DF="0" EFFECT_SIZE="1.4649532710280373" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="107" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.5776037378900544" LOG_CI_START="-0.24595619425496554" LOG_EFFECT_SIZE="0.16582377181754437" NO="1" P_CHI2="1.0" P_Z="0.4299499002109448" STUDIES="1" TAU2="0.0" TOTAL_1="122" TOTAL_2="118" WEIGHT="100.0" Z="0.7892773989051828">
<NAME>Artemisinin</NAME>
<DICH_DATA CI_END="3.7809744088209674" CI_START="0.5676018545084434" EFFECT_SIZE="1.4649532710280373" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="107" LOG_CI_END="0.5776037378900544" LOG_CI_START="-0.24595619425496554" LOG_EFFECT_SIZE="0.16582377181754437" ORDER="191" O_E="0.0" SE="0.4837631808293968" STUDY_ID="STD-HungVNM93_x002d_4" TOTAL_1="122" TOTAL_2="118" VAR="0.23402681512617568" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.292552729365368" CI_END="3.128287425443586" CI_START="1.6663017426919065" DF="5" EFFECT_SIZE="2.2831274140217896" ESTIMABLE="YES" EVENTS_1="870" EVENTS_2="763" I2="5.527629942015673" ID="CMP-003.01.02" LOG_CI_END="0.49530664897521415" LOG_CI_START="0.22175364852344417" LOG_EFFECT_SIZE="0.35853014874932915" NO="2" P_CHI2="0.38122950751239504" P_Z="2.7823442841019994E-7" STUDIES="7" TAU2="0.0" TOTAL_1="934" TOTAL_2="895" WEIGHT="100.00000000000001" Z="5.1376236251107565">
<NAME>Artesunate</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="192" O_E="0.0" SE="0.0" STUDY_ID="STD-KarbwangTHI92a" TOTAL_1="12" TOTAL_2="8" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.5151887200367797" CI_START="0.9299084726891992" EFFECT_SIZE="1.5293447293447293" ESTIMABLE="YES" EVENTS_1="244" EVENTS_2="234" LOG_CI_END="0.4005705766665787" LOG_CI_START="-0.03155979527635547" LOG_EFFECT_SIZE="0.18450539069511157" ORDER="193" O_E="0.0" SE="0.25383551955911926" STUDY_ID="STD-LuxemburgerTHI_x002d_MYA91" TOTAL_1="274" TOTAL_2="278" VAR="0.06443247098984803" WEIGHT="47.23530354650449"/>
<DICH_DATA CI_END="5.188513301898597" CI_START="1.0806823566017572" EFFECT_SIZE="2.3679389312977097" ESTIMABLE="YES" EVENTS_1="141" EVENTS_2="131" LOG_CI_END="0.7150429344811932" LOG_CI_START="0.033698061162450534" LOG_EFFECT_SIZE="0.37437049782182186" ORDER="194" O_E="0.0" SE="0.4002253512989467" STUDY_ID="STD-Nosten_x005b_1_x005d_THI_x002d_MYA92_x002d_3" TOTAL_1="151" TOTAL_2="153" VAR="0.1601803318223653" WEIGHT="16.005394690240443"/>
<DICH_DATA CI_END="9.606310154584962" CI_START="1.8755708734626413" EFFECT_SIZE="4.24468085106383" ESTIMABLE="YES" EVENTS_1="171" EVENTS_2="141" LOG_CI_END="0.9825566043985388" LOG_CI_START="0.27313347977556035" LOG_EFFECT_SIZE="0.6278450420870496" ORDER="195" O_E="0.0" SE="0.4167186551046404" STUDY_ID="STD-Nosten_x005b_2_x005d_THI_x002d_MYA92_x002d_3" TOTAL_1="179" TOTAL_2="169" VAR="0.17365443751222026" WEIGHT="12.039225024172437"/>
<DICH_DATA CI_END="5.273732252506077" CI_START="1.4069427670139716" EFFECT_SIZE="2.723938223938224" ESTIMABLE="YES" EVENTS_1="166" EVENTS_2="148" LOG_CI_END="0.7221180768774184" LOG_CI_START="0.14827643114081124" LOG_EFFECT_SIZE="0.4351972540091148" ORDER="196" O_E="0.0" SE="0.33707742326764145" STUDY_ID="STD-PriceTHI_x002d_MYA93_x002d_4" TOTAL_1="180" TOTAL_2="182" VAR="0.11362118927675272" WEIGHT="21.259343871296387"/>
<DICH_DATA CI_END="106.41548534869021" CI_START="0.23492821479959267" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="58" LOG_CI_END="2.027004830140838" LOG_CI_START="-0.6290648214688006" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="197" O_E="0.0" SE="1.5601884611123216" STUDY_ID="STD-ThanMYA91" TOTAL_1="58" TOTAL_2="60" VAR="2.434188034188034" WEIGHT="0.9053433179746694"/>
<DICH_DATA CI_END="13.33661965679243" CI_START="0.24672123391488096" EFFECT_SIZE="1.813953488372093" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="43" LOG_CI_END="1.1250457658296704" LOG_CI_START="-0.6077934716078826" LOG_EFFECT_SIZE="0.2586261471108939" ORDER="198" O_E="0.0" SE="1.017878345763383" STUDY_ID="STD-ThimasarnTHI93_x002d_4" TOTAL_1="80" TOTAL_2="45" VAR="1.0360763267740012" WEIGHT="2.5553895498115793"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.152880114235347" CI_END="4.833559307541501" CI_START="1.3747505407117389" DF="1" EFFECT_SIZE="2.5777777777777775" ESTIMABLE="YES" EVENTS_1="208" EVENTS_2="191" I2="83.74744865113831" ID="CMP-003.01.03" LOG_CI_END="0.6842670517341185" LOG_CI_START="0.13822389916903094" LOG_EFFECT_SIZE="0.41124547545157475" NO="3" P_CHI2="0.013119901009149726" P_Z="0.003154734983088358" STUDIES="2" TAU2="0.0" TOTAL_1="223" TOTAL_2="227" WEIGHT="100.0" Z="2.9522440375041983">
<NAME>Artemether</NAME>
<DICH_DATA CI_END="8.080166753219052" CI_START="1.84345543528256" EFFECT_SIZE="3.8594594594594596" ESTIMABLE="YES" EVENTS_1="168" EVENTS_2="148" LOG_CI_END="0.9074203235537434" LOG_CI_START="0.2656326431925776" LOG_EFFECT_SIZE="0.5865264833731606" ORDER="199" O_E="0.0" SE="0.376989260344403" STUDY_ID="STD-PriceTHI_x002d_MYA93_x002d_4" TOTAL_1="178" TOTAL_2="182" VAR="0.14212090241502007" WEIGHT="63.24786324786324"/>
<DICH_DATA CI_END="2.0274774052021995" CI_START="0.06828841475638728" EFFECT_SIZE="0.37209302325581395" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="43" LOG_CI_END="0.30695602300616154" LOG_CI_START="-1.1656529688534851" LOG_EFFECT_SIZE="-0.42934847292366174" ORDER="200" O_E="0.0" SE="0.8650178113504302" STUDY_ID="STD-ThimasarnTHI93_x002d_4" TOTAL_1="45" TOTAL_2="45" VAR="0.7482558139534884" WEIGHT="36.75213675213675"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="64.0301174472965" CI_END="5.02836972842199" CI_START="1.788227333916495" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="OR" EFFECT_SIZE="2.9986443926218502" ESTIMABLE="YES" EVENTS_1="1072" EVENTS_2="862" I2="82.82058437725942" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.7014272032044644" LOG_CI_START="0.25242272899544016" LOG_EFFECT_SIZE="0.4769249660999523" METHOD="MH" NO="2" P_CHI2="1.6393767454658814E-9" P_Q="0.0" P_Z="3.131572071065729E-5" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.2230067230754016" TOTALS="SUB" TOTAL_1="1175" TOTAL_2="1177" WEIGHT="300.0" Z="4.163681257433251">
<NAME>Parasite clearance at day 28</NAME>
<GROUP_LABEL_1>Combination</GROUP_LABEL_1>
<GROUP_LABEL_2>MQ alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ctrl</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Expt</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.914126975764088" CI_START="1.3986003945055423" DF="0" EFFECT_SIZE="2.621621621621621" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="74" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="0.6914463739920944" LOG_CI_START="0.14569364640640534" LOG_EFFECT_SIZE="0.4185700101992498" NO="1" P_CHI2="1.0" P_Z="0.002643398176409532" STUDIES="1" TAU2="0.0" TOTAL_1="116" TOTAL_2="112" WEIGHT="100.0" Z="3.006424351292991">
<NAME>Artemisinin</NAME>
<DICH_DATA CI_END="4.914126975764088" CI_START="1.3986003945055423" EFFECT_SIZE="2.6216216216216215" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="74" LOG_CI_END="0.6914463739920944" LOG_CI_START="0.14569364640640534" LOG_EFFECT_SIZE="0.41857001019924983" ORDER="201" O_E="0.0" SE="0.3205778537034048" STUDY_ID="STD-HungVNM93_x002d_4" TOTAL_1="116" TOTAL_2="112" VAR="0.10277016028508161" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="47.680436498804085" CI_END="10.22540838212919" CI_START="1.5844768572357344" DF="8" EFFECT_SIZE="4.025161231213974" ESTIMABLE="YES" EVENTS_1="797" EVENTS_2="641" I2="83.22163011196288" ID="CMP-003.02.02" LOG_CI_END="1.0096806618689644" LOG_CI_START="0.19988590029614156" LOG_EFFECT_SIZE="0.604783281082553" NO="2" P_CHI2="1.1371136854343433E-7" P_Z="0.003416546453915302" STUDIES="9" TAU2="1.3753954918936886" TOTAL_1="876" TOTAL_2="861" WEIGHT="99.99999999999999" Z="2.9275404228881823">
<NAME>Artesunate</NAME>
<DICH_DATA CI_END="5.06333144362535" CI_START="0.036275221449110724" EFFECT_SIZE="0.42857142857142855" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.7044363570582188" LOG_CI_START="-1.4403899276474077" LOG_EFFECT_SIZE="-0.36797678529459443" ORDER="202" O_E="0.0" SE="1.259881576697424" STUDY_ID="STD-KarbwangTHI92a" TOTAL_1="12" TOTAL_2="8" VAR="1.5873015873015872" WEIGHT="7.637265363752757"/>
<DICH_DATA CI_END="353.5614273206203" CI_START="1.0673630202395203" EFFECT_SIZE="19.42622950819672" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="30" LOG_CI_END="2.5484648784689505" LOG_CI_START="0.02831215220176047" LOG_EFFECT_SIZE="1.2883885153353556" ORDER="203" O_E="0.0" SE="1.480350186366536" STUDY_ID="STD-LooareesuwanTHI91" TOTAL_1="39" TOTAL_2="37" VAR="2.1914366742754376" WEIGHT="6.343697357235466"/>
<DICH_DATA CI_END="13.360715880354375" CI_START="1.26255378828789" EFFECT_SIZE="4.107142857142857" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="42" LOG_CI_END="1.1258297286902916" LOG_CI_START="0.10124988933249321" LOG_EFFECT_SIZE="0.6135398090113924" ORDER="204" O_E="0.0" SE="0.6018432693907718" STUDY_ID="STD-LooareesuwanTHI93" TOTAL_1="50" TOTAL_2="57" VAR="0.3622153209109731" WEIGHT="13.021847941719273"/>
<DICH_DATA CI_END="2.1762316888515274" CI_START="0.868760899717322" EFFECT_SIZE="1.375" ESTIMABLE="YES" EVENTS_1="171" EVENTS_2="171" LOG_CI_END="0.3377051299201284" LOG_CI_START="-0.0610997335875655" LOG_EFFECT_SIZE="0.13830269816628143" ORDER="205" O_E="0.0" SE="0.23425995094033192" STUDY_ID="STD-LuxemburgerTHI_x002d_MYA91" TOTAL_1="211" TOTAL_2="226" VAR="0.05487772461456672" WEIGHT="15.81998706615572"/>
<DICH_DATA CI_END="2.597865263185651" CI_START="0.7145197465823312" EFFECT_SIZE="1.3624338624338623" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="90" LOG_CI_END="0.41461662288312523" LOG_CI_START="-0.14598576447519396" LOG_EFFECT_SIZE="0.13431542920396564" ORDER="206" O_E="0.0" SE="0.32930061736084915" STUDY_ID="STD-Nosten_x005b_1_x005d_THI_x002d_MYA92_x002d_3" TOTAL_1="124" TOTAL_2="115" VAR="0.10843889659423639" WEIGHT="15.24894150032948"/>
<DICH_DATA CI_END="74.62048204606536" CI_START="6.869936180950106" EFFECT_SIZE="22.641509433962263" ESTIMABLE="YES" EVENTS_1="150" EVENTS_2="106" LOG_CI_END="1.872858050243138" LOG_CI_START="0.8369527026505337" LOG_EFFECT_SIZE="1.3549053764468357" ORDER="207" O_E="0.0" SE="0.6084959289900667" STUDY_ID="STD-Nosten_x005b_2_x005d_THI_x002d_MYA92_x002d_3" TOTAL_1="153" TOTAL_2="154" VAR="0.3702672955974842" WEIGHT="12.961783884245142"/>
<DICH_DATA CI_END="31.68322173737817" CI_START="5.478236948752269" EFFECT_SIZE="13.174528301886792" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="106" LOG_CI_END="1.5008293367944912" LOG_CI_START="0.7386408127500161" LOG_EFFECT_SIZE="1.1197350747722536" ORDER="208" O_E="0.0" SE="0.4477133119177671" STUDY_ID="STD-PriceTHI_x002d_MYA93_x002d_4" TOTAL_1="153" TOTAL_2="163" VAR="0.2004472096683758" WEIGHT="14.358605566279216"/>
<DICH_DATA CI_END="113.5872376708438" CI_START="1.787722847776614" EFFECT_SIZE="14.25" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="48" LOG_CI_END="2.055329538060803" LOG_CI_START="0.25230019062825476" LOG_EFFECT_SIZE="1.153814864344529" ORDER="209" O_E="0.0" SE="1.0591083638210914" STUDY_ID="STD-ThanMYA91" TOTAL_1="58" TOTAL_2="60" VAR="1.1217105263157894" WEIGHT="9.061250752362492"/>
<DICH_DATA CI_END="15.222368026546597" CI_START="0.024158667849100864" EFFECT_SIZE="0.606425702811245" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="41" LOG_CI_END="1.1824822175374634" LOG_CI_START="-1.6169270171425976" LOG_EFFECT_SIZE="-0.2172223998025669" ORDER="210" O_E="0.0" SE="1.6443868417502672" STUDY_ID="STD-ThimasarnTHI93_x002d_4" TOTAL_1="76" TOTAL_2="41" VAR="2.704008085321418" WEIGHT="5.546620567920441"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.013660997179907" CI_END="191.16902636190284" CI_START="0.04975071746939491" DF="1" EFFECT_SIZE="3.0839578822400187" ESTIMABLE="YES" EVENTS_1="178" EVENTS_2="147" I2="83.37119434452744" ID="CMP-003.02.03" LOG_CI_END="2.2814175282654627" LOG_CI_START="-1.3032006517875552" LOG_EFFECT_SIZE="0.4891084382389539" NO="3" P_CHI2="0.014195599573009643" P_Z="0.5927464854542999" STUDIES="2" TAU2="7.529693633872718" TOTAL_1="183" TOTAL_2="204" WEIGHT="100.0" Z="0.5348602698147362">
<NAME>Artemether</NAME>
<DICH_DATA CI_END="55.008367603576154" CI_START="6.812620939709709" EFFECT_SIZE="19.358490566037737" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="106" LOG_CI_END="1.740428757269742" LOG_CI_START="0.8333142250802748" LOG_EFFECT_SIZE="1.2868714911750085" ORDER="211" O_E="0.0" SE="0.532843566497446" STUDY_ID="STD-PriceTHI_x002d_MYA93_x002d_4" TOTAL_1="148" TOTAL_2="163" VAR="0.28392226635771817" WEIGHT="56.742563414459035"/>
<DICH_DATA CI_END="7.021378811396597" CI_START="0.010936467908894618" EFFECT_SIZE="0.27710843373493976" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="41" LOG_CI_END="0.846422404349479" LOG_CI_START="-1.961122917066441" LOG_EFFECT_SIZE="-0.5573502563584811" ORDER="212" O_E="0.0" SE="1.6491660193731896" STUDY_ID="STD-ThimasarnTHI93_x002d_4" TOTAL_1="35" TOTAL_2="41" VAR="2.719748559455212" WEIGHT="43.25743658554097"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="41.903817278134824" CI_END="-9.850468657239249" CI_START="-31.556065512431076" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-20.70326708483516" ESTIMABLE="YES" I2="90.45433027389804" I2_Q="22.697387376563317" ID="CMP-003.03" NO="3" P_CHI2="1.7465319857024042E-8" P_Q="0.25538250593975076" P_Z="1.8481843289057756E-4" Q="1.293617338486719" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="119.79525926168772" TOTALS="YES" TOTAL_1="277" TOTAL_2="255" UNITS="" WEIGHT="100.0" Z="3.7389119607539922">
<NAME>Parasite clearance time</NAME>
<GROUP_LABEL_1>Combination</GROUP_LABEL_1>
<GROUP_LABEL_2>MQ alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Expt</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Ctrl</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-13.769445360185959" CI_START="-26.23055463981404" DF="0" EFFECT_SIZE="-20.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.03.01" NO="1" P_CHI2="1.0" P_Z="3.144956828347359E-10" STUDIES="1" TAU2="0.0" TOTAL_1="113" TOTAL_2="100" WEIGHT="23.603458703310977" Z="6.291459100657375">
<NAME>Artemisinin</NAME>
<CONT_DATA CI_END="-13.769445360185959" CI_START="-26.23055463981404" EFFECT_SIZE="-20.0" ESTIMABLE="YES" MEAN_1="40.0" MEAN_2="60.0" ORDER="213" SD_1="16.0" SD_2="28.0" SE="3.1789128213374642" STUDY_ID="STD-HungVNM93_x002d_4" TOTAL_1="113" TOTAL_2="100" WEIGHT="23.603458703310977"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="40.610199939648105" CI_END="-6.483091078151052" CI_START="-36.20832939447193" DF="3" EFFECT_SIZE="-21.34571023631149" ESTIMABLE="YES" I2="92.61269335177276" ID="CMP-003.03.02" NO="2" P_CHI2="7.910380461773059E-9" P_Z="0.004879204002575855" STUDIES="4" TAU2="181.09477302159812" TOTAL_1="164" TOTAL_2="155" WEIGHT="76.39654129668902" Z="2.814902463851915">
<NAME>Artesunate</NAME>
<CONT_DATA CI_END="-1.4955094799231263" CI_START="-10.504490520076875" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="26.4" MEAN_2="32.4" ORDER="214" SD_1="7.3" SD_2="14.7" SE="2.2982516799327537" STUDY_ID="STD-CardosoBRZ93_x002d_4" TOTAL_1="51" TOTAL_2="51" WEIGHT="24.51371154806665"/>
<CONT_DATA CI_END="3.100077690160596" CI_START="-72.70007769016058" EFFECT_SIZE="-34.8" ESTIMABLE="YES" MEAN_1="47.5" MEAN_2="82.3" ORDER="215" SD_1="19.6" SD_2="52.3" SE="19.33712965600979" STUDY_ID="STD-KarbwangTHI92a" TOTAL_1="12" TOTAL_2="8" WEIGHT="6.21021605557941"/>
<CONT_DATA CI_END="-17.170458892153896" CI_START="-34.829541107846104" EFFECT_SIZE="-26.0" ESTIMABLE="YES" MEAN_1="37.5" MEAN_2="63.5" ORDER="216" SD_1="10.3" SD_2="25.5" SE="4.5049506916925" STUDY_ID="STD-LooareesuwanTHI91" TOTAL_1="39" TOTAL_2="37" WEIGHT="21.886718505235"/>
<CONT_DATA CI_END="-22.08455877516527" CI_START="-33.915441224834744" EFFECT_SIZE="-28.000000000000007" ESTIMABLE="YES" MEAN_1="37.9" MEAN_2="65.9" ORDER="217" SD_1="10.7" SD_2="20.7" SE="3.01813771655754" STUDY_ID="STD-LooareesuwanTHI93" TOTAL_1="62" TOTAL_2="59" WEIGHT="23.785895187807967"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="16.732031338451932" CI_END="-2.7263845216824576" CI_START="-18.079647520597902" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-10.40301602114018" ESTIMABLE="YES" I2="76.09375742198385" I2_Q="35.92267490891964" ID="CMP-003.04" NO="4" P_CHI2="0.0021789214240858223" P_Q="0.21157531577371635" P_Z="0.007906129127813985" Q="1.5606144585133457" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="46.846854864888364" TOTALS="YES" TOTAL_1="281" TOTAL_2="273" UNITS="" WEIGHT="100.0" Z="2.656052558139367">
<NAME>Fever clearance time</NAME>
<GROUP_LABEL_1>Combination</GROUP_LABEL_1>
<GROUP_LABEL_2>MQ alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Expt</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Ctrl</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-3.432201279022385" CI_START="-14.567798720977615" DF="0" EFFECT_SIZE="-9.0" ESTIMABLE="YES" I2="0.0" ID="CMP-003.04.01" NO="1" P_CHI2="1.0" P_Z="0.0015340719468396981" STUDIES="1" TAU2="0.0" TOTAL_1="117" TOTAL_2="114" WEIGHT="27.934438092119073" Z="3.168159760229847">
<NAME>Artemisinin</NAME>
<CONT_DATA CI_END="-3.432201279022385" CI_START="-14.567798720977615" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="22.0" MEAN_2="31.0" ORDER="218" SD_1="14.0" SD_2="27.0" SE="2.8407658328906553" STUDY_ID="STD-HungVNM93_x002d_4" TOTAL_1="117" TOTAL_2="114" WEIGHT="27.934438092119073"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="15.171416879938587" CI_END="0.26313090974696607" CI_START="-24.931832599935817" DF="3" EFFECT_SIZE="-12.334350845094425" ESTIMABLE="YES" I2="80.22597346219554" ID="CMP-003.04.02" NO="2" P_CHI2="0.0016758738764129921" P_Z="0.054981159939604944" STUDIES="4" TAU2="115.07141901438163" TOTAL_1="164" TOTAL_2="159" WEIGHT="72.06556190788093" Z="1.9190250797367103">
<NAME>Artesunate</NAME>
<CONT_DATA CI_END="0.00173553625273426" CI_START="-6.601735536252736" EFFECT_SIZE="-3.3000000000000007" ESTIMABLE="YES" MEAN_1="25.2" MEAN_2="28.5" ORDER="219" SD_1="5.3" SD_2="10.8" SE="1.684589901802484" STUDY_ID="STD-CardosoBRZ93_x002d_4" TOTAL_1="51" TOTAL_2="51" WEIGHT="30.876107973928825"/>
<CONT_DATA CI_END="17.17920195090689" CI_START="-44.1792019509069" EFFECT_SIZE="-13.500000000000004" ESTIMABLE="YES" MEAN_1="31.2" MEAN_2="44.7" ORDER="220" SD_1="12.4" SD_2="43.1" SE="15.652941683061792" STUDY_ID="STD-KarbwangTHI92a" TOTAL_1="12" TOTAL_2="8" WEIGHT="5.256158914437804"/>
<CONT_DATA CI_END="-17.860927086694286" CI_START="-46.539072913305716" EFFECT_SIZE="-32.2" ESTIMABLE="YES" MEAN_1="37.5" MEAN_2="69.7" ORDER="221" SD_1="24.6" SD_2="37.5" SE="7.315987960192378" STUDY_ID="STD-LooareesuwanTHI91" TOTAL_1="39" TOTAL_2="37" WEIGHT="15.28406822553377"/>
<CONT_DATA CI_END="4.267861268085307" CI_START="-16.267861268085305" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="46.1" MEAN_2="52.1" ORDER="222" SD_1="26.1" SD_2="32.2" SE="5.238800992812565" STUDY_ID="STD-LooareesuwanTHI93" TOTAL_1="62" TOTAL_2="63" WEIGHT="20.649226793980528"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="28.924048690855955" CI_END="1.089741353988999" CI_START="0.6136050310008365" CI_STUDY="95" CI_TOTAL="95" DF="26" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8177229220813816" ESTIMABLE="YES" EVENTS_1="191" EVENTS_2="167" I2="10.109403154823077" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.03732343200973636" LOG_CI_START="-0.21211108822637584" LOG_EFFECT_SIZE="-0.08739382810831972" METHOD="MH" NO="5" P_CHI2="0.3145474899731908" P_Q="0.0" P_Z="0.16962287158821301" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.04876247740383708" TOTALS="SUB" TOTAL_1="2695" TOTAL_2="1953" WEIGHT="700.0" Z="1.3734166016897005">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Combination</GROUP_LABEL_1>
<GROUP_LABEL_2>MQ alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Expt</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Ctrl</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.370573794482371" CI_END="1.1132008669887177" CI_START="0.13549884758287564" DF="3" EFFECT_SIZE="0.3883779532945057" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="11" I2="0.0" ID="CMP-003.05.01" LOG_CI_END="0.04657353590155739" LOG_CI_START="-0.8680643984465959" LOG_EFFECT_SIZE="-0.41074543127251933" NO="1" P_CHI2="0.9462518824662287" P_Z="0.07834669983768093" STUDIES="4" TAU2="0.0" TOTAL_1="834" TOTAL_2="657" WEIGHT="100.0" Z="1.7603605139825136">
<NAME>Vomiting, treatment discontinued</NAME>
<DICH_DATA CI_END="8.415814788736112" CI_START="0.013202656415374575" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9250961691676739" LOG_CI_START="-1.879338678606999" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="223" O_E="0.0" SE="1.647338911759228" STUDY_ID="STD-LooareesuwanTHI91" TOTAL_1="42" TOTAL_2="43" VAR="2.713725490196078" WEIGHT="10.636719565493117"/>
<DICH_DATA CI_END="2.772716237192899" CI_START="0.09149511357175784" EFFECT_SIZE="0.5036764705882353" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4429054256805795" LOG_CI_START="-1.0386020994361636" LOG_EFFECT_SIZE="-0.29784833687779194" ORDER="224" O_E="0.0" SE="0.8702448538340987" STUDY_ID="STD-LuxemburgerTHI_x002d_MYA91" TOTAL_1="274" TOTAL_2="278" VAR="0.7573261056247317" WEIGHT="38.11454115018875"/>
<DICH_DATA CI_END="2.0802724970439717" CI_START="0.07588407581226833" EFFECT_SIZE="0.39731543624161075" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.31812022737198964" LOG_CI_START="-1.1198493507506981" LOG_EFFECT_SIZE="-0.40086456168935425" ORDER="225" O_E="0.0" SE="0.8446704482534771" STUDY_ID="STD-Nosten_x005b_1_x005d_THI_x002d_MYA92_x002d_3" TOTAL_1="151" TOTAL_2="153" VAR="0.71346816615273" WEIGHT="40.45749815664088"/>
<DICH_DATA CI_END="4.083440247747125" CI_START="0.006710306172878275" EFFECT_SIZE="0.1655328798185941" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.6110262050173177" LOG_CI_START="-2.173257663712083" LOG_EFFECT_SIZE="-0.7811157293473826" ORDER="226" O_E="0.0" SE="1.6355021269190804" STUDY_ID="STD-PriceTHI_x002d_MYA93_x002d_4" TOTAL_1="367" TOTAL_2="183" VAR="2.6748672071568356" WEIGHT="10.79124112767725"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.52301880037947" CI_END="3.834674334355992" CI_START="0.061239593924869544" DF="1" EFFECT_SIZE="0.4845966354300042" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="21" I2="86.70746376508379" ID="CMP-003.05.02" LOG_CI_END="0.5837284867210487" LOG_CI_START="-1.212967697738197" LOG_EFFECT_SIZE="-0.31461960550857404" NO="2" P_CHI2="0.006091596839421065" P_Z="0.4924490038085668" STUDIES="2" TAU2="1.9316709362174342" TOTAL_1="400" TOTAL_2="225" WEIGHT="100.0" Z="0.6864188847961481">
<NAME>Vomiting, early</NAME>
<DICH_DATA CI_END="4.1920429012790335" CI_START="0.4692889648559521" EFFECT_SIZE="1.4025974025974026" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.6224257185590223" LOG_CI_START="-0.32855965793008673" LOG_EFFECT_SIZE="0.14693303031446783" ORDER="227" O_E="0.0" SE="0.5586135176032371" STUDY_ID="STD-LooareesuwanTHI91" TOTAL_1="42" TOTAL_2="43" VAR="0.312049062049062" WEIGHT="49.64275053243663"/>
<DICH_DATA CI_END="0.4796914794248105" CI_START="0.06022697986861648" EFFECT_SIZE="0.16997167138810199" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" LOG_CI_END="-0.3190379956713803" LOG_CI_START="-1.2202089143369776" LOG_EFFECT_SIZE="-0.769623455004179" ORDER="228" O_E="0.0" SE="0.5293522584921633" STUDY_ID="STD-PriceTHI_x002d_MYA93_x002d_4" TOTAL_1="358" TOTAL_2="182" VAR="0.28021381357075403" WEIGHT="50.35724946756338"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.337168571038504" CI_END="2.685479353920404" CI_START="0.38908492826036556" DF="1" EFFECT_SIZE="1.022193495266338" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="21" I2="57.2131846888709" ID="CMP-003.05.03" LOG_CI_END="0.429021817849888" LOG_CI_START="-0.4099555918642867" LOG_EFFECT_SIZE="0.009533112992800642" NO="3" P_CHI2="0.12631911825891828" P_Z="0.9644729588214553" STUDIES="2" TAU2="0.285328011504467" TOTAL_1="400" TOTAL_2="225" WEIGHT="100.0" Z="0.04454126633232146">
<NAME>Vomiting, late</NAME>
<DICH_DATA CI_END="5.279789237872156" CI_START="0.6307457279681917" EFFECT_SIZE="1.8248847926267282" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" LOG_CI_END="0.7226165864247163" LOG_CI_START="-0.2001456822707506" LOG_EFFECT_SIZE="0.26123545207698284" ORDER="229" O_E="0.0" SE="0.542035124378615" STUDY_ID="STD-LooareesuwanTHI91" TOTAL_1="42" TOTAL_2="43" VAR="0.2938020760601406" WEIGHT="41.93721730297565"/>
<DICH_DATA CI_END="1.3744132800791191" CI_START="0.32911899999297517" EFFECT_SIZE="0.672566371681416" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="14" LOG_CI_END="0.1381173428180874" LOG_CI_START="-0.4826470452233441" LOG_EFFECT_SIZE="-0.17226485120262833" ORDER="230" O_E="0.0" SE="0.3646400743688157" STUDY_ID="STD-PriceTHI_x002d_MYA93_x002d_4" TOTAL_1="358" TOTAL_2="182" VAR="0.13296238383569545" WEIGHT="58.06278269702435"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.93024917086092" CI_END="2.976471267327873" CI_START="0.6597568270644495" DF="4" EFFECT_SIZE="1.4013376606588215" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="13" I2="0.0" ID="CMP-003.05.04" LOG_CI_END="0.47370169454737776" LOG_CI_START="-0.18061610707065995" LOG_EFFECT_SIZE="0.14654279373835893" NO="4" P_CHI2="0.5695651271385768" P_Z="0.3799883787684394" STUDIES="5" TAU2="0.0" TOTAL_1="351" TOTAL_2="276" WEIGHT="100.00000000000001" Z="0.8779177250284596">
<NAME>Vomiting</NAME>
<DICH_DATA CI_END="2.389198901497208" CI_START="0.02745102582148195" EFFECT_SIZE="0.25609756097560976" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.37825230639572305" LOG_CI_START="-1.5614414216953179" LOG_EFFECT_SIZE="-0.5915945576497974" ORDER="231" O_E="0.0" SE="1.1393856975194847" STUDY_ID="STD-CardosoBRZ93_x002d_4" TOTAL_1="42" TOTAL_2="46" VAR="1.2981997677119628" WEIGHT="11.37918476130053"/>
<DICH_DATA CI_END="73.13296101519425" CI_START="0.11887443739208045" EFFECT_SIZE="2.948497854077253" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8641131575419345" LOG_CI_START="-0.9249115254748714" LOG_EFFECT_SIZE="0.46960081603353143" ORDER="232" O_E="0.0" SE="1.6382869046989113" STUDY_ID="STD-HungVNM93_x002d_4" TOTAL_1="117" TOTAL_2="114" VAR="2.6839839821079394" WEIGHT="5.5039281576747365"/>
<DICH_DATA CI_END="18.614932136060503" CI_START="0.10529181549918863" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2698614572620035" LOG_CI_START="-0.9776053859055274" LOG_EFFECT_SIZE="0.14612803567823798" ORDER="233" O_E="0.0" SE="1.3201731488169053" STUDY_ID="STD-KarbwangTHI92a" TOTAL_1="12" TOTAL_2="8" VAR="1.7428571428571429" WEIGHT="8.475998778451062"/>
<DICH_DATA CI_END="5.062564084553353" CI_START="0.33067685932826835" EFFECT_SIZE="1.293859649122807" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.7043705337815876" LOG_CI_START="-0.4805961958261694" LOG_EFFECT_SIZE="0.11188716897770917" ORDER="234" O_E="0.0" SE="0.6960553226515086" STUDY_ID="STD-LooareesuwanTHI93" TOTAL_1="62" TOTAL_2="63" VAR="0.4844930121914957" WEIGHT="30.4905429844116"/>
<DICH_DATA CI_END="6.499768723641126" CI_START="0.6732210191878121" EFFECT_SIZE="2.0918367346938775" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="4" LOG_CI_END="0.812897903745408" LOG_CI_START="-0.17184233301888918" LOG_EFFECT_SIZE="0.32052778536325943" ORDER="235" O_E="0.0" SE="0.5784412896181358" STUDY_ID="STD-ThimasarnTHI93_x002d_4" TOTAL_1="118" TOTAL_2="45" VAR="0.3345943255350921" WEIGHT="44.15034531816208"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.221142948600829" CI_END="1.5587800058686632" CI_START="0.4099630961738904" DF="3" EFFECT_SIZE="0.7994011993110044" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="43" I2="28.92920148571605" ID="CMP-003.05.05" LOG_CI_END="0.19278482655573131" LOG_CI_START="-0.3872552355958239" LOG_EFFECT_SIZE="-0.09723520452004629" NO="5" P_CHI2="0.23855372864678526" P_Z="0.5111047925184306" STUDIES="4" TAU2="0.1357306334529792" TOTAL_1="158" TOTAL_2="160" WEIGHT="100.00000000000003" Z="0.657118400345534">
<NAME>Dizziness</NAME>
<DICH_DATA CI_END="1.1087970694753186" CI_START="0.13088483055060812" EFFECT_SIZE="0.38095238095238093" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="14" LOG_CI_END="0.04485206943910593" LOG_CI_START="-0.8831106849230574" LOG_EFFECT_SIZE="-0.4191293077419757" ORDER="236" O_E="0.0" SE="0.5450899154020517" STUDY_ID="STD-CardosoBRZ93_x002d_4" TOTAL_1="42" TOTAL_2="46" VAR="0.2971230158730158" WEIGHT="26.819464462497635"/>
<DICH_DATA CI_END="7.770193621876023" CI_START="0.1853235672204947" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.8904318409199152" LOG_CI_START="-0.7320693488246655" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="237" O_E="0.0" SE="0.9530652303663865" STUDY_ID="STD-KarbwangTHI92a" TOTAL_1="12" TOTAL_2="8" VAR="0.9083333333333332" WEIGHT="11.118957683496916"/>
<DICH_DATA CI_END="1.980957824935476" CI_START="0.1764482867414933" EFFECT_SIZE="0.5912162162162162" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.29687522940387995" LOG_CI_START="-0.7533825541491682" LOG_EFFECT_SIZE="-0.22825366237264413" ORDER="238" O_E="0.0" SE="0.6169266209189352" STUDY_ID="STD-LooareesuwanTHI91" TOTAL_1="42" TOTAL_2="43" VAR="0.3805984555984556" WEIGHT="22.48353484574738"/>
<DICH_DATA CI_END="3.045517248540659" CI_START="0.6424747995887452" EFFECT_SIZE="1.3988095238095237" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="16" LOG_CI_END="0.4836610635073847" LOG_CI_START="-0.19214390241563786" LOG_EFFECT_SIZE="0.14575858054587337" ORDER="239" O_E="0.0" SE="0.3969711822717169" STUDY_ID="STD-LooareesuwanTHI93" TOTAL_1="62" TOTAL_2="63" VAR="0.15758611955420468" WEIGHT="39.578043008258085"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1150298043756117" CI_END="3.0601043045831977" CI_START="0.5279921945263245" DF="4" EFFECT_SIZE="1.271106284799322" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="9" I2="0.0" ID="CMP-003.05.06" LOG_CI_END="0.4857362297929845" LOG_CI_START="-0.2773724977298289" LOG_EFFECT_SIZE="0.1041818660315778" NO="6" P_CHI2="0.8918802959358052" P_Z="0.5925390951989926" STUDIES="5" TAU2="0.0" TOTAL_1="276" TOTAL_2="205" WEIGHT="99.99999999999997" Z="0.5351601885799816">
<NAME>Diarrhoea</NAME>
<DICH_DATA CI_END="10.659793676813035" CI_START="0.26866423612619206" EFFECT_SIZE="1.6923076923076923" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="1.0277487988848548" LOG_CI_START="-0.570790141854116" LOG_EFFECT_SIZE="0.22847932851536945" ORDER="240" O_E="0.0" SE="0.9389896866854458" STUDY_ID="STD-CardosoBRZ93_x002d_4" TOTAL_1="42" TOTAL_2="46" VAR="0.8817016317016317" WEIGHT="22.78905940884171"/>
<DICH_DATA CI_END="11.909492696108071" CI_START="0.0340030165867844" EFFECT_SIZE="0.6363636363636364" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0758932624086153" LOG_CI_START="-1.4684825526965517" LOG_EFFECT_SIZE="-0.19629464514396822" ORDER="241" O_E="0.0" SE="1.4945789486561871" STUDY_ID="STD-KarbwangTHI92a" TOTAL_1="12" TOTAL_2="8" VAR="2.2337662337662336" WEIGHT="8.995189631747262"/>
<DICH_DATA CI_END="16.930326405476716" CI_START="0.061981992943918714" EFFECT_SIZE="1.024390243902439" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2286653310995383" LOG_CI_START="-1.2077344637432084" LOG_EFFECT_SIZE="0.010465433678164977" ORDER="242" O_E="0.0" SE="1.431153299864121" STUDY_ID="STD-LooareesuwanTHI91" TOTAL_1="42" TOTAL_2="43" VAR="2.0481997677119628" WEIGHT="9.810151911191333"/>
<DICH_DATA CI_END="5.659872330175242" CI_START="0.044170607642003014" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.752806634911638" LOG_CI_START="-1.3548666262396005" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="243" O_E="0.0" SE="1.238057706751144" STUDY_ID="STD-LooareesuwanTHI93" TOTAL_1="62" TOTAL_2="63" VAR="1.5327868852459017" WEIGHT="13.108900564802036"/>
<DICH_DATA CI_END="6.394460070338931" CI_START="0.4698511541859074" EFFECT_SIZE="1.7333333333333334" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="3" LOG_CI_END="0.8058038797963923" LOG_CI_START="-0.3280397019661188" LOG_EFFECT_SIZE="0.23888208891513676" ORDER="244" O_E="0.0" SE="0.6660253325435479" STUDY_ID="STD-ThimasarnTHI93_x002d_4" TOTAL_1="118" TOTAL_2="45" VAR="0.44358974358974357" WEIGHT="45.296698483417636"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.606879821644567" CI_END="1.0681092139129742" CI_START="0.4211553478613913" DF="4" EFFECT_SIZE="0.6707010567603692" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="49" I2="0.0" ID="CMP-003.05.07" LOG_CI_END="0.028615661470407353" LOG_CI_START="-0.3755576802343542" LOG_EFFECT_SIZE="-0.17347100938197338" NO="7" P_CHI2="0.6256050190942908" P_Z="0.09248524541805563" STUDIES="5" TAU2="0.0" TOTAL_1="276" TOTAL_2="205" WEIGHT="100.00000000000001" Z="1.6824312524740281">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="1.1903599951193717" CI_START="0.047385875055674626" EFFECT_SIZE="0.2375" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.07567832294739456" LOG_CI_START="-1.3243510950256236" LOG_EFFECT_SIZE="-0.6243363860391147" ORDER="245" O_E="0.0" SE="0.8223842103747397" STUDY_ID="STD-CardosoBRZ93_x002d_4" TOTAL_1="42" TOTAL_2="46" VAR="0.6763157894736842" WEIGHT="8.33414414342335"/>
<DICH_DATA CI_END="7.455698128967689" CI_START="0.19008730444494704" EFFECT_SIZE="1.1904761904761905" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8724883157115912" LOG_CI_START="-0.7210468878353545" LOG_EFFECT_SIZE="0.07572071393811834" ORDER="246" O_E="0.0" SE="0.9360504666899516" STUDY_ID="STD-KarbwangTHI92a" TOTAL_1="12" TOTAL_2="8" VAR="0.8761904761904762" WEIGHT="6.432977108417594"/>
<DICH_DATA CI_END="2.257796077381471" CI_START="0.2528413452613208" EFFECT_SIZE="0.7555555555555555" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.3536847141756217" LOG_CI_START="-0.5971519076417988" LOG_EFFECT_SIZE="-0.12173359673308856" ORDER="247" O_E="0.0" SE="0.5585261383727398" STUDY_ID="STD-LooareesuwanTHI91" TOTAL_1="42" TOTAL_2="43" VAR="0.3119514472455649" WEIGHT="18.068559468838885"/>
<DICH_DATA CI_END="2.2671463230169677" CI_START="0.3706323536539944" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.3554795506638399" LOG_CI_START="-0.4310566724426395" LOG_EFFECT_SIZE="-0.0377885608893998" ORDER="248" O_E="0.0" SE="0.4620152708698426" STUDY_ID="STD-LooareesuwanTHI93" TOTAL_1="62" TOTAL_2="63" VAR="0.21345811051693403" WEIGHT="26.4057114639347"/>
<DICH_DATA CI_END="1.2164411815124807" CI_START="0.2831470152847549" EFFECT_SIZE="0.5868830290736985" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="17" LOG_CI_END="0.08509111436660688" LOG_CI_START="-0.5479880120074079" LOG_EFFECT_SIZE="-0.23144844882040053" ORDER="249" O_E="0.0" SE="0.371873812624313" STUDY_ID="STD-ThimasarnTHI93_x002d_4" TOTAL_1="118" TOTAL_2="45" VAR="0.13829013251574268" WEIGHT="40.75860781538549"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2008-10-20 10:31:10 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Combination with mefloquine vs artemisinin drug alone</NAME>
<DICH_OUTCOME CHI2="19.793213089299634" CI_END="4.087876390413951" CI_START="1.6251069020038367" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="OR" EFFECT_SIZE="2.577447601135713" ESTIMABLE="YES" EVENTS_1="476" EVENTS_2="400" I2="39.37315813324268" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.6114977550883103" LOG_CI_START="0.2108819348061667" LOG_EFFECT_SIZE="0.4111898449472385" METHOD="MH" NO="1" P_CHI2="0.07110025212822757" P_Q="0.0" P_Z="5.736584327705536E-5" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="503" TOTAL_2="462" WEIGHT="500.0" Z="4.02339221819852">
<NAME>Parasite clearance at day 28</NAME>
<GROUP_LABEL_1>Combination</GROUP_LABEL_1>
<GROUP_LABEL_2>Artemisinin drug</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ctrl</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Expt</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.733415059709732" CI_END="14.759917472482556" CI_START="2.4038258887156037" DF="2" EFFECT_SIZE="5.956531854666719" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="44" I2="46.429744134703924" ID="CMP-004.01.01" LOG_CI_END="1.1690839292115736" LOG_CI_START="0.38090300812752537" LOG_EFFECT_SIZE="0.7749934686695494" NO="1" P_CHI2="0.15463204127548813" P_Z="1.1604144576564901E-4" STUDIES="3" TAU2="0.0" TOTAL_1="77" TOTAL_2="70" WEIGHT="100.0" Z="3.8543416776872546">
<NAME>Artemisinin</NAME>
<DICH_DATA CI_END="483.9893212804995" CI_START="1.2913508057294028" EFFECT_SIZE="25.0" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="10" LOG_CI_END="2.684835779495413" LOG_CI_START="0.11104423784866176" LOG_EFFECT_SIZE="1.3979400086720377" ORDER="250" O_E="0.0" SE="1.5118578920369088" STUDY_ID="STD-AlinTAZ94" TOTAL_1="17" TOTAL_2="17" VAR="2.2857142857142856" WEIGHT="6.704408856489201"/>
<DICH_DATA CI_END="8.602420486779343" CI_START="0.9331998813723761" EFFECT_SIZE="2.8333333333333335" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="24" LOG_CI_END="0.93462066707471" LOG_CI_START="-0.030025325085449306" LOG_EFFECT_SIZE="0.4522976709946303" ORDER="251" O_E="0.0" SE="0.5666378308695502" STUDY_ID="STD-HienVNM_x0028_94_x0029__x005b_1_x005d_" TOTAL_1="40" TOTAL_2="36" VAR="0.321078431372549" WEIGHT="87.10690604521308"/>
<DICH_DATA CI_END="563.8912520142486" CI_START="1.5209547198345579" EFFECT_SIZE="29.285714285714285" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="10" LOG_CI_END="2.7511953571678722" LOG_CI_START="0.1821162849151224" LOG_EFFECT_SIZE="1.4666558210414975" ORDER="252" O_E="0.0" SE="1.5090897641877725" STUDY_ID="STD-Li-CHI82_x002d_4" TOTAL_1="20" TOTAL_2="17" VAR="2.2773519163763067" WEIGHT="6.188685098297724"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.620595095230879" CI_END="3.128692281079211" CI_START="0.41526342371183367" DF="2" EFFECT_SIZE="1.1398383518647457" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="110" I2="64.41657927472811" ID="CMP-004.01.02" LOG_CI_END="0.4953628507137563" LOG_CI_START="-0.38167631974412264" LOG_EFFECT_SIZE="0.05684326548481682" NO="2" P_CHI2="0.0601871332637226" P_Z="0.799448382042701" STUDIES="3" TAU2="0.0" TOTAL_1="143" TOTAL_2="118" WEIGHT="100.00000000000001" Z="0.25406106560947583">
<NAME>Artesunate</NAME>
<DICH_DATA CI_END="1.37529145713506" CI_START="0.04649562726723591" EFFECT_SIZE="0.25287356321839083" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="29" LOG_CI_END="0.1383947453023138" LOG_CI_START="-1.3325878888951384" LOG_EFFECT_SIZE="-0.5970965717964123" ORDER="253" O_E="0.0" SE="0.8640624808090569" STUDY_ID="STD-KarbwangTHI92c" TOTAL_1="28" TOTAL_2="31" VAR="0.7466039707419018" WEIGHT="83.25595752873363"/>
<DICH_DATA CI_END="229.2910270811801" CI_START="0.6533348063160961" EFFECT_SIZE="12.23943661971831" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="35" LOG_CI_END="2.360387059678137" LOG_CI_START="-0.18486420421895475" LOG_EFFECT_SIZE="1.0877614277295913" ORDER="254" O_E="0.0" SE="1.4950931916101053" STUDY_ID="STD-LooareesuwanTHI91" TOTAL_1="39" TOTAL_2="40" VAR="2.2353036515988913" WEIGHT="6.186306337588072"/>
<DICH_DATA CI_END="26.705038957559154" CI_START="0.09954366981321325" EFFECT_SIZE="1.6304347826086956" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="46" LOG_CI_END="1.426593215858447" LOG_CI_START="-1.001986352438195" LOG_EFFECT_SIZE="0.21230343171012594" ORDER="255" O_E="0.0" SE="1.426559660080193" STUDY_ID="STD-ThimasarnTHI93_x002d_4" TOTAL_1="76" TOTAL_2="47" VAR="2.035072463768116" WEIGHT="10.557736133678302"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.0725591008615103" CI_END="11.18094069281126" CI_START="1.4701629949011246" DF="2" EFFECT_SIZE="4.054356330511078" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="102" I2="34.9076800690596" ID="CMP-004.01.03" LOG_CI_END="1.048478343846535" LOG_CI_START="0.16736548703519694" LOG_EFFECT_SIZE="0.607921915440866" NO="3" P_CHI2="0.21518026899000242" P_Z="0.006839783000309597" STUDIES="3" TAU2="0.0" TOTAL_1="129" TOTAL_2="119" WEIGHT="100.0" Z="2.7045458489588787">
<NAME>Artemether (Looareesuwan 500mg)</NAME>
<DICH_DATA CI_END="9.067606120484655" CI_START="0.5033356683266382" EFFECT_SIZE="2.1363636363636362" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="44" LOG_CI_END="0.9574926469402265" LOG_CI_START="-0.298142292713204" LOG_EFFECT_SIZE="0.3296751771135112" ORDER="256" O_E="0.0" SE="0.7375661790456186" STUDY_ID="STD-KarbwangTHI93" TOTAL_1="50" TOTAL_2="50" VAR="0.5440038684719535" WEIGHT="62.38159108055998"/>
<DICH_DATA CI_END="126.67049769005706" CI_START="1.86185292578357" EFFECT_SIZE="15.357142857142858" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="28" LOG_CI_END="2.1026754769010294" LOG_CI_START="0.26994537157370474" LOG_EFFECT_SIZE="1.1863104242373672" ORDER="257" O_E="0.0" SE="1.076554736029606" STUDY_ID="STD-LooareesuwanTHI92b" TOTAL_1="44" TOTAL_2="38" VAR="1.1589700996677743" WEIGHT="16.13714477324168"/>
<DICH_DATA CI_END="18.918009643257516" CI_START="0.06789532665780344" EFFECT_SIZE="1.1333333333333333" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="30" LOG_CI_END="1.2768754425086737" LOG_CI_START="-1.1681601178634882" LOG_EFFECT_SIZE="0.054357662322592676" ORDER="258" O_E="0.0" SE="1.4362259912838284" STUDY_ID="STD-ThimasarnTHI93_x002d_4" TOTAL_1="35" TOTAL_2="31" VAR="2.0627450980392155" WEIGHT="21.48126414619834"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.37368937001882596" CI_END="5.254731544857147" CI_START="0.5230246851577315" DF="2" EFFECT_SIZE="1.657816127270244" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="122" I2="0.0" ID="CMP-004.01.04" LOG_CI_END="0.7205505335773374" LOG_CI_START="-0.2814778132841725" LOG_EFFECT_SIZE="0.2195363601465825" NO="4" P_CHI2="0.8295726217997491" P_Z="0.39043723373374195" STUDIES="3" TAU2="0.0" TOTAL_1="129" TOTAL_2="130" WEIGHT="99.99999999999999" Z="0.8588247239352513">
<NAME>Artemether (Looareesuwan 750mg)</NAME>
<DICH_DATA CI_END="9.067606120484655" CI_START="0.5033356683266382" EFFECT_SIZE="2.1363636363636362" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="44" LOG_CI_END="0.9574926469402265" LOG_CI_START="-0.298142292713204" LOG_EFFECT_SIZE="0.3296751771135112" ORDER="259" O_E="0.0" SE="0.7375661790456186" STUDY_ID="STD-KarbwangTHI93" TOTAL_1="50" TOTAL_2="50" VAR="0.5440038684719535" WEIGHT="57.62494879147889"/>
<DICH_DATA CI_END="14.76400123062597" CI_START="0.05435635967344646" EFFECT_SIZE="0.8958333333333334" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="48" LOG_CI_END="1.169204072723433" LOG_CI_START="-1.2647496363154342" LOG_EFFECT_SIZE="-0.04777278179600067" ORDER="260" O_E="0.0" SE="1.4297164569546024" STUDY_ID="STD-LooareesuwanTHI92b" TOTAL_1="44" TOTAL_2="49" VAR="2.0440891472868215" WEIGHT="22.5317492830807"/>
<DICH_DATA CI_END="18.918009643257516" CI_START="0.06789532665780344" EFFECT_SIZE="1.1333333333333333" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="30" LOG_CI_END="1.2768754425086737" LOG_CI_START="-1.1681601178634882" LOG_EFFECT_SIZE="0.054357662322592676" ORDER="261" O_E="0.0" SE="1.4362259912838284" STUDY_ID="STD-ThimasarnTHI93_x002d_4" TOTAL_1="35" TOTAL_2="31" VAR="2.0627450980392155" WEIGHT="19.84330192544039"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.5885561824824923" CI_START="0.14282229408812708" DF="0" EFFECT_SIZE="0.7159090909090909" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" I2="0.0" ID="CMP-004.01.05" LOG_CI_END="0.5549197499416451" LOG_CI_START="-0.8452039953348187" LOG_EFFECT_SIZE="-0.14514212269658688" NO="5" P_CHI2="1.0" P_Z="0.6844821043145878" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="100.0" Z="0.40635455842345247">
<NAME>Dihydroartemisinin</NAME>
<DICH_DATA CI_END="3.5885561824824923" CI_START="0.14282229408812708" EFFECT_SIZE="0.7159090909090909" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" LOG_CI_END="0.5549197499416451" LOG_CI_START="-0.8452039953348187" LOG_EFFECT_SIZE="-0.14514212269658688" ORDER="262" O_E="0.0" SE="0.8224396186997112" STUDY_ID="STD-ThanMYA94a" TOTAL_1="25" TOTAL_2="25" VAR="0.6764069264069263" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="21.194763482439118" CI_END="2.8393782666598932" CI_START="-1.132539010225336" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="0.8534196282172786" ESTIMABLE="YES" I2="66.97297421695771" I2_Q="30.784249078513525" ID="CMP-004.02" NO="2" P_CHI2="0.003492339910123987" P_Q="0.23580355156410915" P_Z="0.399648583542921" Q="2.889515714809857" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="11.632585517094531" TOTALS="SUB" TOTAL_1="309" TOTAL_2="345" UNITS="" WEIGHT="300.0" Z="0.8422490290719928">
<NAME>Parasite clearance time</NAME>
<GROUP_LABEL_1>Combination</GROUP_LABEL_1>
<GROUP_LABEL_2>Artemisinin drug</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Expt</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Ctrl</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="12.873818067488775" CI_END="13.576690761156483" CI_START="-10.066839752907237" DF="2" EFFECT_SIZE="1.7549255041246232" ESTIMABLE="YES" I2="84.46459325807352" ID="CMP-004.02.01" NO="1" P_CHI2="0.0016013542657122848" P_Z="0.7710864433312927" STUDIES="3" TAU2="90.48128839549221" TOTAL_1="85" TOTAL_2="83" WEIGHT="100.0" Z="0.2909540757112489">
<NAME>Artemisinin</NAME>
<CONT_DATA CI_END="-2.0354095760288775" CI_START="-11.76459042397112" EFFECT_SIZE="-6.899999999999999" ESTIMABLE="YES" MEAN_1="24.3" MEAN_2="31.2" ORDER="263" SD_1="5.4" SD_2="9.2" SE="2.4819794967368733" STUDY_ID="STD-AlinTAZ94" TOTAL_1="20" TOTAL_2="18" WEIGHT="37.644780645453245"/>
<CONT_DATA CI_END="8.197814823259845" CI_START="-9.197814823259845" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="43.3" MEAN_2="43.8" ORDER="264" SD_1="18.9" SD_2="23.0" SE="4.4377421686659035" STUDY_ID="STD-HienVNM_x0028_94_x0029__x005b_1_x005d_" TOTAL_1="45" TOTAL_2="45" WEIGHT="33.02068183609624"/>
<CONT_DATA CI_END="26.7505438604694" CI_START="4.049456139530598" EFFECT_SIZE="15.399999999999999" ESTIMABLE="YES" MEAN_1="60.1" MEAN_2="44.7" ORDER="265" SD_1="22.4" SD_2="13.0" SE="5.791200221024999" STUDY_ID="STD-Li-CHI82_x002d_4" TOTAL_1="20" TOTAL_2="20" WEIGHT="29.33453751845051"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.31601439116062" CI_END="6.973535747752591" CI_START="-7.363630765463129" DF="1" EFFECT_SIZE="-0.1950475088552685" ESTIMABLE="YES" I2="81.18891473163083" ID="CMP-004.02.02" NO="2" P_CHI2="0.02113034954303561" P_Z="0.957470583974205" STUDIES="2" TAU2="21.751484523580686" TOTAL_1="100" TOTAL_2="140" WEIGHT="100.0" Z="0.05332798391902608">
<NAME>Artemether</NAME>
<CONT_DATA CI_END="8.412205835324084" CI_START="-1.212205835324081" EFFECT_SIZE="3.6000000000000014" ESTIMABLE="YES" MEAN_1="43.52" MEAN_2="39.92" ORDER="266" SD_1="13.97" SD_2="11.61" SE="2.4552521746736917" STUDY_ID="STD-KarbwangTHI93" TOTAL_1="56" TOTAL_2="53" WEIGHT="48.15508867684058"/>
<CONT_DATA CI_END="0.22492001691190833" CI_START="-7.664920016911906" EFFECT_SIZE="-3.719999999999999" ESTIMABLE="YES" MEAN_1="36.7" MEAN_2="40.42" ORDER="267" SD_1="9.7" SD_2="12.9" SE="2.0127512791198883" STUDY_ID="STD-LooareesuwanTHI92b" TOTAL_1="44" TOTAL_2="87" WEIGHT="51.84491132315942"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.11541530897986543" CI_END="3.014089511653224" CI_START="-1.1842880704569545" DF="2" EFFECT_SIZE="0.9149007205981347" ESTIMABLE="YES" I2="0.0" ID="CMP-004.02.03" NO="3" P_CHI2="0.9439258646738237" P_Z="0.3929822116852365" STUDIES="3" TAU2="0.0" TOTAL_1="124" TOTAL_2="122" WEIGHT="100.0" Z="0.8542216257265774">
<NAME>Artesunate</NAME>
<CONT_DATA CI_END="3.357686562761396" CI_START="-1.9576865627613973" EFFECT_SIZE="0.6999999999999993" ESTIMABLE="YES" MEAN_1="26.4" MEAN_2="25.7" ORDER="268" SD_1="7.3" SD_2="6.3" SE="1.3559874486086934" STUDY_ID="STD-CardosoBRZ93_x002d_4" TOTAL_1="51" TOTAL_2="50" WEIGHT="62.38719737102248"/>
<CONT_DATA CI_END="6.093076675264129" CI_START="-4.453076675264128" EFFECT_SIZE="0.8200000000000003" ESTIMABLE="YES" MEAN_1="37.1" MEAN_2="36.28" ORDER="269" SD_1="11.68" SD_2="10.16" SE="2.6903946791152715" STUDY_ID="STD-KarbwangTHI92c" TOTAL_1="34" TOTAL_2="32" WEIGHT="15.848013213161906"/>
<CONT_DATA CI_END="6.0996036869044845" CI_START="-2.8996036869044817" EFFECT_SIZE="1.6000000000000014" ESTIMABLE="YES" MEAN_1="37.5" MEAN_2="35.9" ORDER="270" SD_1="10.3" SD_2="10.1" SE="2.2957583518864544" STUDY_ID="STD-LooareesuwanTHI91" TOTAL_1="39" TOTAL_2="40" WEIGHT="21.764789415815606"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.36072515986433806" CI_END="0.02341898106981466" CI_START="-3.3995853134110305" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.688083166170608" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.03" NO="3" P_CHI2="0.8349674550667247" P_Q="0.7528315272365427" P_Z="0.05321830983147026" Q="0.0991670524058052" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="110" TOTAL_2="108" UNITS="" WEIGHT="200.0" Z="1.9331452279726316">
<NAME>Time to 50/90% parasite clearance</NAME>
<GROUP_LABEL_1>Combination</GROUP_LABEL_1>
<GROUP_LABEL_2>Artemisinin drug</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Expt</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Ctrl</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.26155810745853286" CI_END="0.07270206215373265" CI_START="-3.7060366548409167" DF="1" EFFECT_SIZE="-1.8166672963435921" ESTIMABLE="YES" I2="0.0" ID="CMP-004.03.01" NO="1" P_CHI2="0.609051772318361" P_Z="0.05949122986485207" STUDIES="2" TAU2="0.0" TOTAL_1="65" TOTAL_2="63" WEIGHT="99.99999999999999" Z="1.8845454737114262">
<NAME>Artemisinin, PC50</NAME>
<CONT_DATA CI_END="1.0737665068761348" CI_START="-3.8737665068761356" EFFECT_SIZE="-1.4000000000000004" ESTIMABLE="YES" MEAN_1="9.4" MEAN_2="10.8" ORDER="271" SD_1="3.58" SD_2="4.14" SE="1.2621489610976986" STUDY_ID="STD-AlinTAZ94" TOTAL_1="20" TOTAL_2="18" WEIGHT="58.33327036564079"/>
<CONT_DATA CI_END="0.5269962124443568" CI_START="-5.3269962124443575" EFFECT_SIZE="-2.4000000000000004" ESTIMABLE="YES" MEAN_1="8.7" MEAN_2="11.1" ORDER="272" SD_1="4.4" SD_2="9.0" SE="1.493392855956604" STUDY_ID="STD-HienVNM_x0028_94_x0029__x005b_1_x005d_" TOTAL_1="45" TOTAL_2="45" WEIGHT="41.66672963435919"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="2.940569265332554" CI_START="-5.14056926533255" DF="0" EFFECT_SIZE="-1.0999999999999979" ESTIMABLE="YES" I2="0.0" ID="CMP-004.03.02" NO="2" P_CHI2="1.0" P_Z="0.5936332752425632" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="45" WEIGHT="100.0" Z="0.5335783750799316">
<NAME>Artemisinin, PC90</NAME>
<CONT_DATA CI_END="2.940569265332554" CI_START="-5.14056926533255" EFFECT_SIZE="-1.0999999999999979" ESTIMABLE="YES" MEAN_1="19.3" MEAN_2="20.4" ORDER="273" SD_1="9.0" SD_2="10.5" SE="2.0615528128088303" STUDY_ID="STD-HienVNM_x0028_94_x0029__x005b_1_x005d_" TOTAL_1="45" TOTAL_2="45" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="24.44854859456694" CI_END="0.08312470483933065" CI_START="-4.981231087596696" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.449053191378683" ESTIMABLE="YES" I2="71.36844351752" I2_Q="64.41482511140737" ID="CMP-004.04" NO="4" P_CHI2="9.498661627257432E-4" P_Q="0.06019547170361306" P_Z="0.05800984101146422" Q="5.620318029239559" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="14.277357012547318" TOTALS="SUB" TOTAL_1="321" TOTAL_2="358" UNITS="" WEIGHT="300.0" Z="1.8956235493937144">
<NAME>Fever clearance time</NAME>
<GROUP_LABEL_1>Combination</GROUP_LABEL_1>
<GROUP_LABEL_2>Artemisinin drug</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Expt</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Ctrl</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="14.87954544791582" CI_END="8.60248160808446" CI_START="-8.649204351324766" DF="2" EFFECT_SIZE="-0.023361371620153035" ESTIMABLE="YES" I2="86.5587291829527" ID="CMP-004.04.01" NO="1" P_CHI2="5.874203480187301E-4" P_Z="0.9957647124378626" STUDIES="3" TAU2="49.099578990637895" TOTAL_1="85" TOTAL_2="83" WEIGHT="100.0" Z="0.0053081707043227495">
<NAME>Artemisinin</NAME>
<CONT_DATA CI_END="-4.900275312093445" CI_START="-7.899724687906552" EFFECT_SIZE="-6.399999999999999" ESTIMABLE="YES" MEAN_1="13.8" MEAN_2="20.2" ORDER="274" SD_1="1.9" SD_2="2.7" SE="0.7651797174520506" STUDY_ID="STD-AlinTAZ94" TOTAL_1="20" TOTAL_2="18" WEIGHT="38.9835091203036"/>
<CONT_DATA CI_END="9.039032337166166" CI_START="-5.839032337166162" EFFECT_SIZE="1.6000000000000014" ESTIMABLE="YES" MEAN_1="27.5" MEAN_2="25.9" ORDER="275" SD_1="20.5" SD_2="15.1" SE="3.7954944049198356" STUDY_ID="STD-HienVNM_x0028_94_x0029__x005b_1_x005d_" TOTAL_1="45" TOTAL_2="45" WEIGHT="30.499769287775294"/>
<CONT_DATA CI_END="13.92991816797365" CI_START="-0.9299181679736508" EFFECT_SIZE="6.5" ESTIMABLE="YES" MEAN_1="22.0" MEAN_2="15.5" ORDER="276" SD_1="12.9" SD_2="11.0" SE="3.790844233149128" STUDY_ID="STD-Li-CHI82_x002d_4" TOTAL_1="20" TOTAL_2="20" WEIGHT="30.5167215919211"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.2827062576581545" CI_END="0.05500725573697052" CI_START="-5.41883285285358" DF="2" EFFECT_SIZE="-2.6819127985583044" ESTIMABLE="YES" I2="0.0" ID="CMP-004.04.02" NO="2" P_CHI2="0.526579440426615" P_Z="0.054785666192362775" STUDIES="3" TAU2="0.0" TOTAL_1="127" TOTAL_2="124" WEIGHT="100.00000000000003" Z="1.9205721725784124">
<NAME>Artesunate</NAME>
<CONT_DATA CI_END="0.011707292825696047" CI_START="-5.8117072928257" EFFECT_SIZE="-2.900000000000002" ESTIMABLE="YES" MEAN_1="25.2" MEAN_2="28.1" ORDER="277" SD_1="5.3" SD_2="9.1" SE="1.485592243425325" STUDY_ID="STD-CardosoBRZ93_x002d_4" TOTAL_1="51" TOTAL_2="50" WEIGHT="88.35452474714423"/>
<CONT_DATA CI_END="6.454085230557723" CI_START="-19.234085230557724" EFFECT_SIZE="-6.390000000000001" ESTIMABLE="YES" MEAN_1="24.27" MEAN_2="30.66" ORDER="278" SD_1="32.0" SD_2="20.26" SE="6.553225126517747" STUDY_ID="STD-KarbwangTHI92c" TOTAL_1="34" TOTAL_2="32" WEIGHT="4.540648315809544"/>
<CONT_DATA CI_END="12.667988178465531" CI_START="-7.867988178465534" EFFECT_SIZE="2.3999999999999986" ESTIMABLE="YES" MEAN_1="37.5" MEAN_2="35.1" ORDER="279" SD_1="24.6" SD_2="23.4" SE="5.23886574419638" STUDY_ID="STD-LooareesuwanTHI91" TOTAL_1="42" TOTAL_2="42" WEIGHT="7.104826937046248"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.665978859753406" CI_END="7.911587423838966" CI_START="-13.145516413029242" DF="1" EFFECT_SIZE="-2.6169644945951385" ESTIMABLE="YES" I2="62.490325219889534" ID="CMP-004.04.03" NO="3" P_CHI2="0.10251479684859033" P_Z="0.6261404548503304" STUDIES="2" TAU2="37.66929302319985" TOTAL_1="109" TOTAL_2="151" WEIGHT="100.0" Z="0.4871663451880844">
<NAME>Artemether</NAME>
<CONT_DATA CI_END="2.3638536471968585" CI_START="-20.843853647196863" EFFECT_SIZE="-9.240000000000002" ESTIMABLE="YES" MEAN_1="33.32" MEAN_2="42.56" ORDER="280" SD_1="25.23" SD_2="35.43" SE="5.920442282984063" STUDY_ID="STD-KarbwangTHI93" TOTAL_1="56" TOTAL_2="53" WEIGHT="39.68091525132183"/>
<CONT_DATA CI_END="7.99046531342129" CI_START="-4.510465313421293" EFFECT_SIZE="1.7399999999999984" ESTIMABLE="YES" MEAN_1="31.4" MEAN_2="29.66" ORDER="281" SD_1="20.1" SD_2="15.8" SE="3.1890715149483175" STUDY_ID="STD-LooareesuwanTHI92b" TOTAL_1="53" TOTAL_2="98" WEIGHT="60.319084748678165"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="28.350957141937673" CI_END="2.771294990410624" CI_START="0.9602713795207912" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="OR" EFFECT_SIZE="1.6313170334121654" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="58" I2="64.72782223917348" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="0.4426827567056636" LOG_CI_START="-0.01760601490525569" LOG_EFFECT_SIZE="0.212538370900204" METHOD="MH" NO="5" P_CHI2="0.0015857553332553342" P_Q="0.0" P_Z="0.07029160016426456" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.038021948850428" TOTALS="SUB" TOTAL_1="590" TOTAL_2="546" WEIGHT="200.0" Z="1.8100270003950432">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Combination</GROUP_LABEL_1>
<GROUP_LABEL_2>Artemisinin drug</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Expt</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Ctrl</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.838707050945763" CI_END="3.340079088408198" CI_START="1.0736507210903072" DF="5" EFFECT_SIZE="1.893694358065239" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="23" I2="0.0" ID="CMP-004.05.01" LOG_CI_END="0.5237567504201295" LOG_CI_START="0.030863020121219786" LOG_EFFECT_SIZE="0.2773098852706747" NO="1" P_CHI2="0.4358803450765998" P_Z="0.027425050539230545" STUDIES="6" TAU2="0.0" TOTAL_1="312" TOTAL_2="289" WEIGHT="100.0" Z="2.2054140853357858">
<NAME>Vomiting</NAME>
<DICH_DATA CI_END="2.333478307323398" CI_START="0.0267840501468772" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3680037679151811" LOG_CI_START="-1.5721237505711059" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="282" O_E="0.0" SE="1.1396405081449492" STUDY_ID="STD-CardosoBRZ93_x002d_4" TOTAL_1="42" TOTAL_2="45" VAR="1.298780487804878" WEIGHT="6.454253759583183"/>
<DICH_DATA CI_END="15.678734529416493" CI_START="0.05628394126543747" EFFECT_SIZE="0.9393939393939394" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1953110067495607" LOG_CI_START="-1.2496154988367902" LOG_EFFECT_SIZE="-0.027152246043614773" ORDER="283" O_E="0.0" SE="1.436161931962813" STUDY_ID="STD-KarbwangTHI92c" TOTAL_1="34" TOTAL_2="32" VAR="2.0625610948191593" WEIGHT="4.06419905201542"/>
<DICH_DATA CI_END="11.093947290056747" CI_START="0.6955188429308449" EFFECT_SIZE="2.7777777777777777" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="1.0450860981128656" LOG_CI_START="-0.15769109964744" LOG_EFFECT_SIZE="0.44369749923271273" ORDER="284" O_E="0.0" SE="0.7065172798075547" STUDY_ID="STD-KarbwangTHI93" TOTAL_1="56" TOTAL_2="53" VAR="0.49916666666666665" WEIGHT="16.793306536803833"/>
<DICH_DATA CI_END="123.07864795221792" CI_START="0.24941441908990408" EFFECT_SIZE="5.54054054054054" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0901827167749967" LOG_CI_START="-0.6030784427974784" LOG_EFFECT_SIZE="0.7435521369887593" ORDER="285" O_E="0.0" SE="1.5820349369906253" STUDY_ID="STD-Li-CHI82_x002d_4" TOTAL_1="20" TOTAL_2="20" VAR="2.502834541858932" WEIGHT="3.3492660845498223"/>
<DICH_DATA CI_END="4.235277928916772" CI_START="0.5369797739316635" EFFECT_SIZE="1.5080645161290323" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.6268819150290448" LOG_CI_START="-0.27004207228051696" LOG_EFFECT_SIZE="0.1784199213742639" ORDER="286" O_E="0.0" SE="0.5268575899909788" STUDY_ID="STD-LooareesuwanTHI91" TOTAL_1="42" TOTAL_2="42" VAR="0.2775789201311023" WEIGHT="30.19919107088078"/>
<DICH_DATA CI_END="6.499409244026836" CI_START="1.059309568127571" EFFECT_SIZE="2.623906705539359" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="7" LOG_CI_END="0.8128738837630259" LOG_CI_START="0.025022895030082887" LOG_EFFECT_SIZE="0.41894838939655443" ORDER="287" O_E="0.0" SE="0.46278757070702214" STUDY_ID="STD-ThimasarnTHI93_x002d_4" TOTAL_1="118" TOTAL_2="97" VAR="0.214172335600907" WEIGHT="39.13978349616697"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="15.13389611328473" CI_END="2.5968474265208776" CI_START="0.13412808300573786" DF="4" EFFECT_SIZE="0.5901780809023909" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="35" I2="73.5692648472144" ID="CMP-004.05.02" LOG_CI_END="0.41444643412426563" LOG_CI_START="-0.8724802824202779" LOG_EFFECT_SIZE="-0.22901692414800615" NO="2" P_CHI2="0.004431423538952428" P_Z="0.4854420814958845" STUDIES="5" TAU2="1.8761048396567974" TOTAL_1="278" TOTAL_2="257" WEIGHT="100.00000000000001" Z="0.6975765090734243">
<NAME>Diarrhoea</NAME>
<DICH_DATA CI_END="2.333478307323398" CI_START="0.0267840501468772" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.3680037679151811" LOG_CI_START="-1.5721237505711059" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="288" O_E="0.0" SE="1.1396405081449492" STUDY_ID="STD-CardosoBRZ93_x002d_4" TOTAL_1="42" TOTAL_2="45" VAR="1.298780487804878" WEIGHT="17.999265953628043"/>
<DICH_DATA CI_END="0.39604224363039275" CI_START="0.053087771161153256" EFFECT_SIZE="0.145" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="24" LOG_CI_END="-0.40225848781918994" LOG_CI_START="-1.2750055077108604" LOG_EFFECT_SIZE="-0.8386319977650252" ORDER="289" O_E="0.0" SE="0.5126559196517904" STUDY_ID="STD-KarbwangTHI93" TOTAL_1="56" TOTAL_2="53" VAR="0.26281609195402295" WEIGHT="26.717025644429892"/>
<DICH_DATA CI_END="82.16475480197155" CI_START="0.12105854372842961" EFFECT_SIZE="3.1538461538461537" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9146855635554856" LOG_CI_START="-0.9170045547296883" LOG_EFFECT_SIZE="0.49884050441289873" ORDER="290" O_E="0.0" SE="1.6633487925728614" STUDY_ID="STD-Li-CHI82_x002d_4" TOTAL_1="20" TOTAL_2="20" VAR="2.766729205753596" WEIGHT="12.308345467946376"/>
<DICH_DATA CI_END="5.594677381944907" CI_START="0.04253213953249696" EFFECT_SIZE="0.4878048780487805" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7477750479187422" LOG_CI_START="-1.3712827700302508" LOG_EFFECT_SIZE="-0.3117538610557543" ORDER="291" O_E="0.0" SE="1.2447450517686098" STUDY_ID="STD-LooareesuwanTHI91" TOTAL_1="42" TOTAL_2="42" VAR="1.549390243902439" WEIGHT="16.68243684118134"/>
<DICH_DATA CI_END="6.632912398853134" CI_START="0.7824191850821864" EFFECT_SIZE="2.278095238095238" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.8217042615911669" LOG_CI_START="-0.1065605090982966" LOG_EFFECT_SIZE="0.35757187624643516" ORDER="292" O_E="0.0" SE="0.5452673212877127" STUDY_ID="STD-ThimasarnTHI93_x002d_4" TOTAL_1="118" TOTAL_2="97" VAR="0.2973164516642777" WEIGHT="26.29292609281435"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2008-10-25 18:53:59 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Combination with mefloquine: mefloquine dose/schedule</NAME>
<DICH_OUTCOME CHI2="10.355656094458261" CI_END="1.449402997095182" CI_START="0.41511072213150146" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="0.775669210929339" ESTIMABLE="YES" EVENTS_1="200" EVENTS_2="186" I2="61.373765568165545" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.16118915502320988" LOG_CI_START="-0.3818360488368352" LOG_EFFECT_SIZE="-0.11032344690681266" METHOD="MH" MODIFIED="2008-10-25 18:53:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.03484448745485813" P_Q="0.0" P_Z="0.42580526419621956" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="228" TOTAL_2="207" WEIGHT="400.0" Z="0.7963902266436939">
<NAME>Parasite clearance at day 28</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ctrl</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Expt</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.875791079343958" CI_END="0.6619009917725148" CI_START="0.04314048550552735" DF="1" EFFECT_SIZE="0.1689814491050907" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="96" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="-0.1792069681775346" LOG_CI_START="-1.3651149716306694" LOG_EFFECT_SIZE="-0.7721609699041019" MODIFIED="2008-10-25 18:52:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.34935716513820014" P_Z="0.010700853149075009" STUDIES="2" TAU2="0.0" TOTAL_1="100" TOTAL_2="98" WEIGHT="100.0" Z="2.5523188761232847">
<NAME>Artemether (AM) 300 mg + mefloquine (MQ) 15 vs AM 300 mg + MQ 25</NAME>
<DICH_DATA CI_END="1.383934319291568" CI_START="0.05556719542454124" EFFECT_SIZE="0.2773109243697479" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="68" LOG_CI_END="0.14111547924926995" LOG_CI_START="-1.2551815222785567" LOG_EFFECT_SIZE="-0.5570330215146433" ORDER="293" O_E="0.0" SE="0.8201917704790747" STUDY_ID="STD-BunnagTHI92_x002d_4a" TOTAL_1="73" TOTAL_2="70" VAR="0.6727145403615992" WEIGHT="50.59792718575605"/>
<DICH_DATA CI_END="1.0872170600147073" CI_START="0.0030973068763556727" EFFECT_SIZE="0.058029689608636977" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="28" LOG_CI_END="0.03631625848907985" LOG_CI_START="-2.5090157632885632" LOG_EFFECT_SIZE="-1.2363497523997415" ORDER="294" O_E="0.0" SE="1.495140629188899" STUDY_ID="STD-KarbwangTHI93_x002d_4" TOTAL_1="27" TOTAL_2="28" VAR="2.2354455010513763" WEIGHT="49.40207281424396"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4683270428129807" CI_START="0.3214021323572578" DF="0" EFFECT_SIZE="0.8906882591093117" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="19" I2="0.0" ID="CMP-005.01.02" LOG_CI_END="0.39240270134144384" LOG_CI_START="-0.49295124621636294" LOG_EFFECT_SIZE="-0.05027427243745951" MODIFIED="2008-10-25 18:52:43 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.82385410022799" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="30" WEIGHT="100.0" Z="0.22259066805582123">
<NAME>Artemether (AM) 750 mg + mefloquine (MQ) 10 vs AM 750 mg + MQ 15</NAME>
<DICH_DATA CI_END="2.4683270428129807" CI_START="0.3214021323572578" EFFECT_SIZE="0.8906882591093117" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="19" LOG_CI_END="0.39240270134144384" LOG_CI_START="-0.49295124621636294" LOG_EFFECT_SIZE="-0.05027427243745951" ORDER="295" O_E="0.0" SE="0.5200612913681774" STUDY_ID="STD-ThanMYA93a" TOTAL_1="33" TOTAL_2="30" VAR="0.2704637467795362" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="37.61077415619866" CI_START="0.38667735586279517" DF="0" EFFECT_SIZE="3.8135593220338984" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="59" I2="0.0" ID="CMP-005.01.03" LOG_CI_END="1.5753122727551563" LOG_CI_START="-0.41265125981671974" LOG_EFFECT_SIZE="0.5813305064692182" MODIFIED="2008-10-25 18:53:59 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.251677072458923" STUDIES="1" TAU2="0.0" TOTAL_1="76" TOTAL_2="62" WEIGHT="100.0" Z="1.146285469653505">
<NAME>Artesunate (AS) 600 mg + mefloquine (MQ) 15 vs AS 600 mg + MQ 25</NAME>
<DICH_DATA CI_END="37.61077415619866" CI_START="0.38667735586279517" EFFECT_SIZE="3.8135593220338984" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="59" LOG_CI_END="1.5753122727551563" LOG_CI_START="-0.41265125981671974" LOG_EFFECT_SIZE="0.5813305064692182" ORDER="296" O_E="0.0" SE="1.1677396196109129" STUDY_ID="STD-ThimasarnTHI93_x002d_4" TOTAL_1="76" TOTAL_2="62" VAR="1.3636158192090395" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="72.4418758615024" CI_START="0.7764845861741797" DF="0" EFFECT_SIZE="7.5" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="12" I2="0.0" ID="CMP-005.01.04" LOG_CI_END="1.859989687718102" LOG_CI_START="-0.10986716093470186" LOG_EFFECT_SIZE="0.8750612633917001" MODIFIED="2008-10-25 18:53:11 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.08162519068314962" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="17" WEIGHT="100.0" Z="1.7413331955434317">
<NAME>Artesunate (AS) 600 mg + mefloquine (MQ) 10 concomitant vs sequential</NAME>
<DICH_DATA CI_END="72.44187586150234" CI_START="0.77648458617418" EFFECT_SIZE="7.5" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="12" LOG_CI_END="1.8599896877181015" LOG_CI_START="-0.10986716093470167" LOG_EFFECT_SIZE="0.8750612633917001" ORDER="297" O_E="0.0" SE="1.1571036638473187" STUDY_ID="STD-ThanMYA93b" TOTAL_1="19" TOTAL_2="17" VAR="1.3388888888888888" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2008-10-25 18:57:18 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Combination with sulfadoxine-pyrimethamine vs artemisinin drug alone</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-10-25 18:57:18 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="38" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Parasite clearance at day 28</NAME>
<GROUP_LABEL_1>Combination</GROUP_LABEL_1>
<GROUP_LABEL_2>Artemisinin drug</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ctrl</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Expt</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="24" I2="0.0" ID="CMP-006.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="38" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>Artemisinin</NAME>
<DICH_DATA CI_END="1.423777542806513" CI_START="0.21677682505109266" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="24" LOG_CI_END="0.1534421385433009" LOG_CI_START="-0.6639871487499129" LOG_EFFECT_SIZE="-0.255272505103306" ORDER="298" O_E="0.0" SE="0.4801620096962645" STUDY_ID="STD-HienVNM_x0028_94_x0029__x005b_1_x005d_" TOTAL_1="38" TOTAL_2="36" VAR="0.23055555555555557" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2008-10-25 18:57:35 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Comparison between artemisinin drugs</NAME>
<DICH_OUTCOME CHI2="2.0338420789388603" CI_END="1.7410764201325917" CI_START="0.5676165671690007" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9941145913699057" ESTIMABLE="YES" EVENTS_1="317" EVENTS_2="330" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="0.2408178337902262" LOG_CI_START="-0.2459449371661578" LOG_EFFECT_SIZE="-0.0025635516879657775" METHOD="MH" MODIFIED="2008-10-25 18:53:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5654124889389397" P_Q="0.0" P_Z="0.983529301252253" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="343" TOTAL_2="358" WEIGHT="99.99999999999999" Z="0.020644425912227378">
<NAME>Parasite clearance at day 7</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ctrl</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Expt</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="20" I2="0.0" ID="CMP-007.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2008-10-25 18:53:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Artemisinin vs artesunate</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="20" EVENTS_2="20" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="299" O_E="0.0" SE="0.0" STUDY_ID="STD-AlinTAZ96" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.0338420789388603" CI_END="1.7410764201325917" CI_START="0.5676165671690007" DF="3" EFFECT_SIZE="0.9941145913699057" ESTIMABLE="YES" EVENTS_1="297" EVENTS_2="310" I2="0.0" ID="CMP-007.01.02" LOG_CI_END="0.2408178337902262" LOG_CI_START="-0.2459449371661578" LOG_EFFECT_SIZE="-0.0025635516879657775" MODIFIED="2008-10-25 18:53:33 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5654124889389397" P_Z="0.983529301252253" STUDIES="4" TAU2="0.0" TOTAL_1="323" TOTAL_2="338" WEIGHT="99.99999999999999" Z="0.020644425912227378">
<NAME>Artemether vs artesunate</NAME>
<DICH_DATA CI_END="9.478364293757265" CI_START="0.24578501279287676" EFFECT_SIZE="1.5263157894736843" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="57" LOG_CI_END="0.9767333964638442" LOG_CI_START="-0.6094446025715899" LOG_EFFECT_SIZE="0.18364439694612714" ORDER="300" O_E="0.0" SE="0.93172880834114" STUDY_ID="STD-BunnagTHI92_x002d_4b" TOTAL_1="60" TOTAL_2="60" VAR="0.8681185722928009" WEIGHT="7.744629640375767"/>
<DICH_DATA CI_END="3.279919865522118" CI_START="0.6120617300152297" EFFECT_SIZE="1.416867469879518" ESTIMABLE="YES" EVENTS_1="168" EVENTS_2="166" LOG_CI_END="0.5158632332279325" LOG_CI_START="-0.2132047744998409" LOG_EFFECT_SIZE="0.15132922936404578" ORDER="301" O_E="0.0" SE="0.42825815668413664" STUDY_ID="STD-PriceTHI_x002d_MYA93_x002d_4" TOTAL_1="178" TOTAL_2="180" VAR="0.18340504876649455" WEIGHT="37.800897392013454"/>
<DICH_DATA CI_END="1.8720959877017869" CI_START="0.20519338356203765" EFFECT_SIZE="0.6197916666666666" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="48" LOG_CI_END="0.2723281124899574" LOG_CI_START="-0.6878366471119951" LOG_EFFECT_SIZE="-0.20775426731101887" ORDER="302" O_E="0.0" SE="0.5640055326824006" STUDY_ID="STD-ThimasarnTHI93_x002d_4" TOTAL_1="42" TOTAL_2="55" VAR="0.3181022408963585" WEIGHT="32.27279199027993"/>
<DICH_DATA CI_END="2.422072179952992" CI_START="0.16515990888009158" EFFECT_SIZE="0.6324786324786325" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="39" LOG_CI_END="0.38418708137028446" LOG_CI_START="-0.7820953654006555" LOG_EFFECT_SIZE="-0.1989541420151855" ORDER="303" O_E="0.0" SE="0.6850800824244705" STUDY_ID="STD-WinMYA94_x002d_5" TOTAL_1="43" TOTAL_2="43" VAR="0.4693347193347193" WEIGHT="22.181680977330842"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.7973245072721329" CI_END="1.599699329432791" CI_START="0.48273909028152895" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8787703903832658" ESTIMABLE="YES" EVENTS_1="263" EVENTS_2="285" I2="0.0" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="0.20403836275658438" LOG_CI_START="-0.31628753232654705" LOG_EFFECT_SIZE="-0.05612458478498135" METHOD="MH" MODIFIED="2008-10-25 18:53:45 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7729718572674273" P_Q="0.0" P_Z="0.6724264067118499" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="299" TOTAL_2="318" WEIGHT="200.0" Z="0.42282025886200925">
<NAME>Parasite clearance at day 28</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ctrl</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Expt</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.080921171500068" CI_START="0.11786163470971665" DF="0" EFFECT_SIZE="0.49523809523809526" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" I2="0.0" ID="CMP-007.02.01" LOG_CI_END="0.31825562877916075" LOG_CI_START="-0.9286275396494387" LOG_EFFECT_SIZE="-0.3051859554351389" MODIFIED="2008-10-25 18:53:39 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3373382042906926" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="19" WEIGHT="100.0" Z="0.9594378950421618">
<NAME>Artemisinin vs artesunate</NAME>
<DICH_DATA CI_END="2.080921171500068" CI_START="0.11786163470971665" EFFECT_SIZE="0.49523809523809526" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" LOG_CI_END="0.31825562877916075" LOG_CI_START="-0.9286275396494387" LOG_EFFECT_SIZE="-0.3051859554351389" ORDER="304" O_E="0.0" SE="0.7324253453061864" STUDY_ID="STD-AlinTAZ96" TOTAL_1="20" TOTAL_2="19" VAR="0.5364468864468864" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0634667602254608" CI_END="1.9388314995402243" CI_START="0.5130819948375602" DF="3" EFFECT_SIZE="0.9973863511388135" ESTIMABLE="YES" EVENTS_1="250" EVENTS_2="270" I2="0.0" ID="CMP-007.02.02" LOG_CI_END="0.2875400669437346" LOG_CI_START="-0.28981322541457066" LOG_EFFECT_SIZE="-0.0011365792354180331" MODIFIED="2008-10-25 18:53:45 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7858998790985401" P_Z="0.9938429609402761" STUDIES="4" TAU2="0.0" TOTAL_1="279" TOTAL_2="299" WEIGHT="99.99999999999999" Z="0.007716780683439613">
<NAME>Artemether vs artesunate</NAME>
<DICH_DATA CI_END="23.07312953280059" CI_START="0.17949806155904835" EFFECT_SIZE="2.0350877192982457" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="57" LOG_CI_END="1.3631065042154327" LOG_CI_START="-0.7459402371065783" LOG_EFFECT_SIZE="0.3085831335544271" ORDER="305" O_E="0.0" SE="1.238864495802292" STUDY_ID="STD-BunnagTHI92_x002d_4b" TOTAL_1="59" TOTAL_2="59" VAR="1.5347852389594676" WEIGHT="5.5489312982301895"/>
<DICH_DATA CI_END="5.315879435720671" CI_START="0.4061605235693438" EFFECT_SIZE="1.469387755102041" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="147" LOG_CI_END="0.7255751225726149" LOG_CI_START="-0.39130228976710524" LOG_EFFECT_SIZE="0.1671364164027548" ORDER="306" O_E="0.0" SE="0.6560593206407074" STUDY_ID="STD-PriceTHI_x002d_MYA93_x002d_4" TOTAL_1="148" TOTAL_2="153" VAR="0.43041383219954643" WEIGHT="22.44023134559675"/>
<DICH_DATA CI_END="10.82942585834033" CI_START="0.03927547207194479" EFFECT_SIZE="0.6521739130434783" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="46" LOG_CI_END="1.0346054323257554" LOG_CI_START="-1.4058785862495786" LOG_EFFECT_SIZE="-0.18563657696191163" ORDER="307" O_E="0.0" SE="1.4335523931018763" STUDY_ID="STD-ThimasarnTHI93_x002d_4" TOTAL_1="31" TOTAL_2="47" VAR="2.0550724637681164" WEIGHT="6.774538705981437"/>
<DICH_DATA CI_END="1.8762597774809333" CI_START="0.32643473886793434" EFFECT_SIZE="0.782608695652174" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="20" LOG_CI_END="0.2732929684331801" LOG_CI_START="-0.4862036302617536" LOG_EFFECT_SIZE="-0.10645533091428679" ORDER="308" O_E="0.0" SE="0.44613206164220115" STUDY_ID="STD-WinMYA94_x002d_5" TOTAL_1="41" TOTAL_2="40" VAR="0.19903381642512075" WEIGHT="65.23629865019161"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-007.03" MODIFIED="2008-10-25 18:57:28 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="57" TOTAL_2="59" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Parasite clearance time</NAME>
<GROUP_LABEL_1/>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Expt</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Ctrl</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.03.01" MODIFIED="2008-10-25 18:54:06 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Artemisinin vs artesunate</NAME>
<CONT_DATA CI_END="14.578700020103444" CI_START="-5.378700020103441" EFFECT_SIZE="4.600000000000001" ESTIMABLE="YES" MEAN_1="31.0" MEAN_2="26.4" ORDER="309" SD_1="16.1" SD_2="16.1" SE="5.091267032871091" STUDY_ID="STD-AlinTAZ96" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.03.02" MODIFIED="2008-10-25 18:54:10 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="39" WEIGHT="0.0" Z="0.0">
<NAME>Artemether vs artesunate</NAME>
<CONT_DATA CI_END="5.125262567713866" CI_START="-12.32526256771387" EFFECT_SIZE="-3.6000000000000014" ESTIMABLE="YES" MEAN_1="35.29" MEAN_2="38.89" ORDER="310" SD_1="17.06" SD_2="21.59" SE="4.451746377248575" STUDY_ID="STD-WinMYA94_x002d_5" TOTAL_1="37" TOTAL_2="39" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-007.04" MODIFIED="2008-10-25 18:57:35 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="57" TOTAL_2="59" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Fever clearance time</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Expt</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Ctrl</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.04.01" MODIFIED="2008-10-25 18:54:16 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0" Z="0.0">
<NAME>Artemisinin vs artesunate</NAME>
<CONT_DATA CI_END="14.850436603109792" CI_START="-9.050436603109787" EFFECT_SIZE="2.900000000000002" ESTIMABLE="YES" MEAN_1="21.8" MEAN_2="18.9" ORDER="311" SD_1="20.57" SD_2="17.9" SE="6.097273571031564" STUDY_ID="STD-AlinTAZ96" TOTAL_1="20" TOTAL_2="20" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.04.02" MODIFIED="2008-10-25 18:54:19 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="39" WEIGHT="0.0" Z="0.0">
<NAME>Artemether vs artesunate</NAME>
<CONT_DATA CI_END="5.6711372148859445" CI_START="-5.551137214885947" EFFECT_SIZE="0.05999999999999872" ESTIMABLE="YES" MEAN_1="18.06" MEAN_2="18.0" ORDER="312" SD_1="13.9" SD_2="10.77" SE="2.8628777156855327" STUDY_ID="STD-WinMYA94_x002d_5" TOTAL_1="37" TOTAL_2="39" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>